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Structured Abstract  
Objectives:  This systematic review was undertaken to: (1) evaluate the accuracy of patient 
reporting of cancer family history, (2) identify and evaluate tools designed to capture cancer 
family history that are applicable to the primary care setting, and (3) identify and evaluate risk 
assessment tools (RATs) in promoting appropriate management of familial cancer risk in 
primary care settings. 
 
Data Sources:  MEDLINE®, EMBASE®, CINAHL® and Cochrane Central® from 1990 to  
July 2007. 
 
Review Methods:  Standard systematic review methodology was employed.  Eligibility criteria 
included English studies evaluating breast, colorectal, ovarian, or prostate cancers.  All primary 
study designs were included.  For family history tools (FHxTs) and RATs, studies were limited 
to those applicable to primary care settings.  RATs were excluded if they calculated the risk of 
mutation only, required specialist genetics knowledge, or were stand-alone guidelines. 
 
Results:  Reporting Accuracy:  Of 19 eligible studies, 16 evaluated the accuracy of reporting 
family history and three on reliability.  Reporting accuracy was better for relatives free of cancer 
(specificity) than those with cancer (sensitivity).  Accuracy was better for breast and colorectal 
than for ovarian and prostate cancers.  
Family History Tools:  Of 40 eligible studies, 18 FHxTs were applicable to primary care. 
Most collected information on more than one cancer, employed self-administered questionnaires, 
and favored paper-based formats to collate family information.  Details collected were often 
focused on specific conditions and affected relatives.  Eleven tools were evaluated relative to 
current practice and seven were not.  Irrespective of study design, compared to best current 
practice (genetic interviews) and standard primary care practice (family history in medical 
records) the FHxTs performed well.  
Risk Assessment Tools:  Of 15 eligible studies, three RATs were identified for patient use and 
eight for use by professionals.  They were presented in a range of computer-based and paper-
based formats, and preliminary evidence indicated potential efficacy, but not definitive 
effectiveness in practice. 
 
Conclusions:  Although limited in generalizability, informants reporting their cancer family 
history have greater accuracy for relatives free of cancer than those with cancer.  Reporting 
accuracy may vary among different cancer types.   
FHxTs varied in the extent of family enquiry depending on the tool’s purpose.  These tools 
were primarily developed as an integral part of risk assessment.  The few tools that were 
evaluated performed well against both best and standard clinical practice.  
A number of RATs designed for primary care settings exist, but evidence is lacking of their 
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The systematic collection and assessment of family history information is a potentially 
valuable tool in preventive medicine, and is crucial in the identification of genetic risk.1  In some 
situations, family history information alone can form the basis for offering patients appropriately 
tailored preventive interventions.2,3  In addition, the clinical predictive value of even the most 
accurate DNA test is strongly influenced by prior probability—such as a positive family history.4 
Family history is an important risk factor for many of the more common cancers. 
Primary care providers (PCPs) have always used family history information as a core tool for 
their practice.5  However, the increasing emphasis on identifying and managing genetic 
susceptibility, and the question of what might now be considered an “adequate” family history 
for this purpose, presents real challenges for PCPs.6  There is no single agreed upon approach to 
guide PCPs in taking a genetic family history within office consultations (which are often brief). 
In practical terms, the systematic collection of family history as it pertains to cancer history is 
linked with the interpretation of that information which in turn is linked to whether PCPs take 
appropriate clinical action on the basis of the information collected. 
The aim of this review is to provide a partial contribution to the evidence base underlying 
analytic validity (the ability of a tool to capture accurate family history data) and clinical validity 
(the ability of a tool to correctly assess or predict disease risk) of tools for capturing and 
interpreting family history. 
  
Scope and Purposes of the Systematic Review 
This systematic review addresses three research questions relating to the clinical utility of 
ascertaining family history as follows: 
 
1.  What is the evidence that patients or members of the public accurately know and report their 
family history of each one of, or a combination of, the following cancers: breast, ovarian, 
prostate, and colorectal?  
 
2.  How well do the different systematic family history collection forms and tools, such as take 
home tools, web based tools, etc., improve non-systematic approaches to family history 
collection by PCPs? 
a. Identify tools intended to improve family history collection by PCPs. 
b. Compare these tools against current practice. 
 
3.  What tools exist to enable PCPs to calculate, interpret, and act upon family history based risk 
information, and how well do these tools perform?  For each cancer of interest,  
a.  Identify tools designed to facilitate calculation and/or interpretation of family history 
based risk information, with the purpose of promoting recommended clinical actions.  
b.  Assess the evidence for effectiveness of these tools in facilitating calculating and/or 
interpretation of family history based information. 
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c.  Assess the evidence for effectiveness of these tools in promoting recommended clinical 
actions.  
d.  For each tool, identify the evidence base for each recommendation.  
Methods  
Standard systematic review methodology was employed.  MEDLINE®, EMBASE®, 
CINAHL® and Cochrane Central® from 1990 to July 2007 were searched for primary studies.  
Eligibility criteria included English-only studies evaluating breast, colorectal, ovarian, or 
prostate cancers in adults.  All primary study designs were included and reviews excluded.  For 
family history tools (FHxTs) and risk assessment tools (RATs) studies were limited to those 
applicable to primary care settings.  Primary care practitioners included family 
physicians/general practitioners, general internists, obstetricians, gynecologists (obstetrics and 
gynecology practitioners are PCPs for some women), nurses, nurse practitioners, physician 
assistants, nutritionists, and behavior counselors.  All studies that described or evaluated a tool or 
standardized method to systematically capture/collect/collate information related to family 
history for the relevant cancers or history of illness in other family members by any method 
whether self-report or collected by a professional were eligible.  FHxTs were eligible if 
developed specifically for primary care or developed in other settings but also applicable to 
primary care.  RATs were excluded if they calculated the risk of mutation only or required 
specialist genetics knowledge. 
Results 
A total of 15,390 unique citations were identified in the search for all three research 
questions combined.  During two levels of title and abstract screening, 14,840 articles were 
excluded.  A total of 338 citations proceeded to full text screening.  From these, a total of 56 
studies were eligible for the three research questions.  
 
Question 1: Accuracy of Family History Reporting 
A total of 19 unique studies (20 publications) evaluated the accuracy of reporting family 
history.  From these, 16 studies evaluated accuracy by attempting to verify the cancer status of 
relatives (i.e., accuracy compared with a gold standard), and three evaluated the repeatability or 
reliability of the informant’s knowledge of family history rather than the true status of the 
relatives (i.e., no external gold standard).  For the purposes of this review we use the terms 
“affected” and “unaffected” to refer to those relatives who have had cancer, and those who have 
not, respectively. 
All but three of the 19 studies recruited participants who had cancer; two studies involved 
individuals at high risk for colorectal7 or breast cancer,8 and one involved women undergoing 
mammography.9  There were four case control studies (five publications),10-14 with controls 
derived from the general population matched for age,10,11 spouses of the informants or regional 
general practice lists,14 and from a linkage with license registration and health care 
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administration database.13  In general, family history informant characteristics such as mean age, 
ethnicity, or education were infrequently evaluated. 
Sixteen studies (17 papers)7,8,10-24 evaluated the accuracy of family history reports by 
attempting to confirm the true cancer status of the relatives about whom informants provided 
information.  Eight studies 13,14,19-24 verified the cancer status in relatives reported to be affected 
and those reported to be unaffected.  The other eight studies (nine publications)7,8,10-12,15-18 only 
confirmed the cancer status of relatives reported to be affected.  We considered the former 
studies to be of higher methodological rigor and therefore evaluated these two groups of studies 
separately. 
 For the studies verifying affected and unaffected relatives, specificity across all cancers 
types and with varying modes of collection was consistently high (range 91 to 99 percent), 
suggesting that patients were very accurate in identifying relatives without cancer.  These varied 
as follows for the different cancers: breast 95 to 98 percent; colorectal 91 to 92 percent; ovarian 
96 to 99 percent; prostate 93 to 99 percent.  The sensitivity values showed greater variability, 
with breast cancer having the highest values.  The percent varied as follows: breast 85 to 90: 
colorectal 57 to 90; ovarian 67 to 83; prostate 69 to 79.  The extent to which the verification 
method or the manner of family history collection affected the sensitivity estimates has not been 
well evaluated.  
Fifteen factors were identified within the studies which could influence accuracy of family 
history reporting.  The most frequently reported factors were age (no clear effect), gender (some 
effect depending on type of cancer and family line), education level (mixed effects) and degree 
of relatives (consistent trend towards increased accuracy of reporting for first degree compared 
to second or third).  
Question 2: Family History Tools Designed To Improve 
Collection by Primary Care Professionals  
A total of 39 different tools, implemented in 40 unique studies, and reported in 45 
publications passed full text criteria.  Our initial focus was on identifying studies that described 
FHxTs developed or used in a primary care setting; however, after careful review, we noted that 
many studies described tools used in other settings that appeared potentially relevant to primary 
care (criteria included length, ease of use, complexity of information, need for specialized 
training).  We also sent e-mail queries to all authors of eligible studies that did not provide 
sufficient detail of the FHxT or a copy of the tool.  Fifteen authors (of 16 publications) 
8,10,11,16,17,21,23,25-33 did not respond and therefore we were unable to determine whether the FHxT 
was applicable for use within primary care.  For those studies for which we evaluated the FHxT, 
six tools from seven publications13,18-20,24,34,35 were assessed as inappropriate for primary care; all 
of these had been developed and used in research settings.  Of the remaining 22 publications, 
four 36-39 described the prototype and final versions of the same FHxT (RAGS/GRAIDS), which 
we counted as a single tool; and two 40,41 were companion publications.  Thus 18 distinct tools, 
from 22 publications, were identified as being applicable to primary care settings. 
Fourteen tools 42-55 were designed for completion by patients, and four tools (eight papers)  
36-41,56,57 were designed for use by health professionals.  The majority of tools (n = 15) were 
designed to collect data on family history of breast or breast/ovarian cancer and only two tools 
captured data on prostate cancer.  The published reports indicated that eight of the 
tools46,48,49,51,52,54,55,57 were used in a proactive way (intended for general or targeted population 
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coming into contact with PCP, irrespective of a known cancer risk or concern), eight (12 
papers)36,38-41,43-45,47,53,56 in a reactive manner (intended for individuals with perceived or 
recognized familial risk of cancer, including individuals concerned about cancer risk), and two in 
a mixed approach.42,50  The majority used a paper-based format to collect family history. 
The tools were evaluated using a range of study designs.  Eleven tools were evaluated 
relative to “ideal”, best estimate genetic interview, or current (“standard”) practice and seven 
tools were not evaluated relative to a comparator.  Of the five tools evaluated against genetic 
interview, in three there was no control arm to the study, with interview being completed after 
FHxT.43,45,49  Similarly, when compared to current practice, in three studies, patients completed 
the FHxT followed by capturing information in medical records.47,50,52  Despite these different 
study designs the findings were consistent, with FHxTs performing well against “ideal” 
interviews and significantly better than standard practice.  
Question 3: Risk Assessment Tools Designed To Improve 
Management of Patients 
For the purposes of this review we have defined a RAT in primary care as: An active 
knowledge resource that uses family history data, with or without other relevant evidence to 
generate case specific advice [knowledge component], designed to support decision making 
relating to management of cancer risk in individual patients [target decision component, timing 
component], by health professionals, the patients themselves, or others concerned about them 
[user component].   
Sixteen publications, representing 10 unique studies, were included.  All 10 tools were 
designed to stratify individuals into risk categories, and all had a component which indicated 
some form of clinical or personal action.  Six tools, reported in seven papers,43-45,58-61 were 
designed to assess risk of breast or breast/ovarian cancer only, four tools (seven  
papers)31,36-39,62,63  were designed to assess risk of breast/ovarian and colorectal cancer, and one 
tool (two papers) 40,41 focused on breast/ovarian, colorectal and prostate cancer.  No tool was 
identified that focused solely on ovarian, colorectal, or prostate cancer risk. 
Of the seven tools intended for use by professionals, five were developed explicitly for use 
by PCPs, either family physicians (four tools)36-39,58,60-63 or physicians working in ambulatory 
care settings (one tool, two papers).40,41  Two appeared to have been developed in settings other 
than primary care, but intended for eventual use in that setting.43,59  One patient tool31 was 
developed in a primary care setting, and the other two44,45 were considered potentially applicable 
to use in primary care settings.  
Three tools (five publications) were robustly evaluated in controlled trials.36,60-63  The 
development of one tool was described over four papers from evaluation in “laboratory- type” 
conditions38,39 to controlled trials in routine practice.36,37  The success of two of these RATs was 
confirmed by compliance to referral criteria in two studies (three papers), 36,60,61 however in one 
study there was no subsequent significant difference in patients identified at increased risk by 
genetic specialist.36  The final tool (two papers) did not demonstrate any statistical difference in 
physician confidence and patients’ risk perception.62,63   
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Discussion and Conclusions 
This review explored both the accuracy of family history reporting by patients and the 
effectiveness of tools for collecting and using familial cancer history in a primary care setting.  
Ideally, patients are able to report accurate information on their family history, assisted by 
effective tools, and health care providers are able to use the information to make beneficial 
preventive and clinical management decisions.  
The accuracy of self reported family history has implications for the correct risk assessment 
and management of patients.  Accuracy of cancer family history reporting appears to be 
dependent on cancer type and method of collection, and accurate reporting of absence of cancer 
(specificity) appears to be greater than accurate reporting of presence of cancer (sensitivity).  
Accuracy of recall and reporting may be influenced by both patient factors and by the method 
used to capture the data (the tool).  No studies appear to have examined both of these together, so 
it is impossible to comment definitively on their relative contributions to any lack of accuracy.  
Very few FHxTs have been developed for, and evaluated in, primary care settings.  Further, 
few tools have been compared with either “best practice” (genetic interview) or current primary 
care practice (family history as recorded in charts).  Although the evidence is very limited, and 
depends on extrapolation of studies of tools in settings other than primary care, it suggests that 
systematic FHxTs may add significant genetic family history information compared to current 
primary care practice. 
A number of RATs, of varying format and complexity, have been developed for primary care 
settings, and a few of these have been evaluated in controlled trials.  These studies provide 
tentative evidence for the effectiveness of such tools, but their utility in routine practice has not 
been established.   
Recommendations 
1. Family history is a fundamental element of health information, and the ability to take an 
adequate and accurate family history should be recognized as a core skill for all PCPs, 
irrespective of the availability of tools. 
 
2. Consensus should be reached on the extent of family history enquiry necessary for different 
clinical purposes and circumstances, taking into account the likelihood of accuracy of self 
reported information for different relatives, and the use to which the information will be put 
(e.g., overall or specific risk assessment).  Until the evidence base is clear, it is suggested that 
a minimum adequate cancer family history should include information on siblings, parents 
and grandparents (and the paternal and maternal lineage of the latter), specific enquiry about 
whether other relatives had the cancers of interest, and the ethnicity of the respondent.  When 
cancer is identified, the age of diagnosis should also be noted, and other relatives with similar 
or related conditions identified. 
 
3. The benefits, costs and harms of using patient-completed tools for systematic family history 
collection and risk assessment, as a substitute for, or complement to, professional tools 
should be further examined.  As well as assessing technical outcomes such as accuracy and 
completeness of data captured, evaluations should consider outcomes which relate to patient 
“empowerment” and the use of practitioner and health care resources.   
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4.  Further research is required to identify the specific strategies and tool features which promote 
the most accurate reporting of family history information. 
 
5. The optimum interval for updating a patient’s family history information in primary care 
should be formally evaluated. 
 
6. Further evaluation of FHxTs and RATs in routine clinical settings and practice is required. 
Studies should: adopt appropriate comparators (generally current practice); ensure that tools 
are optimized (in terms of, for example, face and content validity) before evaluation; measure 
outcomes that relate to utility in routine practice; measure outcomes that provide information 
on potential costs or harms as well as benefits; and address or explore contextual factors 














Chapter 1.  Introduction 
Importance of Family History Collection  
for Cancer Risk Evaluation 
A positive family history is a risk factor for many chronic diseases, reflecting “the 
consequences of genetic susceptibilities, shared environment, and common behaviors”.2  The 
systematic collection and assessment of family history information is a potentially valuable tool 
in preventive medicine, and is crucial in the identification of genetic risk.1  In some situations, 
family history information alone can form the basis for offering patients appropriately tailored 
preventive interventions.2,3  In addition, the clinical predictive value of even the most accurate 
DNA test is strongly influenced by prior probability—such as a positive family history.4  For 
example, Rich and colleagues3 illustrated how the positive predictive value of the same DNA-
based test for familial adenomatous polyposis (FAP) could rise from about 11 percent in a 
patient where no family history information was available to over 99 percent if the patient 
accurately reported FAP in just one sibling or parent.  Thus, family history information is 
potentially useful both as a clinical tool in its own right, and also as an important adjunct to 
DNA-based testing.  
Cancers are a group of relatively common conditions in which, for at least some, family 
history appears to be an important risk factor.  A British study suggested that a typical UK family 
physician with 2,000 patients would expect up to 50 of those aged 35 to 64 to have a history of 
familial cancer, and 30 to 40 patients meriting some form of active preventive surveillance.64 
Cancer family histories can broadly be divided into three categories: hereditary, familial, and 
sporadic.65  Hereditary cancers are predominantly single gene disorders with Mendelian patterns 
of inherited risk.  Familial cancers describe other less obvious clusters of cancer within families, 
thought to be due to combinations of multiple low penetrance gene mutations with or without 
contributions from shared environmental and/or behavioral risk factors.  Sporadic cancers are 
those which occur without an apparent hereditary or familial pattern.   
This report focuses on four cancer types: breast, ovarian, prostate, and colorectal.  These are 
some of the most common cancers where the role of family history is widely recognized as a risk 
factor.66-70  For each of them, the contribution of familial risk is reflected in evidence-based 
consensus statements71-73 (e.g., http://www.ahrq.gov/clinic/uspstfix.htm).  In some families, these 
cancers form part of recognized hereditary syndromes; for example, BRCA1 mutations increase 
familial risk of breast, ovarian and prostate cancer while MLH1, MSH2, and other DNA 
mismatch repair genes increase the familial risk of colorectal, endometrial, ovary, small bowel, 
and pancreatic cancers, among others.65  In some cases, ethnic ancestry is also associated with 
risk of cancer-associated genetic mutation, such as breast cancer in the Ashkenazi Jewish 
community.74-77    
 
Primary Care Physicians and Cancer Risk Assessment  
and Management 
 
Primary care providers (PCPs) have always used family history information as a core tool for 
their practice,5 well before the arrival of the “genomics age”.  However, the increasing emphasis 
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on identifying and managing genetic susceptibility, and the question of what might now be 
considered an “adequate” family history for this purpose, presents real challenges for PCPs.6  
While a genetics specialist may be able, indeed advised, to devote substantial time to eliciting 
and confirming family history data (on the order of several hours)65,78,79 family physicians, 
internists, and other non-genetics providers may have only minutes.  Other barriers to more than 
a “minimal” approach include unfavorable reimbursement policies, pressure from colleagues and 
patients to focus on other aspects of care, perceived lack of skills, and lack of confidence.3,80  
Conversely, family physicians and other PCPs may be able to capture family history data over 
time, and are well placed to keep such information up to date.   
The use of family history information to make preventive and clinical management decisions 
also depends on the adequacy of providers’ knowledge, skills and confidence; this is extremely 
challenging in a field where the knowledge base is rapidly evolving.  To complement more 
general educational interventions, there is a strong case for the development of effective tools, 
designed for use in primary care settings, which permit providers to translate an individual’s 
family history data into meaningful risk stratification, with linkage to evidence-based guidance 
on appropriate preventive and clinical management interventions.  Thus, the translation of family 
history information into improved health outcomes depends on the availability and integrated use 
of effective interventions for data capture, risk assessment, and clinical intervention.     
 
Accuracy of Family History Reporting 
 
In order for family history to be of value in clinical decision making, patients must possess, 
and PCPs must be able to ascertain, accurate family health information.  Assessing accuracy 
requires a clear idea of an appropriate gold standard—what patients “should” know, and what 
clinicians “should” be able to obtain.  In simple terms, an “accurate” family history could be 
considered to be one which is sensitive (disease in relatives is correctly identified) and specific 
(lack of disease in relatives is correctly identified).  Work in the field of psychiatry has suggested 
three gold standards for studies of family history taking:  an “ideal” standard, based on 
comprehensive data obtained from the relatives, hospital and physician records and/or disease 
registers;81-83 a “best estimate diagnosis” (BED) standard,84 based on best available data from 
death certificates and medical records;65,85,86 and a “pragmatic BED”, based on the family history 
obtainable in a detailed interview conducted by a trained clinical genetics professional.  Our 
consultation with the key stakeholders in this review has indicated that an appropriate practical 
gold standard for evaluating accuracy would be information obtained directly from relatives’ 
medical records, cancer registries, and/or death certificates.  Such information should be used 
both to confirm reported cases of cancer in the family, and to confirm absence of a cancer 
diagnosis in relatives who were reported not to have cancer.87 
 
Collection of Family History in Primary Care 
 
There is no single agreed-upon approach to guide primary care practitioners in taking a 
genetic family history within office consultations (which are often brief).  Family history taking 
can be conducted as part of a disease specific approach which aims to identify risk of selected 
single gene disorders (e.g., hereditary breast or colon cancer) for the purpose of ensuring 
appropriate specialist intervention.88,89  Alternatively, it can be directed more broadly towards 
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identifying possible risk of a number of common multi-factorial disorders such as cancer, 
diabetes, and coronary heart disease.46,49   
Family history data may be recorded as notes or lists within patient charts, represented as 
family trees or genetic pedigrees, or stored within computer databases which can be linked to 
decision support systems.  In the last few years several computer-based pedigree drawing 
packages have been developed, such as genogram software.38,90  It is not clear whether such 
approaches translate well from specialist use to application in primary care. 
There is also no consensus on the extent or detail of family history information which needs 
to be recorded in primary care, compared with specialist genetics settings.  The extent of cancer 
family history collection has to be adequate to enable PCPs to make appropriate clinical and 
prevention decisions, but it is not clear whether this necessarily requires the same approach as 
that used by a genetics specialist.3   
  
Risk Assessment in Primary Care 
 
There are several issues which may influence the translation of family history information 
into meaningful risk assessment for patients.  These include the level of complexity of family 
history information which is actually required for risk assessment for any given disorder, the 
validity of risk stratification guidelines or algorithms, the kind of tools that exist to facilitate risk 
stratification, (and their effectiveness in practice), and the actual predictive value of risk 
assessment tools (RATs).   
At its most simple, assessing familial risks associated with common adult-onset diseases 
requires setting a threshold where the family history indicates a cause for suspicion (i.e., 
dichotomizing risk into reassuring the patient or recommending further action). A more complex 
approach is to separate risk into three or more strata (e.g., “high”, “moderate” and 
“average”).91,92  In general terms, individuals at “average” risk (the risk level of the general 
population) would be offered standard preventive advice, those at “moderate” risk would be 
offered a higher level of intervention, such as more extensive or more frequent surveillance, and 
those at “high” risk would usually be referred for specialist assessment and possibly considered 
for mutation testing.2   
Risk assessment tools need to be valid, in terms of their clinical predictive value, but they 
must also be feasible for use in the intended settings, and generate benefits in the process or 
outcome of care when compared with current practice.  Feasibility and effectiveness in practice 
may be influenced by the actual implementation format; for example, a risk stratification 
protocol could be presented in paper-and-pencil format, on a personal digital assistant, or on the 
desktop in a web-based format.  Such tools may be passively disseminated, or accompanied by 
educational interventions and/or ongoing support from genetics professionals.  Recent examples 
of web-based tools include Harvard’s “Your Disease Risk”93 and the Centers for Disease 
Control’s (CDC) Family HealthWare.94  
 
The ACCE Framework 
 
Tools for family history collection and risk assessment lend themselves to evaluation using 
the framework developed for genetic predictive testing by the Secretary’s Advisory Committee 
on Genetic Testing.95  This framework (see Table 1, derived from Yoon 2003), widely referred to 
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as the “ACCE” framework, comprises four evaluative elements: analytic validity, clinical 
validity, clinical utility, and ethical legal and social issues.2,96   
 
Table 1. Application of the ACCE framework96 to family history as a screening tool 
Element Definition Components 
Analytic validity An indicator of how well a family 
history tool measures the 
characteristic (“family history”) 
that it is intended to measure 
 
Analytical sensitivity and 
specificity 
Clinical validity A measurement of the accuracy 
with which a RAT based on 
family history information predicts 
disease risk  
 
Clinical sensitivity and  specificity 
 
Positive and negative predictive 
values  
Clinical utility The degree to which benefits are 
provided by using a clinically 
valid RAT based on family history 
information  
Availability of effective preventive 
and clinical interventions 
 
Health risks and benefits of 
preventive and clinical 
interventions 
 
Health risks and benefits of 




Ethical, legal, and social 
implications 
Issues affecting data collection 
and interpretation that might 
negatively impact individuals, 




Risks to privacy and 
confidentiality 
 
Yoon P.W., Scheuner M.T., Khoury M.J.  Research priorities for evaluating  family history in the prevention of common chronic 
diseases.  Am J Prev Med 2003;23 (2):128-135.  
 
Thus, in terms of family history, analytic validity describes the ability of a family history tool 
to correctly identify the pertinent information on disease in relatives.  This is dependent on the 
effectiveness of a tool in promoting acquisition of appropriate family history data, and also on 
the ability of an informant to provide accurate information.  Clinical validity describes the ability 
of a RAT to use valid family history data to correctly predict or stratify cancer risk in the 
informant.  Risk assessment tools may vary in their complexity, from simply identifying an 
elevated cancer risk in the family, to more detailed risk prediction scores—but all are dependent 
on valid risk stratification criteria.  An effective risk prediction tool therefore depends on a valid 
family history tool, and may or may not also take account of non-genetic factors which modify 
disease risk.  Clinical utility considers the evidence that family history assessment, risk 
stratification, and subsequent preventive or clinical interventions actually bring overall health 
benefit to the individual patient.  The ethical, legal, and social issues component of the 
framework considers the impact and consequences of using a family history based approach 
from a broader societal perspective.   
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The aim of this review is provide a partial contribution to the evidence base underlying 
analytic validity (the ability of a tool to capture accurate family history data) and clinical validity 
(the ability of a RAT to correctly predict disease risk).  The main focus is on describing the 
availability and format of available family history and RATs, and the evidence that these are 
more effective than current practice in promoting accurate family history collection and 
assessment in primary care and population settings.  It is not within the scope of the review to 
assess either the evidence underlying risk stratification systems (i.e., the predictive value of 
guidelines or criteria), or the evidence that preventive or clinical interventions based on such 
stratification provide overall benefit to patients (i.e., clinical utility).  However, the evidence 
assembled in this review is a crucial element of determining how best to capture and use family 
history information in primary care to promote the anticipated population health benefits. 
 
Scope and Purpose of the Systematic Review 
 
This systematic review addresses three research questions relating to the clinical utility of 
ascertaining family history as follows: 
 
1.  What is the evidence that patients or members of the public accurately know and report their 
family history of each one of, or a combination of, the following cancers: breast, ovarian, 
prostate, and colorectal?  
 
2. How well do the different systematic family history collection forms and tools, such as take 
home tools, web based tools, etc., improve non-systematic approaches to family history 
collection by PCPs? 
a. Identify tools intended to improve family history collection by PCPs. 
b. Compare these tools against current practice. 
 
3. What tools exist to enable PCPs to calculate, interpret, and act upon family history based risk 
information, and how well do these tools perform?  For each cancer of interest:  
a. Identify tools designed to facilitate calculation and/or interpretation of family history 
based risk information, with the purpose of promoting recommended clinical actions. 
b. Assess the evidence for effectiveness of these tools in facilitating calculating and/or 
interpretation of family history based information. 
c. Assess the evidence for effectiveness of these tools in promoting recommended clinical 
actions.  








An analytic framework is a schematic representation of the strategy for organizing topics for 
review and for guiding literature searches.  Figure 1 illustrates the inter-relationships among the 
three research questions being addressed in this systematic review.  As shown in Figure 1, the 
collection of family history data, a central focus of this systematic review, connects with the 
three questions.  First, the validity of reporting of family history data (in general) by patients 
(Q1), second, characteristics of the systematic family history collection tools, designed to be 
used to capture such data in the primary health care settings (Q2), and, third, the characteristics 
and effectiveness of risk assessment tools (RATs) designed to allow practitioners and patients to 
make use of family history information to improve health outcomes (Q3).  Other important 
questions are the format of various tools, strategies underlying family history collection and risk 
assessment, the settings in which tools are intended for use, the settings in which tools are 
evaluated, and the comparisons against which both family history tools (FHxTs) and RATs are 
actually evaluated. 
 



















While there is some overlap between FHxTs and RATs, some FHxTs do not contain a 
decision support element, while some RATs collect family history data which is so targeted that 
it is unlikely to be sufficient for a complete or generic FHxT, and others have no FHxT 
component at all.  The evaluative framework for both FHxTs and RATs is described in further 
detail in the topic refinement section. 
Note on Terminology.  In the published literature, a number of terms have been used to 
indicate the individuals from whom family history information is collected, including “patient”, 
“consultant”, “subject”, “participant”, and “proband”, but there is no single standard, accepted 







































reduce potential ambiguity and confusion.  Therefore, although it is used with a particular 
meaning in some clinical contexts, we have adopted the use of the term “informant” in the rest of 
the report to indicate the individual who provides the family history information.      
 
Accuracy of Family History Reporting 
 
Accuracy of a test (in this case reporting of family history) represents the proportion of all 
test results that are true (both positive and negative outcomes).  If individuals reporting family 
history were 100 percent accurate they would correctly identify all relatives with cancer and all 
those without cancer.  A number of metrics may be used to convey accuracy.  Of these, 
sensitivity and specificity are not influenced by the underlying prevalence of the characteristic of 
interest in the population (in this case, positive family history).  We therefore report sensitivity 
and specificity, where this is reported in (or can be calculated from) eligible papers.  Consider 
the situation where “reporting of family history by the informant” is considered the “test”, and is 
compared to a “gold standard” (the real situation).  In this context, sensitivity indicates how 
accurate informants are at identifying relatives who truly have cancer.  If reporting is highly 
sensitive, only a few relatives with cancer will be reported as cancer-free.  Conversely, if 
reporting is highly specific, only few relatives who are truly cancer-free are misreported as 
having cancer.  
It is likely that accuracy of reporting will be influenced by both informant factors and factors 
relating to the method of capturing the family history data.  As much as possible, we captured 
information on such attributes and considered how the results appeared to be influenced by them, 
although we did not attempt a formal regression analysis to examine their independent effects(s).   
We also examined reliability (repeatability and reproducibility) where this was possible, 
recognizing that this is also a product of accuracy of recall and consistency of reporting 
(informant factors) and performance of the instrument used to capture the data (tool factors).  
There are several measures of test-retest reliability such as intra-class correlation co-efficient and 
Cohen’s kappa statistic.  We note that there is no consensus on the ideal interval for assessing 
reliability of family history information, bearing in mind that the medical status of relatives 
inevitably changes over time.  
As discussed in Chapter 1, three gold standards have been suggested for studies of family 
history taking:  an “ideal” standard, a “best estimate diagnosis” (BED) standard and a “pragmatic 
BED” standard.  We accepted the following gold standards for the presence or absence of cancer 
in the first and second degree relatives of the informant: (1) the relative’s medical record,  
(2) confirmation of status by the relative’s physician, (3) death certificate, (4) cancer registration, 
(5) direct confirmation by the relative in question.  Ideally, accuracy studies should demonstrate 
verification of health status (presence or absence of cancer) both in relatives who are reported to 
have had cancer, and relatives reported not to have had cancer; however, in order to evaluate as 
wide a range as possible of the available literature, we did not exclude review studies which 
verified only the status of relatives reported to have had cancer.  
We defined a priori what we meant by the degree of the relative.  First degree relatives were 
defined as those who share one-half of their genetic information with the individual reporting 
family history—their full siblings, parents and children.  Similarly, second degree relatives were 
those who shared one-quarter of their genetic information with the informant—their 
grandparents, grandchildren, uncles, aunts, and half-siblings. 
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Family History Collection Tools 
 
We defined a FHxT as: 
“A systematic and coherent approach used to capture and document family history, 
appropriate for the clinical setting, with the potential to lead to decision making by a 
clinician.” 
This review focused on FHxTs which could be applied in the clinical setting, but we also 
included studies that described tools developed for research purposes, and for settings other than 
primary care, where we judged they appeared potentially applicable within primary care settings.  
We captured data on the following tool characteristics that may influence the clinical utility of 
the tool in current primary care practice.   
 
1. Patient targeting—”reactive” or “proactive”. 
• Reactive—the tool was intended to be used only to collect family history information 
from individuals with perceived or recognized familial risk of cancer, including 
individuals concerned about cancer risk.  
• Proactive—the tool was intended to be used to collect family history information from a 
general or targeted population coming into contact with primary care, irrespective of a 
known cancer risk or concern. 
 
2. Study setting in which the FHxT is being administered—”clinical” or “research”. 
• Clinical—the primary objective of the study was to assess the use of the FHxT in routine 
clinical practice. 
• Research—the primary objective of the study was to use the FHxT for purposes other 
than routine clinical practice, for example designed for data capture in epidemiological 
studies. 
 
3. Type of comparator—”best estimate” or “current practice”. 
• Best estimate—the comparator was information collected by a clinical genetic specialist 
interview or equivalent. 
• Current practice—the comparator was information collected in a way that was “standard” 
for the primary care setting, e.g., family history information recorded in patient charts. 
 
Where a tool was not described as designed for or evaluated in a primary care setting, 
applicability was assessed by two independent reviewers against five criteria: length of tool, ease 
of completion, need for specialist knowledge, whether it was designed to capture data on at least 
all first degree relatives, and clarity of layout (including appropriate structure and logical 
sequence).   
 
Risk Assessment Tools 
 
While there is no one commonly accepted definition of a RAT, for the purposes of this study, 
we have followed the approach of Liu et al. who define a decision tool as: 
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“…an active knowledge resource that uses patient data to generate case specific advice, 
which supports decision making about individual patients by health professionals, the 
patients themselves or others concerned about them.”97 (p90) 
 
Defined thus, RATs have four essential characteristics: 
 
1. The tool is designed to aid a clinical decision by a health professional and/or patient (“user”); 
 
2. The tool focuses on decisions concerning individual patients (“target decision”); 
 
3. The tool uses patient data and knowledge from family history to generate an interpretation 
that aids clinical decision making (“knowledge component”); 
 
4. The tool is designed to be used before the health professional or patient takes the relevant 
decision (“timing”). 
 
This definition encompasses a wide range of potential tool “technologies”, including 
computer-based decision support systems, reminder cards, guidelines, predictive scores, 
checklists, etc.  Drawing on this definition, we have developed the following working definition 
of a “family history based cancer risk assessment/decision tool”, for use in this review:   
“An active knowledge resource that uses family history data and other relevant evidence 
to generate case specific advice [knowledge component], designed to support decision 
making relating to management of cancer risk in individual patients [target decision 
component, timing component], by health professionals, the patients themselves, or others 
concerned about them [user component].”  
We translated the four “essential characteristics” into this specific form for the context of this 
review:  
 
1. Users—health professionals, patients, members of the general population 
  
2. Target decision—clinical management (e.g., referral for genetic counseling), or 
individualized preventive management strategies (e.g., disease screening or surveillance) 
 
3. Knowledge component—a defined model or set of criteria which transform family history 
data into information which serves the target decision making process 
 
4. Timing—designed to be used before the health professional or patient takes the relevant 
decision.  
 
The breadth of this definition potentially allows for the inclusion of a large number of 
guidelines, algorithms, statistical models, etc.  In order to maintain the focus of this review on 
tools most likely to be feasible for use in primary care, we included only those which were 
explicitly developed for primary care, or where specialist genetics knowledge did not appear 
necessary to use the tool.  We excluded tools where the only output was risk of carrying a 
cancer-associate mutation (e.g., BRCAPRO98 or BOADICEA99), rather than risk of disease, as 
we judged this required genetics specialist knowledge for interpretation.  Noting also that there 
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are many hundreds, possibly thousands, of guidelines which have been developed over the past 
few years around familial cancer risk, we included them only if they were part of a package, 
system, or intervention designed to foster their effective implementation in practice.  Thus, 
widely used guidelines such as the modified Amsterdam criteria,100 the Manchester scoring 
system,101 the UK NICE guidelines on familial breast cancer72 were not included unless they 
were part of such a system.  For each tool which met the inclusion criteria, we collected data on 




The first step during the topic assessment and refinement process was a teleconference with 
partner organizations.  The Task Order Officer (TOO) invited topic experts and the McMaster 
multidisciplinary research team to define the scope of the topic to be addressed and to 
refine/clarify the preliminary research questions for this evidence report.  An international 
Technical Expert Panel (TEP) was assembled to provide high level content expertise on this 
topic (Appendix E*) and to participate in conference calls on an as-needed basis throughout the 
data refinement and extraction phase.  The TEP assisted in refining the research questions and 
raising methodological issues of relevance to this review. 
The initial work order specified that the systematic review should be limited to adult 
populations and should examine the family history of at least one of the following cancers:  
(1) breast, (2) ovarian, (3) prostate, and (4) colorectal.  The second and third questions of the 
review were limited to primary care settings or practitioners. 
The first research question in this systematic review focuses on the accuracy of family 
history knowledge and reporting.  The investigative team considered, but ultimately rejected, 
addressing this question by updating a previous systematic review.102  This review included 
original articles describing the accuracy of self-reported family history for breast, colon, ovarian, 
prostate, endometrial, and uterine cancers using verification from identified relatives’ medical 
records, physician, death certificate, and/or verification within a population cancer registry.  The 
limitations of this review included: lack of a delineated search strategy, overly specific search 
terms, non-reporting of agreement between reviewers, non-reporting of data collection forms 
used, and lack of clarity of reasons for excluding reports.  
A number of issues relevant to the identification and evaluation of FHxTs were identified and 
discussed with the TEP, including: (1) the most important attributes that should be considered 
within each of these tools; (2) which of these elements were most relevant for primary care; and 
(3) the incremental value of the tool relative to current practice.  The TEP recognized that the 
selection of gold standards for family history reporting and collection is arbitrary and that an 
“adequate” family history (for the purposes of making decisions relating to familial cancer risk) 
requires not only identifying relatives with and without the cancer, but also the relationship of 
the affected relative, the age of onset of cancer in those affected, and identification of several 
cancer types beyond the “target” cancer in question (e.g., family history of endometrial and 
kidney cancer is relevant in considering risk for hereditary nonpolyposis colorectal cancer).   
For the purposes of the review, a definition of primary care was established with the 
participation of the partner at the CDC and the TEP.  Primary care practitioners included family 
physicians/general practitioners, general internists, obstetricians, gynecologists (obstetrics and 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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gynecology practitioners are PCPs for some women), nurses, nurse practitioners, physician 
assistants, nutritionists, behavior counselors. 
Family history information is of clinical value only if it can be used for some form of 
meaningful risk stratification.  Issues around risk assessment and stratification were explored 
with the TEP, particularly whether the various risk stratification algorithms or guidelines on 
which tools are based are themselves evidence-based—i.e., whether such algorithms or 
guidelines have adequate predictive value (i.e., clinical validity) and their use has been shown to 
improve patient or clinical outcomes (i.e., clinical utility).  It was recognized that exploration of 
this would broaden the scope of the review to such an extent that it would become 
unmanageable.  Therefore, it was determined that the validity of underlying algorithms or 
guidelines should be taken at face value.  Thus, the focus of the review should be confined to 
evaluating whether tools were effective in facilitating the translation of a patient’s family history 
information into a specific risk stratum, compared with current primary care practice, on the 
assumption that such stratification was worthwhile.   
 




The systematic review protocol search included the electronic databases MEDLINE®, 
EMBASE®, CINAHL® and Cochrane Controlled Trials Register (CCTR)® from 1990 to July 
2007.  In addition we retrieved and evaluated references from eligible articles. Hand searching 
was not undertaken for this review.  However, we did review the publication types “letters” 
(normally excluded from reviews); the investigators suggested that, within the content area of 
cancer genetics, primary data information might be published as letters in some journals.  We 
also undertook a search of relevant grey literature sources.  Detailed search strategies and 




A list of eligibility criteria was determined and standardized forms were developed in 
Systematic Review Software (SRS) for the purposes of this systematic review. The forms and 
help guides detailing the eligibility criteria can be found in Appendix B.* 
 
Publication Year, Type and Language   
Inclusion:   
Language:  Only English language studies were eligible.   
Publication Date: 1990 to July 2007.  
Exclusion:  
Publication type: Narrative and systematic reviews (except for Q2b), editorials, letters (with 
no primary data), comments, opinions, abstracts and unpublished studies.   
 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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Study Design  
Inclusion:   
There was no restriction of primary study designs for both quantitative and qualitative types. 
Exclusion:  




Any subject 18 years of age or older. 
 
Intervention Cancer Type 
Inclusion:  
Examination of family history of breast, ovarian, prostate, or colorectal cancer.  
Exclusion:  
Tools that do not include at least one of the four specified cancers or cancer data presented in 
aggregated form that includes non-eligible cancers. 
 
Intervention Practitioner Type (Applicable Only to Q2 and Q3) 
Inclusion:  
Studies with practitioners from primary care settings; the definition of primary care for this 
review was established as follows: 
family physicians/general practitioners  
general internists  
obstetricians 
gynecologists (obstetrics and gynecology practitioners are primary care providers for 
some women)  
nurses 
nurse practitioners  




All other health/medical professional groups. 
 
Intervention Tool 
Inclusion Question 2: 
Tool or standardized method to systematically capture/collect/collate information related to 
family history for the relevant cancers or history of illness in other family members by any 
method whether self report or collected by a professional.  
Exclusion Q2: 
Any ad hoc approach that is not systematic, or uses open questions, when collecting family 
history for the relevant cancers or a personal medical history taking only with no components 
dealing with family history.  
 Inclusion  Q3: 
 A standardized method or tool designed to stratify, or interpret level of familial cancer risk, 
in order to support decisions made by PCPs relating to management of risk of familial 
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cancer.  The cancer risk calculation method or stratification method must be based primarily 
on family history information.  The tool meets the definition of RAT (defined as one that 
specifies a user, target decision, knowledge, and timing), and, at a minimum, stratifies 
individuals into categories on the basis of risk of disease. 
Exclusion Q3: 
Family history tools without a risk calculation, stratification or patient-specific decision 
support component tool which calculate risk of mutation only, tools which require specialist 
genetics knowledge, and stand-alone guidelines.  
Also explicitly excluded from Question 2 and Question 3: 
•   Articles with a primary focus on genealogy (non-medical family history) 
•   Articles which include mention of family history in some form but do not describe a 
tool or measure for use in clinical settings. 
 
Applicability of Tools 
Inclusion:  
Tools designed specifically for use by PCPs, or tools developed for other practitioners with 
the potential to be used in primary care.  
Exclusion:  
Tools depending on specialist expertise in genetics for their use or interpretation. 
 
Study Selection  
 
A team of study assistants was trained to apply the eligibility criteria in preparation for 
screening the title and abstract lists and the full text papers.  All levels of screening were done in 
web-based Systematic Review Software (SRS) (TrialStat Corporation, Ottawa, Ontario Canada). 
Standardized forms and a training manual explaining the criteria were developed and reviewed 
with the screeners (Appendix B*).  For the title and abstract phase, two reviewers evaluated each 
citation for eligibility.  Articles were retrieved if either one of the reviewers judged it as meeting 
eligibility criteria or if there was insufficient information to determine eligibility.  For screening 
of full text articles, two screeners came to consensus on the identification, selection, and 
abstraction of information.  Disagreements that could not be resolved by consensus were 
resolved by one of our McMaster research team members.  The level of agreement for inclusion 




Appropriate data collection forms were developed for use in the systematic review 
(Appendix B*).  All eligible studies from the selection phase (full text screening) were abstracted 
onto a data form according to predetermined criteria.  One data extractor transferred the data 
onto these forms, and another checked the answers for accuracy before they were entered into 
SRS.  Data entries were verified by the investigators responsible for summarizing the different 
report results sections.  
Quality Assessment of Included Studies.  To assess the quality of primary studies, we 
utilized standardized rating scales with acceptable reliability and validity.  The specific scale 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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used was dependent on the study design and the research question.  The Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS)103 was selected to evaluate studies primarily focused 
on accuracy (i.e., included in Q1).  The Jadad scale was used for studies that were randomized 
controlled trials (RCTs).104  For true observational study designs, the Down’s and Black quality 
assessment scale was used.105  Studies that were neither of these study designs were evaluated 
qualitatively without the use of formal checklists.  The instruments used to evaluate quality are 
shown in Appendix B.* 
 
Summarizing Our Findings: Descriptive and Analytic Approaches 
 
A qualitative descriptive approach was used to summarize study characteristics and 
outcomes.  Multiple publications on the same study cohort were grouped together and treated as 
a single study with the most current data reported for presentation of summary results. 
Standardized summary tables explaining important study population and population 
characteristics, as well as study results, were created.  Meta-analysis was not undertaken for 
eligible studies within this review as the clinical heterogeneity between studies was considerable.  
For those papers evaluated for research Q1, where the actual numbers of true and false 
positive and negative results (TP, FP, TN, FN) were presented, or where enough information was 
given to allow us to calculate and estimate these numbers, we recalculated the sensitivities and 
specificities with the accompanying 95 percent confidence intervals (CI) where possible.   
For those papers evaluated for research Q2, descriptive data on the attributes of FHxTs were 
presented.  For those FHxTs that had been formally evaluated, we reported outcome data 
separately for those tools compared with best estimate, and those compared with current practice 
comparators.  
For those papers evaluated for research Q3, we presented descriptive data on the attributes of 
RATs, including the evidence base, if any, underlying each tool.  For those RATs that had been 
formally evaluated, we reported data on outcomes relevant to the use of the tool in supporting 
decisions by users in practice (e.g., the pattern of referrals from primary to specialist care, patient 
perceptions of their cancer risk, health professional confidence in counseling patients concerned 
about their risk, etc.).  Data regarding the validity of the knowledge component of each RAT 
(e.g., the scientific basis for guidelines, the predictive value of a stratification system, etc.) were 
captured where possible, but it is not within the scope of this review to consider the quality of 
such evidence (see “Topic Refinement”, above).   
 
Peer Review Process 
 
A list of potential peer reviewers was assembled at the outset of the study from a number of 
sources including our TEP, our partners, the McMaster research team, and the AHRQ.  During 
the course of the project, additional names were added to this list by the McMaster Center and 
AHRQ.  The content experts were asked to review the draft report and their comments and 
suggestions have been incorporated where possible for the final report (see Appendix E*). 
                                                 




Chapter 3.  Results 
 
The original search yielded 15,390 unique citations for all three research questions combined.  
During two levels of title and abstract screening, 14,840 articles were excluded.  A total of 338  
citations proceeded to full text screening.  After the final eligibility screening a total of 56 studies 
were abstracted for data for the three research questions.  Figure 2 details the number of eligible 
studies for each research question.  The results of the systematic review are presented in this 
chapter according to the three main areas of investigation: accuracy, family history collection, 
and risk stratification.  
 




Title and Abstract Screening 
n=15,390 
 








Not an included publication year................1 
Not an included population.........................3 
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Question 1: What is the Evidence That Patients or Members 




We undertook a broad approach to identifying studies evaluating accuracy of reporting 
family history.  We did not limit studies to those presenting specific diagnostic accuracy metrics 
and included studies whose primary aim was to ascertain repeatability (variation observed when 
conditions are kept constant by using the same instrument and individual and repeating within a 
short time interval).  
Studies Reviewed 
 
A total of 20 publications evaluated the accuracy of reporting family history and were 
eligible for data extraction.  One study was based on two publications10,11 leaving a total of 19 
unique studies.  Study and patient characteristics (such as study design, setting recruited, cancer 
type, relatives evaluated and criterion standard evaluated) are detailed in Appendix C* evidence 
tables.   
We further classified studies by the type of accuracy that was evaluated as follows: 1) those 
studies (16 studies in 17 publications) which evaluated accuracy of family history reporting by 
attempting to verify the cancer status of relatives (i.e., accuracy compared with a gold standard), 
and 2) those (three) which evaluated the repeatability or reliability of the informant’s knowledge 
of family history rather than the true status of the relatives (i.e., no external gold standard).  
For the purposes of this review we use the terms “affected” and “unaffected” to refer to those 
relatives who have had cancer, and those who have not, respectively.  We present the results for 
accuracy according to these groupings, and with regard to specific participant characteristics, 
type of accuracy evaluated (gold standard or reliability), method of verification, and potential 
predictors or confounders of accuracy of reporting family history (Figure 3).   
In general we can summarize the accuracy studies as predominantly having recruited 
participants who had cancer.  Within the 19 studies (20 publications), there were three that 
recruited an entire sample of patients who were free of cancer; two studies involving individuals 
at high risk for colorectal7 or breast cancer,8 and one involving women undergoing 
mammography.9 In the four case control studies (five publications),10-14 the controls were derived 
from the general population matched for age,10,11 spouses of the informants or regional general 
practice lists,14 and from a linkage from license registration and health care administration 
database.13 
All studies were classified as case series except four which were case control studies.  
Several important factors restrict comparisons across accuracy studies, such as the cancer 
diagnosis of the informants and the cancer information collected about the relatives.  There were 
more studies evaluating informants with breast cancer than other types of cancers; there was a 
single study evaluating ovarian cancer syndromes within the informants. Some studies probed 
only specific cancers within relatives while others reported on all cancers within their family  
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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Figure 3:  Flow of accuracy studies 
 
 
histories. While there were only three studies with fewer than 100 informants, the number of 
relatives reported varied greatly between studies. 
 
Studies Evaluating the Accuracy of Reporting by Verifying no Presence or Absence of 
Cancer in Relatives.  Sixteen studies7,8,10-17,19-24 evaluated the accuracy of family history reports 
by attempting to confirm the true cancer status of the relatives about whom informants provided 
information.  Eight studies 13,14,19-24 verified the cancer status in relatives reported to be affected 
and those reported to be unaffected.  The other eight studies (nine publications)7,8,10-12,15-18 only 
confirmed the cancer status of relatives reported to be affected.  We considered the former 
studies to be of higher methodological rigor and therefore evaluated these two groups of studies 
separately. 
Studies With Verification in Both Affected and Unaffected Relatives.  Table 2 shows the 
eight studies that verified the cancer status both of relatives reported to be affected and 
unaffected.  Three were case control studies13,14,19 that recruited participants with colon or 
colorectal cancer.  The remaining five studies evaluated breast cancer patients and a single study 
evaluated patients with breast, ovarian or colorectal.24  A single study22 evaluated the accuracy of 
relatives’ perception of “awareness of cancer” rather than informants’ accuracy in reporting 
family members with cancer.  Three studies13,14,23 recorded the informant’s recollection of any 
type of cancer in relatives, and the remaining studies examined reporting of relatives’ colorectal 
cancer,19,22 breast cancer,20 breast or ovarian cancer,21 or one syndromic group of cancers24 
(breast, ovarian or colorectal).  In general, family history informant characteristics such as mean 
age, ethnicity, or education were poorly reported (Table 2).  Similarly, characteristics of the 
relatives were also poorly reported within these studies.  
The methods of family history collection varied with face-to-face interviews in two 
studies,13,14 mailed survey in four studies,19,21-23 and two with telephone interviews.20,24  The 
methods of verification of relatives’ cancer status varied between studies; also, within some 
studies different methods were used for checking the status of relatives reported to be affected 
and those reported to be unaffected.  The methods used were: (1) personal interview (reportedly 
affected) and cancer registry; (reportedly unaffected23) (2) face-to-face interview, survey, and 
death registry;24 (3) self report from mail-in survey of relatives;22 (4) relatives’ medical chart 
records and survey; (type not specified)19 (5) cancer registry alone;13,14,20 and (6) combined 
strategy (medical record or cancer registry or death certificate).21 
Accuracy related studies 
n=19 
(20 publications) 
 Status of relatives verified 
Both               n=8 
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Table 3 shows the sensitivities and specificities in studies that evaluated the status of both 
reportedly affected and reportedly unaffected relatives, where sufficient data were presented to 
compute these.  One study22 was excluded from Table 3 as it evaluated accuracy only in terms of 
“awareness” of parent or sibling’s colorectal cancer.  The sensitivity varied by the cancer of 
interest; for ascertainment of relatives with breast cancer, the range was 85 to 95 percent based 
on three studies; for colon cancer, 57 to 65 percent (studies using personal interview) and 86 to 
90 percent (studies using telephone interview and self report) based on four studies; for ovarian 
cancer, 67 to 83 percent based on two studies; and for prostate cancer, 69 to 79 percent based on 
two studies.  It is not clear to what extent the verification method of cancer registry versus 
medical records/death certificates contributed to the ranges observed within a cancer type and 
between the different cancer types.  Similarly, it is difficult to establish how the various methods 
of collecting family history may have influenced the estimates of sensitivity.  
In general, specificity across all cancer types and with varying modes of collection was 
consistently high, (Table 3).  For ascertainment of relatives with breast cancer, the specificities 
were 95 to 98 percent; for colon cancer, 91 to 92 percent; for ovarian cancer, 96 to 99 percent; 
and for prostate cancer, 93 to 99 percent.
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Table 3. Accuracy for studies evaluating patients who report cancer in first degree relatives in studies that verified the status of both affected and 
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Table 3. Accuracy for studies evaluating patients who report cancer in first degree relatives in studies that verified the status of both affected and 
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There were three case control studies that therefore allowed for comparison of reporting 
accuracy between cases and controls.  They all involved cases who were patients with colorectal 
cancer, and controls who did not have cancer.  The first study19 suggested that cases were 
slightly more accurate than controls (82 percent vs. 76 percent) in reporting history of colorectal 
cancer in relatives.  The second14 indicated a sensitivity of 57 percent (95 percent CI 43-69) in 
cases compared with 53 percent (95 percent CI 31-74) in controls in reporting relatives with 
colorectal cancer.  Within this study, the corresponding specificities were 99 percent (95 percent 
CI 98-99) in both cases and controls.  The third study13 compared cases and controls with respect 
to accuracy of reporting several cancer types in their relatives: (1) sensitivity of reporting 
relatives’ breast cancer – cases 85 percent (95 percent CI 55-98), controls 82 percent (CI NR); 
(2) sensitivity of reporting relatives’ colorectal cancer – cases 65 percent (95 percent CI, 38-86), 
controls 81 percent (CI NR); (3) sensitivity of reporting relatives’ ovarian cancer – cases 67 
percent (95 percent CI, 9-99),  controls 50 percent (CI NR); and (4) sensitivity for reporting 
relatives’ prostate cancer – cases 69 percent (95 percent CI, 41-89), controls 70 percent (CI NR).  
The corresponding specificities were:  1) relatives’ breast cancer status - cases 98 percent, 
controls 91 percent; 2) relatives’ colorectal cancer status – cases 91 percent, controls 94 percent; 
3) relatives’ ovarian cancer status – cases 96 percent, controls 98 percent; and 4) relatives’ 
prostate cancer status – cases 93 percent, controls 94 percent.  Taken together, these data suggest 
broadly similar specificities across the reporting of cancer types and between cases and controls 
– i.e., generally, the participants with and without cancer themselves were fairly good at 
correctly identifying relatives without a history of cancer, irrespective of the specific cancer 
family history being enquired about.  In contrast, the sensitivities were generally lower, meaning 
that informants appeared to miss some cancers in affected relatives; the highest sensitivities were 
seen for reporting relatives’ history of breast cancer.  The results also suggested some differences 
in sensitivities of reporting between cases and controls – controls being more likely than cases to 
miss colorectal and ovarian cancers in relatives.  In addition, the data from this study would 
suggest differences in sensitivities such that controls are more accurate for colorectal cancer but 
less accurate for ovarian cancers.  In contrast, the specificities were similar for the cancers 
evaluated, suggesting no difference between cases and controls with respect to their accuracy in 
identifying who of their relatives does not have specific cancers.  These observations are based 
on a single study and therefore should be interpreted cautiously. 
Studies With Verification in the Affected Relatives Only.  Table 4 shows the eight studies 
(nine publications)7,8,10-12,15-18 that verified the cancer status only of relatives reported to be 
affected by cancer.  A single study (two publications) was a case control design10,11 and the 
remaining were case series.  Two studies involved participants who did not have cancer but who 
were at high risk for breast8 or colorectal cancer.7  Two studies15,17 involved patients who had 
prostate cancer, and one study involved colorectal cancer patients;16 one study combined Li-
Fraumeni Syndrome (LFS) and Hereditary Breast-Ovarian Syndrome (HBOCS)12 (both women 
at genetic high risk and some with cancer) and one study (two papers)10,11 involved women with 
breast cancer.  A single study involved a range of participants with and without cancer.18 
Five studies7,12,16-18 assessed the informant’s ability to report any cancer within relatives, and 
the remaining studies appeared to assess reporting of relative’s breast cancer 8,10,11 or prostate 
cancer15 history.  In general, informant characteristics such as mean age, ethnicity, or education 
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The methods of family history collection varied with face-to-face interviews used in three 
studies (four papers),10,11,15,16 telephone interviews in one study,7 interview with mode not 
reported in one study,17survey completed in the clinic in one study,8 and mailed survey in two 
studies.12,18  The methods of verification of the relatives actual cancer status included:  
(1) personal or telephone interview with relatives and medical records,8 (2) relatives’ medical 
chart records alone,10,11,15,17,18 and (3) a combined strategy (medical record or cancer registry or 
death certificate).7,12,16 
     From five studies7,12,16-18 that reported on the informant’s ability to report any cancer within 
relatives, only two studies provided information on the percent agreement as a function of the 
cancer reported.  One study18 indicated that breast and colorectal cancers had 93 percent and 89 
percent agreement and lower rates of agreement for other cancers (42 percent for extra-colorectal 
alimentary tract and 37 percent uterine cancer).  Another study17 showed similar results with 
higher percent agreements for breast, colon, and prostate cancer (95, 92, and 86 percent 
respectively) in patients with prostate cancer.  One study 12 who evaluated subjects with LFS and 
HBOCS found differences in the accuracy of reporting, with 85 percent agreement and 92 
percent agreement with the reported cancers within their relatives. 
     Two studies reported on the accuracy of breast cancer within relatives and the percent 
agreement varied from 89 percent in one study8 (with greater accuracy in living relatives with 
unilateral disease 94 percent) to a sensitivity of 90 percent (CI 95 percent 81-96) in a second 
study.10,11  The specificity for this latter study10,11 was estimated at 3 percent suggesting errors in 
reporting of unaffected relatives.  One study15 reported 90 percent agreement for relatives with 
prostate cancer.  Another study16 reported on the accuracy of colorectal cancer in relatives, with 
a sensitivity of 61 percent (CI 95 percent 36 – 83) and a specificity of 96 percent (CI 95 percent 
88-99).  Although, the magnitude of the agreements are generally high for reporting on some 
cancers, caution should be used when interpreting the results from studies that evaluate accuracy 
by confirming the status of the affected relatives only, as these contain errors and bias.  
Other Factors That May Affect Reporting Accuracy.  A variety of factors which could 
potentially influence accuracy of family history reporting were considered in some studies.  
Table 5 shows the factors that have been evaluated within some of these studies and, indirectly, 
the degree of evidence for each of these.  We examined 15 characteristics, although some were 
only evaluated in a small number of studies.  Those characteristics infrequently evaluated were: 
(1) type of first degree relative (1DR), (2) vital status of the relative, (3) number of relatives,  
(4) cancer history of interest, (5) cancer type of the informant, (6) race of the informant, (7) 
marital status, (8) laterality within breast cancer, (9) population versus clinic setting recruitment, 
(10) health insurance status, and (11) gender or age of diagnosis of the relative.  It is difficult to 
generalize for these factors from this heterogeneous series of studies evaluating informants with 
different cancers and reporting on different cancers within their relatives.  Moreover, some of the 
studies did not actually statistically evaluate differences between the factors of interest; thus, 
these findings should be regarded as indicating attributes that could be further evaluated in the 
future research.  
Eight studies (nine publications)8,10,11,13-15,18,19,24 evaluated the effect of age of the informant 
on accuracy; no clear trend was observed, and it was not possible to separate any effect of 
informant age from the possible effects of their own cancer type, gender, or differences in how 
age was categorized. 
 
  
Table 5.  Factors that can influence accuracy of reporting cancer family history 
Factors Main Findings 
Infrequently evaluated factors  
Type of 1DR 
(n=2) 
 
1) Anton-Culver 199620: Slightly lower sensitivity identifying breast cancer for sisters than mothers when evaluating 
individuals versus families in informants with breast cancer. 
2) King 200217: Most accurate for identifying any cancer within brothers, then mothers; accuracy was lowest for fathers and 
sisters in informants with prostate cancer. 
Deceased versus 
living relative  
(n=1) 
1) Breuer 19938: In informants who were free but high risk for breast cancer, reporting accuracy for laterality was better for 
living than deceased relatives (higher percent) with breast cancer.  
Number of relatives 
within a family of the 
Informant 
(n=1) 
1) Breuer 19938: In informants who were free but high risk for breast cancer, there was no statistical difference as a function 
of the number of affected relatives (p=0.6) with respect to accuracy of reporting laterality of breast cancer. 
Cancer type/site in 
relative as identified 
by the Informant 
(n=3) 
 
1) King 200217: In prostate cancer informants, the greatest inaccuracies occurred with reporting of bone, liver, and uterus 
was the most inaccurate.  
2) Mitchell 2004 14: In informants with and without colorectal cancer, accuracy was greatest for breast and colorectal and 
least accurate for bronchus, lung, and stomach. 
3) Ziogas 200324: In informants with cancer (breast, ovarian, or colorectal) the negative predictive values and the probability 
of not having cancer did not differ as a function of the type of cancer in the relative. This was not the case for the positive 
predictive value and probability of having cancer, where the type of cancer did affect accuracy. 
Type of cancer within 
the Informant 
(n=1) 
1) Schneider 200412: Age at diagnosis was less accurately reported than cancer sites by LFS relative to HBOCS. Overall, 
those with HBOCS cancer, were shown to be more accurate in reporting than those with LFS in a multivariate analysis 
(OR=3.3 p<0.01). 





Table 5. Factors that can influence accuracy of reporting cancer family history (continued) 
Factors Main findings 
Race of the 
Informant 
(n=2) 
1) Kupfer 20067: In cancer free but high risk patients for colorectal cancer, Blacks were more likely to lack knowledge 
compared to Whites with regards to paternal family history (p<0.05). However, there were no differences with accuracy of 
maternal history (p<0.9).  
2) Ziogas 200324: White informants with cancer (breast, colorectal or ovarian) were more accurate for all cancer sites but 
not statistically significant for false positive rates relative to other races. 
Marital Status 
(n=2) 
1) Aitken 199519: In informants with and without colorectal cancer, marital status had no effect on accuracy or reporting 
colorectal cancers in relatives. 
2) Gaff 200415: In men with prostate cancer, the relationship status (yes or no relationship) made no difference (p=0.32) 
to reporting prostate cancer within the relatives. 
Reporting of laterality 
in Breast cancer 
(n=2)  
1) Breuer 19938: In informants who are free but at high risk for breast cancer, women reported more accurately relatives 
with single rather than bilateral cancer (statistically significant, p<0.0005); this was likely confounded by the status of 
living versus dead relatives. That is unilateral living relatives showed best accuracy and bilateral deceased showed worst 
for percent correct. 
2) Theis 199423: Informants with breast cancer were more accurate in reporting laterality for first degree than second 
degree relatives; however, the authors noted that some medical records did not actually provide information on laterality. 




Ziogas 200324: Although majority of sample with cancer (either breast, ovarian, or colorectal) was population based, they 
showed that clinic based informants were more accurate (less false negatives) than population based sample when 




Aitken 199519: In informants with and without colorectal cancer, there was higher accuracy for those with private 
insurance (p=0.01).  
Attributes of the 
Relatives  
(n=1) 
Ziogas 200324: In informants with cancer (breast, ovarian, or colorectal) the gender of the relative or age of diagnosis of 
the relative were not significant predictors of accuracy; the exception was for prostate cancer where younger age (60-69) 
of relative did affect accuracy. 
More frequently evaluated factors  
Age of the Informant 
(n=8) 
1) Aitken 199519: In informants with and without colorectal cancer, accuracy increased with age (p=0.03) 
2) Kerber 199713: In informants with and without colon cancer, younger subjects (<66) generally reported family histories 
of cancer with greater accuracy than older (>67) patients with the exception of female reproductive tact cancers. 
3) Mitchell 200414: In informants with and without colon cancer, no differences in accuracy were found due to age. 
4) Sijmons 200018: Age did not affect accuracy of reporting both organ and type of disease. 
5) Breuer 19938: In informants without but at high risk for breast cancer, older women were shown to be more accurate 
reporting laterality. 
6) Parent 1995, 199710,11: Age of the informant with and without breast cancer had no effect on the accuracy of the age 
of diagnosis of the relative (no differences between cases and controls with regards to accuracy +/- 5 yrs); similarly, age 
was not a factor with the exception of informant over the age of 70, who made more mistakes than those younger. 
7) Gaff 200415: Men with prostate cancer and younger than 55 years were more accurate (OR=4.0 (95% CI 1.1-8.1, 




Table 5. Factors that can influence accuracy of reporting cancer family history (continued) 
Factors Main findings 
8) Ziogas 200324: Younger informants were more likely to have lower false negative rates, particularly for breast 
(p=0.0008), colon (p=0.027) and prostate (p=0.02). 
1DRs versus 2DRs 
or 3DRs 
(n=6) 
1) Gaff 200415: Informants with prostate cancer were more accurate reporting prostate cancer in 1DRs (OR 4.0 (95% CI 
1.2-10.7, p < 0.0006) and more complete in their reporting (OR = 12.7 (95% CI 6.0-27.1, p< 0.001) compared to reporting 
for 2DRs or 3DRs). 
2) Mitchell 200414: Better sensitivity to detecting any cancer for 1DRs of informants with colorectal cancer; however, there 
were fewer 2DRs identified overall. 
3) Schneider 200412: Multivariate analysis showed more accurate for reporting any cancer within 1DRs (OR = 0.2, p < 
0.01) in informants with LFS or HBOCS.  
4) Theis 199423:  The reporting of the age of diagnosis for any cancer within relatives was more accurate for 1DRs than 
2DRs in informants with breast cancer; this improved if age categories were dichotomized to above or below 50 yrs. 
Informants with breast cancer were more accurate for laterality for 1DRs than 2DRs. The authors did note that it was 
more difficult to obtain records for 2DRs overall. 
5) Ziogas 200324: Informants with cancer (breast, ovarian or colorectal) showed better positive predictive, negative 
predictive and % agreement was for 1DRs versus 2DRs. Conversely, there was greater risk of over-reporting in 1DRs 
rather than 2DRs.  
6) Sijmons 200018: The degree of kinship (closer relatives) improved the accuracy of reporting accuracy of age at 
diagnosis.  
 
Gender of the 
Informant 
(n=6)  
1) Aitken 199519: Informants with or without colorectal cancer showed no statistically significant differences with regards 
to gender. 
2) Mitchell 200414 Informants with and without colorectal cancer showed no difference in accuracy due to gender. 
3) Kerber 199713: In informants with or without colorectal cancer there was some evidence that women reported more 
accurately for ovarian cancer, but not much difference for other types of cancers. 
4) Kupfer 20067: Men who are free of colorectal cancer (but at high risk) were more likely to lack knowledge of family 
history relative to women. Of those that lacked family history, men were more likely to lack paternal history compared to 
women (p<0.01). No difference in the maternal family history between men and women. 
5) Ziogas 200324 Male informants with cancer (type not specified) were more likely to over-report cases that were not true 
for all cancers compared to females. 
6) Sijmons 200018: There was no evidence that gender affected accuracy of reporting organ and type of cancer. 
Education Level of 
the Informant 
(n=5) 
1) Aitken 199519: Informants with or without colorectal cancer showed no statistically significant differences with regards 
to education level. 
2) Gaff 200415: Education level not significant for accuracy or completeness in informants with prostate cancer. 
3) Kerber 199713: Education level had no influence on sensitivities or level of agreement in informants with or without 
colorectal cancer; however, those with college education were more likely to report breast and prostate cancer more 
accurately. 
4) Parent 1995, 99710,11: Women with or without breast cancer showed no difference in accuracy due to education level. 




Six studies7,13,14,18,19,24 evaluated the effect of the informant’s gender on accuracy, and 
suggested no general effect.  One study13 suggested that women might be more accurate in 
correctly identifying relatives who had ovarian cancer.  Another7 suggested that there were 
gender differences in knowledge of paternal versus maternal family history.  A third24 suggested 
that men may over-report cancers compared to women.   
Six studies12,14,15,18,23,24 evaluated whether accuracy varied with the degree of relative whose 
status was being reported; there was a consistent trend towards increased accuracy of reporting 
for 1DRs compared to second degree relatives (2DR) or third degree relatives (3DRs) (Table 5).  
Several studies14,23 noted challenges in confirming the true status of  2DRs and also that fewer 
2DR and 3DRs were identified overall, suggesting the potential for reporting and confirmation 
biases.  
Five studies (six publications)10-13,15,19 evaluated the effect of education level using a variety 
of categorizations; all but one study12 showed an effect on accuracy of reporting. 
 
Quality Assessment of Studies  
 
We evaluated quality of the accuracy studies at several different levels.  At one level, we 
considered that the method by which the cancer status of the relatives was evaluated was of great 
importance in determining accuracy of reporting.  At another level, we applied traditional 
internal validity criteria for study designs that included a comparison group or were considered 
diagnostic in their design.  Since so few of the studies were of traditional study design with 
control groups, the majority of standardized assessment scales could therefore only be applied to 
a subset of papers.  If we considered all the studies as “diagnostic” in their design, the QUADAS 
(a quality assessment scale for diagnostic studies) could be applied to most studies.  However, 
not all 14 criteria (or biases) applied to the “diagnostic test” of “family history collection” were 
relevant in the context of accuracy of reporting; we selected three criteria from the QUADAS to 
compare the different studies.  
Methodological Issues in the Verification of the Cancer Status of the Relatives.  For 
accuracy of family history reporting, we considered verification of the status of both the affected 
and unaffected relatives to be of the highest quality.  Studies that verified the status of the 
affected relatives only were considered to be of lesser quality or more susceptible to bias with 
respect to accuracy of reporting.  
A number of difficulties were identified by authors with regards to ascertaining the cancer 
status of the relatives.  The range of estimates of difficulties in obtaining some type of 
confirmation varied from 31 percent19 to 9 percent.21  Some of the difficulties with verification of 
cancer status of the relative included: (1) errors in medical records or pathology reports,8,21 (2) 
death of relative prior to registry formation or other form of record keeping,21 (3) relative 
emigrated to another geographic region, for which medical records were not available to the 
researchers,8,21 (4) informants provided incorrect address or contact information for hospitals 
where relatives were treated,8 (5) retrieval of death certificate information was impossible due to 
peculiar national laws affecting access by researchers or it was certain the files had been 
destroyed,18 (6) some difficulty obtaining medical records of fathers compared to brothers, 
mothers, and sisters,17 (7) reports concerned relatives for a branch of the family not of interest to 
the genetic investigation,18 (8) the reported cases were late onset common type tumors in distant 
relatives not likely of interest in the referral,18 and (9) informants were not in touch with the 
relatives concerned, so consent could not be obtained.18  Some studies found it difficult to obtain 
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medical records of deceased relatives when recruitment of relatives for consent depended upon 
the informants contact.9  There was some suggestion that verification rates were lower among 
negative relatives19 as these tended to have less physician visits.  Studies undertaken in countries 
with longstanding national cancer and death registries linked with service provision databases, 
tended to report very high rates of retrieval (97-98 percent) of verification of diagnoses on 
relatives.16  
Although there were a variety of possible factors that impeded verification of the cancer 
status of the relative, not all studies excluded from the analysis those informants or relatives for 
which there were some difficulties in complete confirmation.  Note that many studies did not  
compare the characteristics of the informants who did not wish to contact relatives for their 
medical records relative to those that did; similarly, comparisons between those relatives that 
provided consent to medical records and those that did not were not consistently undertaken.  
QUADAS Assessment of Methodological Quality for Diagnostic Studies.  We applied the 
QUADAS to those studies that verified the status within their relatives.  The QUADAS, a 14 
item quality assessment scale for diagnostic studies, was used to evaluate all studies eligible for 
accuracy of reporting.  From these items, three were considered to be of greatest relevance to 
identifying potential biases within these studies that considered the collection of family history 
as the “diagnostic test” of interest and the method of verification as the “reference test”.  The 
first challenge was to assume that the “diagnostic test” was the same method of family history 
collection, in order to compare ratings across studies; clearly, the tools or methods used to collect 
family history varied significantly amongst studies.  The second assumption, we made was that 
the reference standards specified within each study were equivalent across studies; that is that 
cancer registry verification and death certificate verification were equivalent.  
Three items from the QUADAS were selected to evaluate spectrum bias, verification bias 
(both differential and partial), and blinding of those who verified the cancer status of the 
relatives. If present within the studies, each of these biases will result in overestimation of 
accuracy.  
Spectrum Bias.  The first question within the QUADAS asks: Was the spectrum of patients’ 
representative of the patients who will receive the test in practice?  Theoretically, being asked to 
take the “test” of cancer family history collection may be received by any person (with or 
without cancer) in clinical practice.  Thus, it was challenging to define which informants are not 
“typical” of those likely to be tested in practice.  
We would indicate the presence of spectrum bias, when the study population did not reflect 
the spectrum of informants likely to be seen within the clinical setting.  For example, patients 
recruited due to their high risk for familial cancer syndromes would not reflect the spectrum of 
patients who would report cancer “family history”, albeit they are an important group to 
evaluate.  Similarly, in those studies with informants with cancer of differing severity or who 
were differentially assigned to study groups, the likelihood of spectrum bias is evaluated as high.    
We considered a sufficient spectrum of disease should include participants who reflect a 
complete range of staging (severity) of their cancer if the informant had cancer when the family 
history was collected.  Additionally we believe that an adequate spectrum should reflect 
informants that included both genders in those studies that did not affect sex-specific organs, 
such as ovaries or prostate. 
When considering the eight studies that verified the status of both the affected and unaffected 
relatives, the potential for spectrum bias was evident.  In general, these studies did not report 
information on the informants with respect to the severity of disease.  One case control study13 
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specified that the cases were “first primary cases” while the others of the same study design did 
not specify; however, there is still potential for spectrum bias in these studies.  One of the studies 
evaluating breast cancer informants included women of restricted age (< 40 yrs), one third of 
subjects with bilateral breast cancer, referred to university hospital oncology centre.21  Another23 
included informants that were English speaking, North American born, without brain metastases 
and had a least one 1DR with breast cancer.  Both these studies, although they reflect patients 
likely to be seen in cancer clinics, do not represent the spectrum of breast cancer patients and 
therefore these studies have spectrum bias.  
When considering those studies that evaluated the status of the affected relatives alone, the 
potential for spectrum bias was also evident.  Two studies7,8 recruited cancer free informants 
who were at very high risk for familial cancers due to a history of 1DRs already diagnosed with 
the cancer of interest.  For the remaining studies, the severity of cancer within the informants 
was not detailed.  This suggests the potential for spectrum bias. 
Verification Bias.  The fifth question within the QUADAS asks: Did the whole sample or a 
random selection of the sample, receive verification using a reference standard?  Partial 
verification bias occurs when not all members of the study group receive confirmation of the 
diagnosis by the reference standard.  Similarly, differential verification bias can occur if a 
subgroup of patients is given a different reference standard test.  Partial verification bias can 
occur if some of the relatives identified by the informant did not have their cancer status verified. 
Even in studies where both affected and unaffected relatives were evaluated, we did observe that 
some studies were not able to verify the status of some of the relatives for many of the reasons 
stated above.  One study,19 (which employed very rigorous ascertainment methods of reportedly 
affected relatives, even sending notes to hospitals overseas for determining the status of deceased 
relatives), indicated that they did not attempt to check the medical record of all relatives who 
were cancer free (the overwhelming majority).  Other studies7,13,19,20,22 limited their evaluation or 
reporting to 1DR only; this in itself may reflect a type of differential verification bias in that not 
all relatives reported by the informants were verified.  In those studies that evaluated only the 
affected relatives, clearly partial verification bias was present.  The presence of partial or 
differential biases may lead to overestimation of accuracy.106 
Blinding of Those Verifying Cancer Status in Relatives to the Status of the Informant. 
The eleventh question of the QUADAS states: Were the reference standard results interpreted 
without knowledge of the results of the index test?  In the context of family history collection, 
our interest was in having those who verified the status of the relatives blinded to the cancer 
status of the relative and possibly the informant.  It is possible that the research assistant 
extracting the cancer status of the relative, having knowledge of their cancer status, might 
interpret information (for example, from medical charts) differently than if they were not aware 
of the cancer status of the relative.  Problems with lack of blinding may be less likely to occur in 
studies that use linkages with cancer or hospital registries; presumably the criteria for 
verification are not dependent on interpretation by a research assistant.  However, there are errors 
associated with linking databases. 
Of the eight studies that evaluated the status of both affected and unaffected relatives, 
three13,14,20 relied solely on linkages with cancer or population health registries, and one7 on 
patient report or health records alone; the remaining four studies used a combination of 
interview, health records and death registries.  For those studies that evaluated the affected 
relatives alone, a single study18 used computerized linkage alone with patient records to ascertain 
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the status of the relative.  Overall, blinding of the status of the relative or the informant was not 
undertaken in the majority of studies. 
Methodological Quality Assessment for Case Control Studies.  We applied traditional 
internal validity criteria to the four case control studies (five publications),10,11,13,14,19 using the 
Down’s and Black standardized quality assessment scale.105  One study19originated as a case 
control study but undertook a sample from the original to perform a validation study on accuracy 
of reporting; informants were selected on the basis of having relatives with cancer rather than 
their cancer status.  We did not evaluate the quality of this study using the Down’s and Black 
scale.  The range of composite quality scores varied between 14 and 17 (from a possible score of 
23), indicating a moderate level of quality for the three case control studies.  One of the main 
methodological flaws was the omission of descriptions of the distribution of principal 
confounders in two of the studies (three publications).10,11,13  In addition, only one study13 
enrolled subjects who appeared to be representative of the general population from which they 
were recruited and only one study (two publications)10,11 indicated that cases and controls were 
recruited over the same time period.  It was impossible to tell, based on the information 
contained in the studies, whether cases and controls were recruited from the same source 
population.  There was insufficient information in all four studies to assess blinding, but all 
studies had reports of losses to follow up.  The authors of one study12 adjusted for potential 
confounders in the analysis. 
The potential for selection or information bias in these four case control studies is difficult to 
assess.  The lack of reporting on recruitment and blinding does not necessarily mean that the 
authors ignored these issues.  It is possible that all subjects were recruited from the same source 
population and all subjects and investigators were blinded.  The authors may simply not have 
reported this information in the published manuscripts.  
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Abbreviations: Ca=Cases; Co=controls; 1DR=first degree relative; 2DR=second degree relative; F to F=Face to face; LFS=Li-Fraumeni Syndrome; HBOCS=hereditary breast-
ovarian cancer syndrome; NR=not reported; OR=odds ratio 
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Question 2: Improvement of Family History Collection by 
Primary Care Professionals Through the Use  




A total of 39 different tools, implemented in 40 unique studies, and reported in 45 
publications passed full text criteria.  Our initial focus was on identifying studies that described 
FHxTs developed or used in a primary care setting; however, after careful review, we noted that 
many studies described tools used in other settings that appeared potentially relevant to primary 
care (criteria for “primary care applicability” is outlined in Chapter 2).  We also sent email 
queries to all authors of eligible studies that did not provide sufficient detail of the FHxT or a 
copy of the tool.  Fifteen authors (of 16 publications) 8,10,11,16,17,21,23,25-33 did not respond in time 
for the publication of this review and therefore we were unable to determine whether the 
reported FHxT was applicable for use within primary care.  For those studies for which we 
evaluated the FHxT, six tools from seven publications13,18-20,24,34,35 were assessed as 
inappropriate for primary care; all of these had been developed and used in research settings.  
The scoring system and scoring of actual FHxTs is displayed in Appendix B.*  Of the remaining 
22 publications, four 36-39 described the prototype and final versions of the same FHxT 
(RAGS/GRAIDS), which we counted as a single tool; and two40,41 were companion publications.  
Thus, 18 distinct tools, from 22 publications, were identified as being applicable to primary care 
settings (Figure 4).  Full study details are summarized in the evidence table (Appendix C,*  
Table 2). 
 
Figure 4.  Flow of accuracy studies 
 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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Description of Tools  
 
Target User.  Fourteen tools42-55 were designed for completion by patients, and four tools 
(eight publications)36-41,56,57 were designed for use by health professionals.   
Format.  Eleven tools43,45-49,51-55 were paper-based, generally in some form of questionnaire 
or structured questions.  Four tools (eight publications)36-41,44,50 were presented in a form for use 
on a desktop or laptop computer, including web-based and touch screen applications, and one on 
a personal digital assistant.57  One tool42 was an automatic telephone interview, and one was a 
structured interview schedule.56    
Cancer Type.  Fifteen tools, reported in nineteen articles,36-43,45-50,52,53,55-57 were designed to 
collect data on family history of breast or breast/ovarian cancer.  Nine tools (ten publications) 40-
42,46-50,52,57  captured data on colorectal cancer and two40,41 tools (three publications)40-42 on 
prostate cancer.  Five tools (six papers)36,37,42,47,48,57 also captured data on one or more additional 
cancer types.  For two,51,54 the tool appeared to invite information on any cancer type.  
Clinical Setting.  Four tools (seven publications)36-39,48,49,56 described tools which were 
implemented in family practice settings, and four tools46,52,54,57 in internal medicine clinics.  One 
tool47 was implemented in a gastrointestinal clinic, and another45 in a screening mammography 
setting.  Three tools46,54,55 were designed for use in cancer centers or clinics and three42-44 were 
implemented in genetic clinics.  One tool (two publications)40,41 was web-based and designed for 
use by any health professional, and the remaining tool53 was used in a large population-based 
research study.  The published reports indicated that eight of the tools were used in a proactive 
way,46,48,49,51,52,54,55,57 eight (12 papers) in a reactive manner,36,38-41,43-45,47,53,56 and two in a mixed 
approach.42,50 
Links to Risk Assessment Tools.  The output of five tools (nine publications)36-41,44,45,57 was 
linked directly to some form of defined risk assessment tool (RAT) (i.e., the family history data 
were converted directly into a risk categorization), although several of the publications 
describing other tools also described companion RATs.   
Content of FHxTs.  Fourteen tools36-39,42-45,47-52,54-56 reported in seventeen publications, were 
designed to capture data on all, or selected, 1DRs.  Eleven tools (fourteen papers)36-
39,42,44,45,47,49,50,52,54-56 were designed to capture data on all or some 2DRs, and one49 on 
grandparents only.  Five tools42,44,45,47,50 explicitly went beyond 2DRs, although not necessarily 
to capture all 3DRs.  For the remaining tools, the extent of family history enquiry was not 
explicitly described.  For all tools except five48,51,53,55,57 there were explicit instructions for users 
to capture data on relatives on both sides of the family.  Two tools49,54 were designed to 
explicitly capture ethnicity data.  Further details of the data captured are presented in Summary 
Table 7. 
Other Family History Tools.  Eleven web-based FHxTs were also identified during the grey 
literature search.  Nine tools were actually available from the web, and these are listed with 
relevance scores in Appendix B.*  For all except one, (JamesLink)50 which was included in the 
main review, no information was provided on their development or evaluation, which precluded 
their inclusion in the main review.  The highest scoring of these tools  for applicability to 
primary care were the Family History Tool developed by American Academy of Family 
Practice107 and the U.S. Surgeon General’s Family History Initiative.108
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
 
 
Table 7.  Characteristics of family history tools 
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Braithwaite44 Genetic Risk 
Assessment 
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(GRACE) 
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Abbreviations: 1DR=first degree relative; 2DR=second degree relative; 3DR=third degree relative; EsPeR= Personalized Estimate of Risks; NR=not reported; NS=not specified; 
1Separate companion risk assessment tool (FCAT) described in Q3 results 





Table 7.  Characteristics of family history tools (continued) 
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Table 7.  Characteristics of family history tools (continued) 
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Evaluating the Family History Tools 
 
The tools were evaluated using a range of study designs.  In order to avoid ambiguity in 
terminology, we drew a distinction between the concepts of “comparator” and “control” (or 
“controlled”).  In keeping with the methods described in Chapter 2, we use the term 
“comparator” to refer to the use of a reference method to assess the extent, nature and/or 
accuracy of the family history data captured by the tool in question, the comparators being either 
“ideal”, best estimate interview, or current (“standard”) practice.  We use the term “controlled” 
to indicate a study design where there are at least two arms, one of which is the tool in question 
and the other an alternative method of capturing family history data.  Thus, in a controlled 
design, participants are assigned (randomly or otherwise) to either the “tool” group or the control 
group.  We considered crossover studies, where the order of data capture (tool or comparator 
method) was reversed for some participants, to be controlled studies.  Table 8 describes the 
distribution of studies, in which tools were used, between the four possible categories of study 
design.  We noted that one tool 44 was evaluated in a controlled study, but that no comparator for 
family history data capture was used, and no outcomes were reported which were relevant to the 
tool performance as a method of family history data collection (although outcomes relevant to 
performance as a RAT are presented under Question 3).     
Using this approach, for the purposes of this review, we considered those studies which were 
uncontrolled studies with no comparator as descriptive, and those which either had a comparator 
or were controlled to be evaluative, so long as outcomes were reported which were directly 
relevant to the use of the tool as a method of capturing family history data.  
 
Table 8.  Classification of study types 
  Controlled Not controlled
























Validity and Reliability  
 
Six tools (nine publications) were described as having undergone a development or piloting 
phase36-39,42,45,48,49,51 including one tool (two publications) (Risk Assessment in Genetics, 
RAGS)38,39 which was the prototype for the Genetic Risk Assessment and Decision Support 
(GRAIDS) tool,36,37 and a self-completion tool which was developed from a previously validated 
interview schedule.51  Five studies assessed acceptability and ease of completion of the 
tool.36,37,42-44  Qualitative techniques were also described in studies of four tools, including semi-
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structured interviews with practitioners38,39 and patients,49 and focus groups with 
practitioners.40,41,49  Three studies,42,44,45 reported how long it took to complete the tool, ranging 
from 8 to 30 minutes.  One study42 reported test-retest reliability of 97 percent for 1DR, and 93 
percent for 2DR respectively, and 98 percent for cancers identified. 
Six tools were presented in seven descriptive papers,40,41,48,53-56 without a comparator group 
or control arm.  One study of a family history tool embedded in a RAT44 presented no outcome 
data pertaining specifically to performance in capturing family history data.  
The performance of the 11 remaining tools was assessed in some way against a defined 
comparator.  For five tools,42,43,45,49,51 this was a genetics interview.  For one tool,51 the self-
completion questionnaire was assessed against the parent interview schedule administered by 
non-genetics investigators.  Six tools (eight publications)36-39,47,50,52,57 were compared with 
current practice in some form.  This included the family history as recorded in patient charts, and 
accuracy or completeness of pedigrees derived from simulated patient histories drawn without 




Evaluated Against Genetics Interview.  Acheson and colleagues42 described an automated 
telephone interview tool which was evaluated in a sample of genetics patients.  Pedigrees 
obtained by the tool were blindly compared with those obtained from their clinic interview with 
a genetic counselor.  There was an overlap between the data captured by the tool and the 
interview.  The tool was statistically significantly better than genetics interview at identifying 
2DRs and first cousins, and identified more cancers in 2DR and distant relatives.  When the risk 
stratification based on the tool and interview pedigrees was compared, there was good agreement 
(kappa=0.70) for the breast cancer risk assessment, and moderate agreement for colorectal 
cancers and all cancers combined.  Three families classified as high risk by the tool would be 
classified low risk on the basis of the interview, and one family classified as low risk by the tool 
would be classified high risk by the interview pedigree.  The tool showed high test-retest 
reliability.  
Qureshi and colleagues49 described a paper-based, self-completion family history 
questionnaire, which was compared with a genetics interview conducted by trained researchers.  
On the basis of the family history captured, 24 percent of tool histories, and 36 percent of 
interview pedigrees, suggested possibly elevated disease risk which would warrant further 
investigation.  The interview identified 15 percent more 1DRs, and 51 percent more 2DRs, than 
the tool.  The validity of the risk assessments was not determined by a full genetics assessment, 
so it is not possible to conclude whether the tool was less sensitive or more specific than the 
interview comparator. 
Benjamin and colleagues43 assessed a standard paper-based, mailed, self-completion family 
history questionnaire with a clinical genetics interview, as part of a study whose primary aim was 
to evaluate a companion RAT.  Using the interview as the gold standard, the tool had 95 percent 
sensitivity and 96 percent specificity for family breast cancer risk assessment.  On the basis of 
the tool data alone (before the interview), 51 percent of patients would be assessed as having an 
elevated risk of familial breast cancer; following the genetics interview, this figure was 62 
percent. 
Fisher and colleagues45 assessed a paper-based, patient-completed family history 
questionnaire in a study whose primary aim was to assess its embedded risk categorization 
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scheme.  The participants were women attending for routine breast screening, and the history 
obtained by the tool was confirmed by follow up telephone interview by a genetic counselor.  
The authors report that this was to check that the tool data reflected the women’s current 
knowledge of their family history, not to verify it.  Of 45 women classified at population risk by 
the tool, none were reassigned a higher risk on the basis of the genetics interview.  Of 45 women 
classified at elevated risk, none were reclassified as population risk.  Further validation of the 
risk status of the participants through full genetic assessment was not reported. 
Kelly and colleagues51 describe a paper-based, patient-completed tool which was assessed in 
a sample of cancer patients.  In a study whose primary aim was to explore psychosocial 
outcomes related to accuracy of family history reporting, they compared the questionnaire with 
an interview-based version of the same tool, using a randomized crossover trial design.  The 
authors report around 77 percent concordance for reporting relatives’ age, 81 percent 
concordance for reporting of relatives’ diagnoses, and 82 percent concordance for reporting of 
age of diagnosis.  There were no discrepant data on whether or not a relative had cancer.  The 
order of completion of tools was not associated with differences in these outcomes. 
Evaluated Against Current Practice.  Emery and colleagues describe the development of a 
family history tool and RAT (GRAIDS), the prototype for which was RAGS.36-39  GRAIDS was 
evaluated using a pragmatic cluster randomized controlled trial,36,37 but no outcomes relating to 
performance as a FHxT were specifically reported.  However, data were reported from a 
evaluation of the RAGS prototype,39 in which 36 family physicians used three different methods 
to draw pedigrees and assess the risk of simulated patients.  Pedigrees produced using the RAGS 
tool were statistically significant and more likely to be accurate than those prepared by a genetics 
software package (Cyrillic) or by traditional pen and paper methods (median correct pedigrees, 
5.0/6 for RAGS, 3.5/6 for Cyrillic, 2.0/6 for pen and paper).  Participating physicians also 
preferred RAGS (75 percent) over the other methods (8 percent preferring Cyrillic and 17 
percent preferring pen and paper).      
Frezzo and colleagues46 compared a paper-based, patient-completed family history 
questionnaire with a genetics interview in a quasi-randomized parallel group study.  Of the 39 
internal medicine patients who completed the tool, two were identified at elevated risk of 
breast/ovarian cancer, three at risk of colorectal cancer, and one at risk of prostate cancer.  
Review of these patients’ charts revealed only one patient at elevated risk, of colorectal cancer.  
In the group whose risk was assessed by interview, the corresponding figures are five at risk for 
breast/ovarian, and four at risk of colorectal cancer, on the basis of the interview, compared with 
two and two, respectively, on the basis of chart audit.  No data were presented regarding the 
outcome of eventual genetic risk assessment, if any, of the participants. 
Schroy and colleagues57 developed an educational intervention for internal medicine 
residents and assessed the effect of a software tool designed for use on a personal digital 
assistant.  Patients’ family history relevant to colorectal cancer risk was assessed by a structured 
interview with a research assistant.  Patients’ charts were then audited to assess whether positive 
and negative colorectal cancer family histories were correctly documented.  Of 33 residents to 
whom the software was sent, 29 acknowledged receipt, two acknowledged downloading it, and 
one indicated that they had used it clinically.  Residents supplied with the tool were no more 
likely than control residents to document a positive cancer family history in patients’ charts (41 
percent versus 48 percent), but they were statistically significantly more likely to document a 
negative family history (89 percent versus 48 percent).  The study had low statistical power to 
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detect small to medium effects, and the residents supplied with the tool also received extra 
educational intervention compared with controls. 
Sweet and colleagues50 describe the JamesLink system, which is a touch screen, patient-
completed tool for capturing family history data.  In a study of 362 ambulatory cancer patients, 
data for 165 indicated moderate or high risk status when reviewed by a geneticist; of these, 16 
percent were consistent with a family cancer syndrome.  Of 101 patients in the high risk category 
on the basis of tool data, the chart records suggested family cancer history for 69; seven of the 
latter had received a full genetics assessment.  It was noted that the charts of only 69 percent of 
patients using JamesLink had family history information available.  
Grover and colleagues47 prospectively assessed concordance between family history 
information captured by a paper-based, patient-completed family history questionnaire and then 
subsequently (and independently) recorded in their cancer clinic charts.  They noted discordance 
between data recorded by the two methods.  For 127 (41 percent) of the cases in which there was 
discordant data, 37 charts (29 percent) had reported a negative cancer history, or not documented 
a cancer history, which was captured by the tool.  For 69 patients (54 percent), only some 
cancers captured by the tool were documented in the notes, and in 21 patients (17 percent), the 
tool and the notes were completely discordant.  Charts did not document 32 percent of cancers 
reported by patients in the tool, and a third of notes missed cancers in 1DRs captured by the tool. 
Murff and colleagues52 compared a paper-based, self-completion family history questionnaire 
with the charts of 310 internal medicine patients.  They noted that the tool identified more 1DRs 
and 2DRs with colorectal, breast, or ovarian cancer than the charts and were more likely to 
capture the age of diagnosis for affected relatives, as well as more likely to identify relatives who 
were diagnosed before the age of 50.  For all cancers together, the age of diagnosis was recorded 
in the chart for about 62 percent of affected 1DRs compared with 95 percent of those captured in 
the tool.  The corresponding figures for 2DRs were 27 percent and 76 percent, respectively.  
These differences were highly statistically significant.  Out of 48 patients who were identified as 
being at increased risk, the tool identified 29 who would have been missed by charts alone.   
In summary, compared to genetic interviews as a gold standard, many FHxTs performed 
well.  However, the studies reported here are limited because the genetic interviews were not 
supplemented with confirmation of relatives’ reported medical histories.  Compared with current 
practice, generally the family history documented in patient charts, FHxTs appeared to identify 
more relatives, more relatives with cancer, and more details about these relatives.  In some cases, 
this would lead to reassignment of risk category and altered prevention plans.  Again, validation 
of the “true” status of relatives was not performed. 
 
Quality Assessment of Studies 
 
Quality assessment using standardized checklists was undertaken on seven observational 
studies, five parallel RCTs, and one study51 that was a crossover trial in which cancer patients 
were randomized to the order of either a personal interview or a survey and a second study.  The 
quality scores for the seven observational studies10,11,13,34,46,48,53 ranged from 14 to 21, thereby 
indicating a moderate to high level of quality.  Initial reporting of hypotheses, interventions, 
outcomes, and sample characteristics was transparent and complete.  However, the authors of 
only three of the studies34,46,53 listed important confounders (two adjusted for confounding in the 
analysis46,53) and one author53 reported on blinding.  Reporting of subject recruitment was also 
lacking.  Confirmation that subjects were representative of the entire population from which they 
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were drawn was provided in two studies;11,46 recruitment of cases and controls from the same 
source population was mentioned in three studies.19,48,53   
The five parallel RCTs scored either a 436,44,55 or 539,57 on the extended Jadad quality scale.109  
Major quality issues centered around a failure to describe randomization,44,55 non-reporting of 
blinding,36,39,44,55,57 and non-reporting of withdrawals,44,55 or methods used to assess adverse 
effects.36,39,57 
The absence of information on issues such as recruitment, randomization, and blinding 
suggests potentially biased results.  Since it is not possible to assess whether the absence of 
information is linked to poor methods or poor reporting, the actual impact of any biases cannot 
be ascertained.   
Other Methodological Aspects.  Few studies described a sample size 
calculation.23,36,37,39,42,49  Further, for comparative studies where concealment was necessary in 
qualitative assessment of the FHxT, only a few studies provided evidence that this had been 
performed.43,49   
The participants of most studies would have had a better recall of their family history than 
the general public due to the fact that very few studies used an unselected general 
population.46,48,49,54  Special populations included, for example, respondents with the cancers of 
interest,47,51 or on a cancer registry,25 and patients seen in specialist clinics.42-45,50  Also, the 
sequence of FHxT evaluation against comparator may have affected patient recall.  The FHxT 
was given first followed by the best estimate in six studies.23,43-45,47,49  In one study, interpretation 
would have been affected by the paper family history questionnaire and structured “best 
estimate” interview having identical formats, with both approaches being delivered immediately 
after each other.51  Other study designs affecting interpretation included non-randomized 
allocations46,49,52 and variable response rate to FHxT.  When reported, this varied from 40 
percent49 to 98 percent.47  Non-completion of items accounted for about half the errors in an in-
office self-completed FHxT.45 
 
Research Q3: Risk Assessment Tools 
 
General Approach  
 
For the purposes of this review we followed the definition of RAT as described in Chapter 2.    
Some papers were identified which described tools consistent with this definition but which were 
not developed for use by PCPs, or were evaluated in settings other than primary care.  We 
included some where we considered them to be “potentially applicable to primary care”, in that 
they did not appear to require specialist genetics knowledge to be applied as intended.   
 
Studies Reviewed  
 
Sixteen publications, representing ten distinct tools, were included in this section of the 
review.  Full study details are summarized in evidence tables (Appendix C*), which include 
information on the evidence cited in support of risk stratification and/or recommended clinical 
actions.  Table 9 presents a description of the tools, assessed against the defined tool 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
 
 
Table 9. Assessment of risk assessment tool characteristics  
Characteristics 
Paper Tool User Target Dcision Knowledge Cmponent 






Braithwaite44 Genetic Risk Assessment in the Clinical 
Environment (GRACE) 












epidemiological data,  
risk calculation,  
clinical guidelines 
Emery36-39 Genetic Risk Assessment in an Intranet and 
Decision Support (GRAIDS), and its prototype 
Risk Assessment in Genetics (RAGs) 





risk stratification,  
clinical guidelines 








risk scoring system 




risk stratification criteria, 
benchmark ranges,  
clinical guidelines 
Skinner31 Cancer Risk Intake System (CRIS) patient preventive 
behavior 
clinical guidelines 











risk stratification criteria, 
clinical guidelines 




characteristics.  All tools fulfilled the criterion of timing of use (designed to be used before the 
health professional or patient takes the relevant decision).   
 
Description of Tools  
 
Cancer Type.  Six tools, reported in seven papers,43-45,58-61 were designed to assess risk of 
breast or breast/ovarian cancer only, four tools (seven papers) were designed to assess risk of 
breast/ovarian and colorectal cancer,31,36-39,62,63 and one tool (two papers) focused on 
breast/ovarian, colorectal and prostate cancer.40,41  No tool was identified that focused solely on 
ovarian cancer risk, colorectal cancer risk, or prostate cancer risk. 
 Clinical Purpose of Tool.  All ten tools (16 papers) were designed to, in simple or complex 
ways, stratify individuals into risk categories, and all had a component which indicated some 
form of clinical or personal action.     
Target User.  Three of the tools31,44,45 were designed for use by patients or the general 
population, the remainder having been designed for health professionals.   
Knowledge Component.  Each of the ten tools indicated at least one basis for the knowledge 
component.  These components included:  the Claus model;36-39,43,44  the Gail model;31,40,41 
national recommendations (e.g., French National Agency for Health Evaluation,40,41 the 
Australian National Breast Cancer Centre,45 the U.S. Preventive Services Task Force,58 and the 
Scottish Executive Health Department;62,63  guidelines developed by professional groups (e.g., 
the UK Cancer Family Study Group43,60,61 and the American Medical Association;31,58) and 
guidelines developed by local groups.36,37,58,59  For one tool (four papers),36-39 it was indicated 
that it was designed to facilitate the implementation of appropriate knowledge components in 
general, not any specific guideline or risk calculation program. 
 Implementation Format.  Five of the tools (nine papers)36-41,44,62,63 were presented in a 
computer or web-based format and the other five (six papers)43,45,58-61 were presented in 
document-based format (Table 10).  The five computer-based tools incorporated some form of 
family history data capture with risk calculation and guideline-based recommended actions.31,36-
41,44,62  Of the document-based tools, one was a paper-based form with checklist for each relative 
and an embedded scoring system,59 two were paper questionnaires incorporating suggested 
actions;43,45 one was a pocket laminated card;58 and one was an information pack with a 
laminated card and other components.60,61 
Applicability to Primary Care.  Of the seven tools intended for use by professionals, five 
were developed explicitly for use by PCPs—either family physicians (four tools, 9 papers)36-
39,58,60-63 or physicians working in ambulatory care settings (one tool, two papers).40,41  Two 
appeared to have been developed in settings other than primary care, or without involving 
primary care practitioners, but intended for eventual use in that setting.43,59  One patient tool31 
was developed in a primary care setting, and the other two 44,45 were considered potentially 
applicable to use in primary care settings.  
Evidence of Effectiveness.  Findings related to the development of one distinct tool 
(RAGS/GRAIDS)36-39 is presented across a number of publications.  In general, we report 
findings for this as one distinct tool, but, where appropriate, we present (and clearly indicate) 
separate data relating to the evaluation of the prototype version (RAGS)38,39 and the current 
version (GRAIDS).36,37  For four tools (nine papers)36-39,44,60-63 data were presented relating to 
effectiveness against a defined comparator, in achieving outcomes relevant to supporting 
decisions by users in practice.  One tool31 was evaluated in an uncontrolled before-after study. 
 
 





Study and details 
Patients Computer-based  Braithwaite 200544 
GRACE - Structured family history collection with risk stratification and management advice. 
Skinner 200531 
CRIS – stand-alone, touch screen system, capture of family history and other risk factor data, with 





Structured family history questionnaire with binary risk stratification and advice to see doctor if high risk 
Professionals Computer-based Colombet 200340,41 
EsPeR - web-based, directed clinical and family history questions with risk calculation and individualized 
patient guidelines; also risks of avoidable causes of death according to demographic characteristics and 
printable summaries. 
Emery36-39 
RAGs - computer-based, pedigree drawing, risk calculation, guideline-based recommendations. 
GRAIDS, developed from RAGs - web-based, pedigree drawing, risk calculation, guideline-based risk 
reports and recommendations, patient information.  
Wilson 200662,63 
Computer-based, directed family history questions, guideline-based recommendations, background 





Information pack, laminated card with referral guidelines, booklet with background information, patient 
leaflets.  
Benjamin 200343 
Paper-based, directed family history questions, algorithm, suggested onward management. 
Gramling 200458 
Pocket laminated card, risk stratification criteria, benchmark risk ranges for breast cancer, screening 
recommendations, contact numbers. 
 
Abbreviations:  CRIS=Cancer Risk Intake System; EsPeR=Personalized Estimate of Risks; GRACE=Genetics Risk Assessment in the Clinical Environment; GRAIDS=Genetic 




 Data are reported to the evaluation of four tools (seven papers)31,36,37,60-63 implemented in 
routine practice settings, including the GRAIDS tool, and three studies of two tools38,39,44 where 
evaluations were conducted under “laboratory-type” conditions, including the RAGS prototype 
tool.38,39  Table 11 summarizes the key points of these studies, including the range of outcomes 
measured.  The remaining studies were tool development or descriptive studies, or the outcomes 
presented related to the validity or evidence base underlying the stratification system used rather 
than practice related outcomes. 
 
Quality Assessment of Studies 
 
Standardized quality assessment checklists were employed on the five studies that used 
randomized trial design.  The Jadad scores ranged from 4 to 6.36,39,44,60-63  Major problem areas 
were a failure to report whether the studies were blinded39,44,60,62 and a failure to report numbers 
of withdrawals.44,60,61  
The potential for bias in these studies appears quite low.  Concerns about non-differential 
misclassification are always relevant when there is no blinding, but it is impossible to say 
whether subjects and investigators were not blinded or whether the authors of the manuscripts 
simply omitted mention of blinding in their published articles. 
 
 
Table 11. Summary of evaluative studies 
Study Tool Users Design Comparator Outcomes 
Braithwaite44 “GRACE” 
Computerized family history 
and risk assessment tool 
 
Patients RCT  Consultation with 
clinical nurse specialist 
1. Acceptability 
2. Risk perception 
3. Anxiety, cancer worry 
Emery38,39 “RAGs” prototype 
Computer-based decision 
support system 
Practitioners RCT 1. Pen and paper with 
available guidelines 
2. Cyrillic risk 
calculation package 






Practitioners Cluster RCT Education session 1. Appropriateness of referrals 
2. Patient risk perception 
3. Patient knowledge 





Computerized cancer risk 




None Discussion of preventive 
action with physician 
Watson60,61 
 
Hereditary breast cancer 
information pack 
Practitioners Cluster RCT 1.  No intervention 
2.  Tool plus education 
session 
 
Rate of correct referral 
decisions 
Wilson62,63 Multifaceted computer-
based decision support 
system 
Practitioners Cluster RCT Guidelines document 
disseminated by mail 
1. Physician confidence 
2. Patient understanding of 
cancer risk and risk factors 
3. Proportion of referred 
patients at low and elevated 
risk  
Abbreviations: CRIS=Cancer Risk Intake System; GRACE=Genetic Risk Assessment in the Clinical Environment; GRAIDS=Genetic Risk Assessment in an Intranet and Decision 






Of the evaluative studies of tools directed towards professionals, one (two papers) (the 
RAGS prototype) was conducted under “laboratory-type” conditions38,39 and three (five papers) 
were implemented in routine practice settings,36,60-63 including the GRAIDS tool.36,37  In the first 
of these, the computer-based RAGS prototype application38,39 was compared with pen and paper 
risk calculation and a specialist risk calculation software package, Cyrillic.  The evaluation 
showed a statistically significant effect of the tool on clinical management decision making for 
hypothetical cases presented in vignette form.  In the study by Watson and colleagues,60,61 a 
hereditary breast cancer information pack (presented with or without an active educational co-
intervention)  was compared with no intervention.  An analysis of referral letters subsequently 
received by the relevant genetics centers and breast clinics indicated a statistically significant 
trend across the three groups in terms of compliance with referral criteria.  In the study by Emery 
and colleagues,36 a randomized controlled cluster trial was used to evaluate a complex 
intervention which comprised a web-based decision support system (the GRAIDS software, for 
which RAGS was the prototype) and a nominated “lead clinician” within the practice who 
received extra training in use of the software and was expected to manage all patients expressing 
concerns about family history of colorectal or breast cancer.  All physicians and nurses in 
intervention practices also received a short educational session on cancer genetics and an 
introduction to the GRAIDS software.  The control intervention was a mailed paper copy of the 
relevant regional guidelines, along with a short educational session on cancer genetics.  The 
intervention arm contained an “adaptive” sub-group, in which extra training or software 
adjustment was used to increase actual use of the intervention.  The primary outcome was 
appropriateness of referrals made to the regional genetics clinic, as assessed by comparison of 
each referral letter with the regional guidelines.  For both cancer groups combined, 95 percent of 
referrals made by physicians in the intervention group met the guideline criteria, compared with 
79 percent in the control group, a statistically significant result.  For breast/ovarian cancer 
referrals, the proportions were 93 percent and 73 percent, respectively (statistically significant) 
and for colorectal cancer referrals, the proportions were 99 percent and 92 percent (not 
statistically significant).  Overall, there were no statistically significant differences in proportions 
of patients who were subsequently assessed as being at increased cancer risk by genetics 
specialists.  At the patient level, cancer worry scores were lower in those referred from 
intervention practices than from control practices, but no statistically significant differences were 
observed in knowledge or risk perception scores.  The fourth study62,63 compared a stand-alone 
computer based decision support tool with a control intervention of national guidelines 
disseminated by mail to family physicians.  All practices within the health care administrative 
region were included in the trial, and all intervention practices received the intervention in some 
form.  The primary outcome was physician confidence in four domains related to assessing risk, 
making clinical management decisions, and counseling patients, and no statistically significant 
differences were detected between intervention and control groups for any of the four domains.  
No statistically significant differences between groups were observed in secondary outcomes 
related to patients’ risk perceptions, beliefs about breast cancer causation, or the risk of referred 
patients as assessed by genetics specialists.    
Of the evaluation of tools directed towards patients, one was conducted under laboratory-
type conditions,44 and one was evaluated under conditions approaching routine practice.31  The 
former44 was an evaluation of the patient oriented “GRACE” tool.  It was framed as an 
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equivalence or non-inferiority trial, but was not statistically powered for testing of a priori 
hypotheses.  The comparator was a consultation with a nurse specialist who used the same 
evidence base to assess risk and offer advice.  Outcomes related to patient acceptability, risk 
perception, anxiety and cancer worry, were all either statistically non-significant, or favored the 
control arm.  In the second study;31 the Cancer Risk Intake System (CRIS), a touch screen 
system for patients, was implemented in three primary care clinics.  On the basis of family and 
other history, patients received tailored printouts including up to three messages regarding cancer 
prevention, to be used as an aid for discussions with their physician.  A before-after evaluation 
suggested that the proportion of patients reporting a physician discussion about tamoxifen use 
increased from 4.8 percent at baseline to 27.7 percent after using CRIS; the corresponding pre- 
and post-figures for cancer genetic counseling were 2.8 percent and 28.2 percent, and for 
colonoscopy were 16.1 percent and 45.2 percent.  The lack of a control intervention makes it 




Chapter 4.  Discussion  
 
This review explored both the accuracy of family history reporting by patients and the 
effectiveness of tools for collecting and using familial cancer history in a primary care setting.  
Ideally, patients are able to report accurate information on their family history, assisted by 
effective tools, and health care providers are able to use the information to make beneficial 
preventive and clinical management decisions.  
 
Accuracy of Family History 
 
In order to fully interrogate this question, evidence of accuracy had to be explored beyond 
the primary care setting.  Although this encompassed broader clinical settings than the most 
comprehensive published review,102 the results were fairly similar.  Most eligible studies 
examining accuracy of reporting of cancer family history focused on breast or colorectal cancer, 
with fewer examining accuracy for ovarian and prostate cancers.  In contrast to a previous 
review, 102 we did not limit studies to those verifying the status of unaffected relatives.  This 
strategy yielded a broader set of studies that evaluated aspects of reliability but there were no 
significant gains in the number or quality of studies evaluating the primary question of accuracy.   
Overall, the few rigorous studies which fully evaluated accuracy (i.e., accuracy of reported 
absence and accuracy of reported presence of cancer in relatives) appeared to suggest that 
informants are more accurate in identifying which relatives are free of cancer (specificity) than in 
identifying relatives who have been affected by cancer (sensitivity).  Our results indicate that 
family history reporting may be more accurate for first degree relatives than second degree or 
beyond, although few studies examined accuracy in the latter.  Our findings also suggest that 
accuracy may be different for different cancer types, and influenced by the method of 
ascertainment of family history.  
Future efforts to improve accuracy of reporting would be improved by explicit consideration 
of whether sensitivity or specificity is the primary goal, which is dependent on the clinical 
context and purpose of a family history oriented strategy.  For example, maximizing sensitivity 
prioritizes the goal of missing as few “at risk” family histories as possible, and is consistent with 
a policy in which the potential benefits from finding potential cases carry more weight than the 
potential costs and harms of investigating individuals or families with false positive histories.  In 
contrast, maximizing specificity prioritizes avoiding the potential costs and harms of false 
positives, and is consistent with a policy which directs limited resources towards only identifying 
individuals or families with the greatest likelihood of being at significant disease risk, at the cost 
of missing some true positives.       
The studies reviewed focused on accuracy as a binary concept (presence or absence of 
cancer); we do not have evidence relating to the accuracy of other information which is relevant 
in cancer risk assessment such as information on age of onset.  We are unable to comment on 
which gold standard is “best” for judging accuracy, nor on the effect of clinical setting or tool 
format.  The accuracy of reporting by patients or members of the population cannot be 
completely separated from the performance of tools to gather such data,51 but we had limited 
information on the latter and it was not always evident whether a structured Family History Tool 
(FHxT) was utilized in data collection.   
 
 70
We also have little insight into which informant characteristics are associated with more 
accurate reporting; future evaluations could consider formally examining factors such sex, age, 
and cultural background.  It is possible that informants affected by cancer may seek out more 
complete information on their family history after their initial diagnosis, but we were unable to 
confirm this speculation.  
 Future research should also consider the issue of reliability of patient recall, including the 
issue of what is an “adequate” interval for studies of repeatability.  We suggest that it would be 
helpful to try to separate the reliability of reporting as a psychometric property in an individual 
from the reliability of reporting as a function of extra knowledge sought by an individual from 
other family members in the period between first and second data collections.   
In general, we might expect that the accuracy of family history reporting will improve in 
future, as current initiatives lead to more awareness on the part of the general public. It is not 
clear whether this will be countered by the effect that increased population mobility has on 
people’s abilities to keep up to date with the health of more distant family members.       
 
Family History Tools 
 
The review identified a number of FHxTs developed for use in a primary care setting, most 
of which had not been evaluated against either best estimate gold standard or current primary 
care practice.  Because of the limited number of studies, the evaluation of FHxTs was extended 
to relevant tools in non-primary care settings.  Taken together, there was reasonable agreement 
between FHxTs and accepted best estimate gold standard, and, when compared to current 
primary care standard practice, FHxTs identified significantly more genetically relevant family 
history information.  The clinical significance and added benefit of this added information still 
needs to be explored. 
The tools identified in this review varied considerably, from those which took a 
comprehensive approach, emulating the geneticist’s pedigree drawing interview to those which 
focused on identifying selected cancers in specific relatives.  Many were designed to be used in 
the physician’s office, in paper-based or electronic format.  It has been suggested that other 
formats, such as web-based or mailed surveys, allow patients and consumers to (potentially) take 
“ownership” of their family history, offer them the opportunity to gather information from 
relatives,37,43,45,49,52 and may make for better use of primary care provider (PCP) time.  Some 
electronic tools require patients to assemble family history information in advance of the office 
visit, which may also promote accuracy and ownership.  Some studies have shown high response 
rates to mailed FHxTs from PCPs48,54 and “consumer empowerment” was the basis of the 
previous U.S. Surgeon General’s Thanksgiving “Family History Day.” 110,111  Several 
organizations have set up similar web-based FHxTs for public use50,112 
(http://www.norwichunion.com/healthtree/index.htm113; http://www.ama-assn.org/ama/ 
pub/category/13333.html114).       
The acceptability and ease of completion of FHxTs were assessed in only a few studies. 
These aspects of the tools’ content and face validity should be an integral part of any evaluation 
of future primary care FHxTs.   
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While some authors3 have identified elements that could be included in an “appropriate” family 
history (see Figure 5), there is no explicit consensus on a minimum data set covering the extent 
and the nature of family history data appropriate to primary care practice.  Until the evidence 
base is clear, it is suggested that a minimum adequate cancer family history should include 
information on siblings, parents and grandparents (and the paternal and maternal lineage of the 
latter), specific enquiry about whether other relatives had the cancers of interest, and the 
ethnicity of the respondent.  When cancer is identified, the age of diagnosis should also be noted, 
and other relatives with similar or related conditions identified. 
    
Figure 5. Typical information obtained in Three-Generation Pedigree 
Age or year of birth 
Age and cause of death (for those deceased) 
Ethnic background of each grandparent 
Relevant health information (e.g., height and weight) 
Illnesses and age at diagnosis 
Information regarding prior genetic testing 
Information regarding pregnancies, including infertility, spontaneous abortions, stillbirths, and    
pregnancy complications 
Information also obtained for half-siblings 
Consanguinity issues directly addressed 
Rich EC, Burke W, Heaton CJ, et al.  Reconsidering the family history in primary care.   
J. Gen Intern Med 2004 Mar;19(3):273-80. 
 
In assessing individual tools, it is important to consider the notion of “appropriateness” in 
relation to individual patient factors (e.g., age) and in terms of patient population characteristics.6  
For instance, for a 40-year old patient it may be appropriate to enquire about all siblings, parents 
and grandparents, but children’s health may not be as relevant for eventually determining cancer 
risk.  Where there is concern about risk of familial breast cancer, information on aunts and uncles 
may be more informative than that on grandparents.  Also, while some authors have suggested 
that a minimum family history should cover three generations3,115,116 the reliability of 
information beyond first degree relatives and grandparents is unclear (see comments on 
accuracy, above).  On the other hand, some genetic RATs require a count of the number of 
unaffected relatives, as well as those with a cancer of interest (e.g., Yang 199853).  Accurate risk 
assessment generally requires information on the side of the family (maternal or paternal) to 
which relatives with cancer belong, and most FHxTs identified this.  Finally, ethnicity (an 
indication of ancestry 117) may be associated with increased risk of particular disorders, including 
some cancers, but few tools were designed to capture such data on ethnicity.  
We suggest that, in future FHxT development studies, it would be useful to distinguish 
between two different purposes for FHxTs – assembly and updating of “complete” family history 
information in a generic approach, and ascertainment of targeted information for specific disease 
risk assessment.  For the latter, it may be logical to evaluate the performance of a FHxT as part 
of a disease-specific RAT, rather than as a stand-alone tool.  For more generic tools, approaches 
to their rational development and evaluation would benefit from agreement on the “minimum 
family history dataset” for primary care purposes, bearing in mind that the goal in this setting is 
usually to stratify or triage risk rather than ascertain or diagnose a genetic condition.  An 
evidence-based minimum dataset would take into account evidence on accuracy of patient 
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reporting of family history under primary care office conditions and might not necessarily have 
to replicate the extent or type of data captured in a clinical genetics setting.  Table 12 lists some 
of the elements which could be considered for inclusion in a minimum dataset. It is presented to 
foster discussion and evaluation only as it is not within the scope of this review to formally 
assess its utility or feasibility.   
Family histories are not static;45,49 however, practical issues of updating family history have 
not been explored.  On the one hand, PCPs may be able to assemble a patient’s family history 
information over time, but on the other, necessary updates consume time and resources.  
Acheson1 has reported that most family histories were completed on the first visit.  It would be 
worth considering formally whether a staged approach over several visits leads to more accurate 
or extensive information, and clarifying the optimum interval for updates.   
It seems logical that FHxTs are likely to produce most benefit if they are accompanied by 
management plans for patients at familial cancer risk; otherwise “proactive” family history 
collection by PCPs and/or consumers may be wasteful of time, energy, health care resources, and 
may even be harmful.  While some guidelines118 recommend that family history information 
should only be collected in response to patient enquiry about familial breast cancer risk or if the 
provider suspects increased cancer risk, others argue that family history collection is an integral 
part of good clinical practice in primary care and that failure to do so should be considered 
negligence.51,119  
 
Risk Assessment Tools 
 
An inclusive definition of RAT was used to capture the widest range of interventions 
potentially applicable to primary care.  Their formats varied from fairly simple tools designed 
solely to stratify risk to those in which the capture of family history data was closely linked with 
management recommendations within a format designed to promote implementation in practice.  
We chose to focus on only those guidelines that had been formally evaluated in their own right, 
or embedded in some form of tool designed to promote use in practice.  This decision recognized 
the very large number of familial cancer stratification guidelines which had been published over 
the time period of the review.  We judged that an exhaustive approach to describing such 
guidelines would have provided little insight into the review questions and would likely be 
quickly out of date.  However, for information, we listed the guidelines developed by national 
agencies or professional organizations in an Appendix B.*  
Similarly, we focused only on those RATs which produced as output a risk of cancer, and 
excluded those for which the only output was risk of a given mutation.  Our rationale was that 
family history reflects an integration of risk generated by genetic factors (including gene variants 
which may confer only modest increase in risk), shared environments, and common behaviors2 
and is an important predictor, in its own right, of disease risk.  We suggest that this approach is 
consistent with the overall primary care perspective of the review, and increases the likelihood 
that the tools included would be accepted as relevant and usable by the target professional 
groups, outside the specialist genetics setting.  In addition, clinically valid RATs which generate 
disease risk strata should, by definition, allocate families with high risk of mutation into the 
highest risk category, therefore alerting practitioners to their need for specialist assessment. 
                                                 
* Appendixes cited in this report are provided electronically at http://ahrq.gov/clinic/tp/famhisttp.htm 
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Table 12:  Potential items for inclusion in minimum family history dataset 
 
(a)  Relatives on whom data may be captured 
Degree of relatedness Relationship 
 Informant 1  
 Spouse/partner2 





Second degree  
Blood relatives 
Grandparents (both sides) 
Aunts and uncles (both sides) 
Half-brothers and half-sisters 
Grandchildren 
Third degree  
Blood relatives 
Cousins (both sides) 
Nephews and nieces (both sides) 
 
(b) Items of information that may be captured 
Individual Item 
Informant/patient Age or date of birth 
 History of cancer, for each 
• age at diagnosis  
• specific information (e.g., bilaterality) 
 History of other relevant medical conditions  
(depending on cancer) 
 Results of relevant investigations, including genetic tests 
 Ethnicity or ancestry 
• Self-identified ethnic group 
• Ethnic group of grandparents 
Relatives History of cancer, for each  
• age at diagnosis 
• specific information (e.g., bilaterality) 
• source/certainty  of information 
 History of other relevant medical conditions  
(depending on cancer) 
 History of relevant investigations, including genetic tests 
Living relatives  Current age/date of birth 
Deceased relatives Age at death  
• Source of information 
• Certainty of information 
 Cause of death 
• Source of information 
• Certainty of information 
1 Personal medical history important in risk assessment 




A large number of studies reported outcomes in terms of the distribution of patients across 
risk strata compared with an independent standard (e.g., an accepted guideline or an assessment 
by a specialist geneticist).  This is an approach to assessing clinical validity (i.e., predictive 
value) and is of course dependent on the validity of the gold standard comparator.  This review 
was not designed to assess this component of clinical validity, which ultimately requires studies 
that rigorously evaluate how well risk categorization predicts eventual disease outcome.  We 
found that very few studies examined effectiveness in terms relevant to the questions posed in 
this review—either professional practice outcomes (e.g., improved confidence in clinical 
decision making) or patient outcomes (e.g., more accurate risk perception).  Taken together, the 
evidence is not sufficient to make definitive recommendations, but it does tentatively indicate 
that RATs may improve the appropriateness of referral of patients for genetic counseling.  
Whether this is clinically or administratively worthwhile depends on the local clinical context.  
The extra benefit from a RAT must be set against the costs of implementation, particularly if 
there is already high compliance with referral guidelines.  There is insufficient evidence to 
determine whether RATs, by themselves, are likely to improve physician confidence or skills in 
broader aspects of patient care related to familial cancer. 
Just as with FHxTs, the potential effectiveness of RATs may be confounded by the strategy 
used to implement them in practice.  Decision tools are complex interventions, and thus present 
challenges in their development, application, and evaluation.36,120  Recent analyses have begun to 
identify the characteristics of decision tools that appear most likely to promote effectiveness in 
practice but few studies have evaluated patient outcomes.  One of the most significant predictors 
of decision tool effectiveness appears to be the automatic provision of decision support as part of 
a practitioner’s workflow.121  This should become increasingly straightforward to achieve as 
electronic medical records become more widely implemented and linked with computer-based 
RATs.  Other predictors of tool effectiveness include the provision of actionable 
recommendations (rather than just assessments); the  provision of decision support at the time 
and location of decision making; the periodic feedback on performance to users; built-in features 
that promote the sharing of recommendations with patients; and systems that request 
documentation of reasons for not following recommended actions.121  It is plausible that this 
emerging evidence on desirable characteristics of decision tools, while still preliminary, is 
applicable to family history based RATs.  It should be noted that many tools have been evaluated 
by the same investigators who developed them, and that such studies seem to report higher levels 
of practitioner performance than studies where tools are evaluated by independent observers.       
The barriers to the use of FHxTs and RATS tools in practice include lack of time,122 lack of 
PCPs’ confidence in their knowledge and skills in genetics,80,123,124 and reimbursement policies.3 
Finally, even though a typical PCP may provide care to a significant number of patients with a 
history of familial cancer,64 they may make up only a very small part of his or her daily practice. 
Hyland et al.125 suggested that the rate of physician contact with women with a family history of 
breast cancer was about 0.6 consultations per month per family physician.  Systems to implement 
apparently efficacious tools therefore need to take account of these barriers, and broader 
consideration could be given to the cost-effectiveness of developing tools which assess familial 
risk across a range of common chronic disorders.  
All of these factors taken together suggest that effective RATS require a coherent, evidence-
informed approach to their design, consideration of their integration with other clinical and office 
systems, and attention to contextual factors which might moderate their effect, and their marginal 





The studies reviewed in this report were limited to those published in English; however, the 
impact of any language bias is offset by the optimal applicability to English speaking countries 
for which this report was prepared.  Our peer review process allowed content experts in this area 
to identify any additional studies (both published and unpublished) of relevance for this review 
thereby minimizing the likelihood of publication bias.  In addition to using several web-based 
search engines, our search of relevant grey literature was limited to sites specified by the 
investigators, our technical expert panel (TEP), and peer reviewers.  We contacted the authors of 
eligible studies to request copies of the tools or methods used to ascertain eligibility of family 
history method for this review. The majority of authors contacted did respond, but some did not. 
Language bias also limited the ability to interpret non-English FHxT, however this had a 
minimal impact on the studies described and evaluated.  The budget and timelines available, 
however, were limiting factors in pursuing complete retrieval of all the instruments used to 
collect family history in the eligible studies. 
Our criteria for defining a systematic FHxT or RAT resulted in the exclusion of guidelines, 
recommendations or mutation risk calculators (see above).  These are all “decision tools” and, 
even though a rationale was provided, their exclusion was arbitrary.  The result may be that the 
review has underplayed the value of guidelines (however published) in promoting effective 
clinical practice, and overlooked “specialist” tools which might actually be useful in primary 
care without further modification.  Similarly, the definition used for applicability to family 
practice was based on criteria developed within our investigative team and has not been subject 
to external scrutiny.  In the context of accuracy of family history reporting, eligible studies did 
not use the same method to ascertain family history or verify status within all relatives.  As such, 
interpretation of the metrics of accuracy was limited to the methods of family history 




The accuracy of self reported family history has implications for the correct risk assessment 
and management of patients.  Accuracy of cancer family history reporting appears to be 
dependent on cancer type and method of collection, and accurate reporting of absence of cancer 
(specificity) appears to be greater than accurate reporting of presence of cancer (sensitivity).  
Accuracy of recall and reporting may be influenced by both patient factors and by the method 
used to capture the data (the tool).  No studies appear to have examined both of these together, so 
it is impossible to comment definitively on their relative contributions to any lack of accuracy.  
Family history is a fundamental element of health information, and the ability to take an 
adequate and accurate family history should be recognized as a core skill for all PCPs, 
irrespective of the availability of tools.  Very few FHxTs have been developed for, and evaluated 
in, primary care settings.  Further, few tools have been compared with either “best practice” 
(genetic interview) or current primary care practice (family history as recorded in charts).  
Although the evidence is very limited, and depends on extrapolation of studies of tools in 
settings other than primary care, it suggests that systematic FHxTs may add significant genetic 
family history information compared to current primary care practice. 
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A number of RATs, of varying format and complexity, have been developed for primary care 
settings, and a few of these have been evaluated in controlled trials.  These studies provide 
tentative evidence for the effectiveness of such tools, but their utility in routine practice has not 




1. Consensus should be reached on the extent of family history enquiry necessary for different 
clinical purposes and circumstances, taking into account the likelihood of accuracy of self 
reported information for different relatives, and the use to which the information will be put 
(e.g., overall or specific risk assessment).   
 
2. The benefits, costs and harms of using patient-completed tools for systematic family history 
collection and risk assessment, as a substitute for, or complement to, professional tools 
should be further examined.  As well as assessing technical outcomes such as accuracy and 
completeness of data captured, evaluations should consider outcomes which relate to patient 
“empowerment” and the use of practitioner and health care resources.   
 
3. Further research is required to identify the specific strategies (e.g., sending tools home with 
patients) and tool features which promote the most accurate reporting of family history 
information. 
 
4. The optimum interval for updating a patient’s family history information in primary care 
should be formally evaluated. 
 
5. Further evaluation of FHxTs and RATs in routine clinical settings and practice is required. 
Studies should: adopt appropriate comparators (generally current practice); ensure that tools 
are optimized (in terms of, for example, face and content validity) before evaluation; measure 
outcomes that relate to utility in routine practice; measure outcomes that provide information 
on potential costs or harms as well as benefits; and address or explore contextual factors 
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1DR First Degree Relatives 
2DR Second Degree Relatives 
3DR Third Degree Relative 
BED Best Estimate Diagnosis 
BRCAPRO Breast Cancer Program 
BOADICEA Breast and Ovarian Analysis of Disease 
Incidence and Carrier Estimation 
Algorithm 
CDC Centers for Disease Control and Prevention 
CFHF Comprehensive FH Form 
CI Confidence Interval 
CR Cancer Registry 
CRC Colorectal Cancer 
CRIS Cancer Risk Intake System 
CVD Cardio Vascular Disease 
Cyr Cyrillic 
DOB Date of Birth 
DOR Diagnostic Odds Ratio 
DQ  Direct Question 
EsPeR Personalized Estimate of Risk 
FAP Familial Adenomatous Polyposis 
FCAT Familial Cancer Assessment Tool 
FHAT Family History Assessment Tool 
FHQ  Family History Questionnaire 
FHS Family History Score 
FHxT Family History Tool 
GCI Genetic Counsellor interview 
GI Genetic Interview 
GNI Genetic Nurse Interview 
GP General Practitioner 
GRACE Genetic Risk Assessment in the Clinical 
Environment 
GRAIDS Genetic Risk Assessment in an Intranet and 
Decision Support trial 
HBOCS Hereditary Breast-Ovarian Cancer 
Syndrome 
HNPCC Hereditary Nonpolyposis Colorectal 
Cancer 
IM Internal Medicine 
LFS Li-Fraumeni Syndrome 
LR- Negative Likelihood Ratio 
LR+ Positive Likelihood Ratio 
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MR Medical Records 
N/A Not Applicable. 
NICE National Institute for Clinical Excellence 
NIDDM Non-Insulin Dependent Diabetes Mellitus 
NPV Negative Predictive Value 
NR Not Reported 
NSW New South Wales 
PAC Probability of Agreement of Cancer 
PANC Probability of Agreement of No Cancer 
PC Primary Care 
PCP Primary Care Provider 
PDA Personal Digital Assistant 
PMH Past Medical History 
PPV Positive Predictive Values 
PSI Physician Structured Interview 
Q Question 
QOL Quality Of Life 
RAGS Risk Assessment in Genetics 
RAT Risk Assessment Tool 
RCT Randomized Controlled Trial 
SD Standard Deviation 
SE Standard Error 
SRS Systematic Review Software 
















Appendix A.  Exact Search Strings and Web  
Sites Searched 
All searches updated to July 22, 2007 
Ovid MEDLINE(R)  
 
1     Breast Neoplasms/  
2     exp Colorectal Neoplasms/  
3     exp Ovarian Neoplasms/  
4     exp Prostatic Neoplasms/ 
5     ((breast or ovar$ or prostate or colon or colorectal) adj3 (cancer$ or neoplasm$ or  
 carcinom$)).ti,ab.  
6     or/1-5  
7     (note or comment or editorial or letter).pt.  
8     exp Medical History Taking/  
9     exp Family/ or exp Family Health/  
10   exp Pedigree/  
11   limit 10 to humans  
12   ((family or familial) adj3 (histor$ or history-taking or risk$)).ti,ab.  
13   anamnesis.ti,ab.  
14   (human adj2 pedigree).ti,ab.  
15   (genetic adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
16   genogram$.mp.  
17   ((famil$ or heredi$ or inherit$) adj3 (cancer$ or carcinom$ or neoplasm$)).ti,ab.  
18   or/8-9,11-17  
19   6 and 18  
20   limit 19 to yr="1990 - 2007"  
21   20 not 7  
22   exp Neoplasms/  
23   cancer$.ti,ab.  
24   or/22-23  
25   (method$ or tool$ or form$).ti,ab.  
26   ((genetic or famil$ or heredit$ or inherit$) adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
27   26 and 25  
28   (famil$ histor$ adj3 (method$ or tool$ or form$)).ti,ab.  
29   27 or 28  
30   29 and 24  
31   limit 30 to yr="1990 - 2007"  
32   31 not 7  







1    exp Neoplasms/  
2    cancer$.ti,ab.  
3    or/1-2  
4    (method$ or tool$ or form$).ti,ab.  
5    ((genetic or famil$ or heredit$ or inherit$) adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
6    4 and 5  
7    (famil$ histor$ adj3 (method$ or tool$ or form$)).ti,ab.  
8    or/6-7 
9    3 and 8  
10  limit 9 to yr="1990 - 2007"  
11  exp Breast Cancer/  
12  exp Colon Cancer/  
13  exp Ovary Cancer/  
14  exp Prostate Cancer/  
15  ((breast or ovar$ or prostate or colon or colorectal) adj3 (cancer$ or neoplasm$ or  
carcinom$)).ti,ab.  
16  or/11-15  
17  (note or comment or editorial or letter).pt.  
18  exp anamnesis/  
19  ((family or familial) adj3 (histor$ or history-taking or risk$)).ti,ab.  
20  anamnesis.ti,ab.  
21  (human adj2 pedigree).ti,ab.  
22  (genetic adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
23  ((famil$ or heredi$ or inherit$) adj3 (cancer$ or carcinom$ or neoplasm$)).ti,ab.  
24  genogram$.mp.  
25  or/18-24  
26  16 and 25  
27  limit 26 to yr="1990 - 2007"  
28  27 not 17  
29  10 not 17  
30  or/28-29  
 
CINAHL - Cumulative Index to Nursing & Allied Health Literature  
 
1    (note or comment or editorial or letter).pt.  
2    exp Medical History Taking/  
3    exp Family/ or exp Family Health/  
4    exp Pedigree/  
5    limit 4 to humans [Limit not valid in: CINAHL; records were retained]  
6    ((family or familial) adj3 (histor$ or history-taking or risk$)).ti,ab.  
7    anamnesis.ti,ab.  
8    (human adj2 pedigree).ti,ab.  
9    (genetic adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
 A-3
10  ((famil$ or heredi$ or inherit$) adj3 (cancer$ or carcinom$ or neoplasm$)).ti,ab.  
11  or/2-3,5-9,10  
12  exp Breast Neoplasms/  
13  exp Colorectal Neoplasms/  
14  exp Ovarian Neoplasms/  
15  exp Prostatic Neoplasms/  
16  ((breast or ovar$ or prostate or colon or colorectal) adj3 (cancer$ or neoplasm$ or  
carcinom$)).ti,ab.  
17  or/12-16  
18  11 and 17  
19  limit 18 to yr="1990 - 2007"  
20  19 not 1  
21  exp Neoplasms/  
22  cancer$.ti,ab.  
23  or/21-22  
24  (method$ or tool$ or form$).ti,ab.  
25  ((genetic or famil$ or heredit$ or inherit$) adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
26  24 and 25  
27  (famil$ histor$ adj3 (method$ or tool$ or form$)).ti,ab.  
28  or/26-27  
29  23 and 28  
30  limit 29 to yr="1990 - 2007"  
31  30 not 1  
32  20 or 31  
 
EBM Reviews - Cochrane Central Register of Controlled Trials  
 
1    Breast Neoplasms/  
2    exp Colorectal Neoplasms/  
3    exp Ovarian Neoplasms/  
4    exp Prostatic Neoplasms/  
5    ((breast or ovar$ or prostate or colon or colorectal) adj3 (cancer$ or neoplasm$ or  
carcinom$)).ti,ab.  
6    or/1-5  
7    (note or comment or editorial or letter).pt.  
8    exp Medical History Taking/  
9    exp Family/ or exp Family Health/  
10  exp Pedigree/  
11  limit 10 to humans [Limit not valid; records were retained]  
12  ((family or familial) adj3 (histor$ or history-taking or risk$)).ti,ab.  
13  anamnesis.ti,ab.  
14  (human adj2 pedigree).ti,ab.  
15  (genetic adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
16  genogram$.mp.  
17  ((famil$ or heredi$ or inherit$) adj3 (cancer$ or carcinom$ or neoplasm$)).ti,ab.  
 A-4
18  or/8-9,11-17  
19  6 and 18  
20  limit 19 to yr="1990 - 2007"  
21  20 not 7 
22  exp Neoplasms/  
23  cancer$.ti,ab.  
24  or/22-23  
25  (method$ or tool$ or form$).ti,ab.  
26  ((genetic or famil$ or heredit$ or inherit$) adj2 (risk adj3 (assessment or evaluation))).ti,ab.  
27  26 and 25  
28  (famil$ histor$ adj3 (method$ or tool$ or form$)).ti,ab.  
29  27 or 28  
30  29 and 24  
31  limit 30 to yr="1990 - 2007" 
32  31 not 7  
33  32 or 21  
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Internet Sites Searched 
Title Website address Type 
The Genetic Family History 




NCHPEG Newsletter for Health 
Care Professionals 
The Genetic Family History 




NCHPEG Newsletter for Health 
Care Professionals 
The Genetic Family History 




NCHPEG Newsletter for Health 
Care Professionals 
The Genetic Family History 




NCHPEG Newsletter for Health 
Care Professionals 





Genetic Tools Website– 
Genetics Through a Primary 
Care Lens 





Genetic Tools Website – 
Genetics Through a Primary 
Care Lens 
BRCA and Breast/Ovarian 




Draft Genetic Test Review 
American Medical 





Electronic Family History Form 
Decision aid for the 
introduction of population-
based genetic screening 
programs (work in progress). 
www.aetmis.gouv.qc.ca 
 
Agence d’évaluation des 
technologies et des modes 
d’intervention en santé 
(AETMIS) Report 
 
Contribution of BRCA1/2 
Mutation Testing to Risk 
Assessment for Suceptibility 





Summary Report from Agence 
D’Évaluation des Technologies 
et des Modes D’Intervention en 
Santé Summary Report 
Predictive Genetic Testing 
for Breast and Prostate 
Cancer 
www.ccohta.ca Canadian Coordinating Office 
for Health Technology 
Assessment (CCOHTA) 
Technology Report 
Molecular Diagnosis for 
Hereditary Cancer 
Predisposing Syndromes: 
Genetic Testing and Clinical 
Impact 
www.ccohta.ca Canadian Coordinating Office 
for Health Technology 
Assessment (CCOHTA) 
Technology Report 
BRCA1 and BRCA2 
Predictive Genetic Testing 
for Breast and Ovarian 
Cancers: Asystematic 
Review of Clinical Evidence 
www.ccohta.ca Canadian Coordinating Office 




Title Website address Type 
The U.S. Surgeon General’s 
Family History Initiative 
http://www.hhs.gov/familyhistor
y/downloads/portraitEng.pdf 




Appendix B.  Forms/Guides and Internet Family 
History Tools 
 
Title and Abstract Screening Level 1 
 
Reviewer Comments (Add a Comment) __________________________________________     
         
1. Does this article focus on providers' attitudes (views, opinions) towards collecting or using 
family history in clinical practice?   
Yes  
No (neutral)  
  
2. Does this citation focus on either: capturing/collecting/collating information related to family 
history of disease or history of illness in other family members by any method whether self-
reported or by a professional. (exclude if it is personal medical history taking only with no 
components dealing with family history) OR a method/approach/tool/guidelines to assist a health 
professional use family history information in clinical decision making (e.g. genetic/familial risk 
assessment)  
  Yes   
No (exclude)  
  
3. Does the citation include the following cancers?  (Check all that apply) 
Breast, Colorectal/Colon, Ovarian, Prostate  
Cancer Unspecified  
None of the Above (exclude)  
  
4. Is this a primary study, conference proceedings, thesis, technical report or letter with primary 
study data? OR GUIDELINES   
Yes  
None of the above (exclude)  
This a review (exclude)  
  
5. Is this article in English?   
Yes  




Screening Instructions for Family History (Fam_Hx) 
 
General: The first two questions are mandatory and the rest optional.  Your answers to question 1 
should not effect how you answer the rest of the form. Once you mark your first “exclude” 
answer, you do not need to fill out the rest of the form. 
 
1.  Does this article focus on providers' attitudes (views, opinions) towards collecting or using 
family history in clinical practice?  
 Yes  
 No (neutral) 
 
Mandatory—Most of the articles that would fit the “yes” criteria for this question will use 
surveys, opinion polls or focus groups to determine how providers feel about collecting or using 
family history in their practice.   
 
2.  Does this citation focus on either: capturing/collecting/collating information related to family 
history of disease or history of illness in other family members by any method whether self-
reported or by a professional. (exclude if it is personal medical history taking only with no 
components dealing with family history) OR  a method/approach/tool/guidelines to assist a 
health professional use family history information in clinical decision making (e.g. 
genetic/familial risk assessment)  
Yes  
 No (exclude) 
 
We are interested in both how family medical history is gathered and how it is used in clinical 
practice. This would include such things as online tools, questions asked in the doctor’s office 
etc. (we are interested in ANY means). Personal medical histories are a bit tricky. If it is only 
about the individual’s medical history (e.g. what childhood illness did you have?) exclude, but if 
there is even one question about the medical history of other family members, then answer “yes”.  
We are also interested in tools, methods, approaches or guidelines that help practitioners use the 
family history that they have collected. Genetic/familial risk assessment or risk management are 
common terms in these types of articles. 
  
Exclude:  
• Articles that focus on genealogy (non-medical family history) 
• Articles that purely focus on molecular genetics (terms such as          
      methylate/methylation” “micro satellite” “polymorphisms” are unlikely to be in  
      the title of articles we want to include)  
• Study collects family history and describes aspects of patients with and without  
      positive FHx but does not emphasize attributes (including accuracy) of the tool or  
      measure (we know some measure was used to establish family history…but it  
      appears the focus is not on the measure)          
• If a study focuses on the patient and their risk evaluation (their feelings about own  
      family history or perception of the magnitude of risk)…the study does not focus  




3.  Does the citation include the following cancers?  
Breast, Colorectal/Colon, Ovarian, Prostate 
Cancer Unspecified 
None of the Above (exclude) 
 
Mandatory—mark the answer that applies. We are interested in articles on the specific cancers 
listed or those that refer to cancer generally without specifying types. If you answer “none of the 
above” you do not need to answer any more questions 
 
4.  Is this a primary study, conference proceedings, thesis, technical report or letter with primary 
study data?  
Yes 
None of the above (exclude) 
This a review (exclude) 
 
Look carefully at any letters and include them if they contain primary study data (they will 
normally be more than 1 page long) 
 
5.  Is this article in English?  
Yes 




Title and Abstract Screening Level 2 
  
Reviewer Comments (Add a Comment) __________________________________________     
      
Family History:   
 1.  Does this citation FOCUS on the accuracy of family histories?   
Yes  
No  
   
2.  Is this citation about the capturing/collecting/collating or use of family history or in the 
PRIMARY CARE setting?   
Yes  
No => Exclude  
Can't Tell  
   
Primary Care:  
Include: family physicians, general internists, obstetricians, gynecologists, nurses, nurse 
practitioners, physicians assistants, nutritionists, behaviouralists, etc. 




Screening Instructions Level 2  
  
Question 1: Answer yes if the paper describes any method of validation of the family histories 
(e.g. medical records, death certificate, histology report, etc.). 
 




Question 2: Answer yes if the paper describes a tool for capturing/collecting/collating or 
assessing risk of cancer used in a primary care setting or applicable to primary care. 
 
2.  Is this citation about the capturing/collecting/collating or use of family history or in the 
PRIMARY CARE setting OR is it applicable to PRIMARY CARE?   
Yes  
No => Exclude  
Can't Tell  
  
Primary Care:  
  Include: family physicians, general internists, obstetricians, gynecologists, nurses,  
 nurse practitioners, physicians assistants, nutritionists, behaviouralists, etc. 




Full Text Screening 1 
 
Reviewer Comments (Add a Comment) __________________________________________     
 
1. Year of publication 1990-2007:   
Yes  
No => Exclude  
   
2. Is the population comprised of:   
Adults 18+  
Other => Exclude  
   
3. Is the article in English?   
Yes  
No (Specify) => Exclude      
   
4. Does the study report data?   
Yes (Any data, Quantitative data and also Qualitative description of tool  
   development data)      
  No (narrative description of a tool) => Exclude      
  No (any other) => Exclude      
   
5. Study type:   
Primary study      
  Tool development and testing (reports data)      
  Review => Exclude       
  Other => Exclude      
     
6. Does this article include the following cancers: (check all that apply)   
Breast cancer  
Ovarian cancer  
Prostate cancer  
Colo-rectal cancer  
Presents aggregate data for breast and ovarian cancers only => Include      
Presents aggregate date for two or more of the above cancers other than breast and        
    ovarian cancer => Include      
  Presents aggregate data for the above cancers and for other types of cancer  
                => Exclude      
  None of the above (specify) __________________________________________     
    => Exclude       
 
7. Does this article examine the accuracy of patients or members of the public in knowing and 
reporting their family history AND is the accuracy verified by a method such as relative's 
medical record, physician, death certificate, a population cancer registry?   
Yes => Include      
  No => Include      
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 8. If you answered yes to question 7, was the verification done for: (Check all that apply)   
Positive family history only: please specify method of verification      
  Negative family history: please specify method of verification      
    
9. Where did the probands/participants came from?  (Check all that apply) 
General population (e.g. from a population survey database)      
  Specialty clinic (including cancer centers, genetic counseling clinics etc.)      
  Primary care (as defined for this study)      
  Other (Specify) __________________________________________     
    
10. Does this original article contain a standardized method, approach or tool to collect, capture, 
collate information related to family history of disease or history of illness in other family 
members either self-reported or by any primary care practitioners   
Yes => Include  
No => Include  
  
11. Does this original article contain a standardized method, tool or measure to help primary care 
health practitioners to identify, calculate, interpret, make clinical management decisions, 
promote the uptake of risk stratification and assessment for cancers of interest   
Yes => Include  
No => Include  
  
12. Did you answer NO to questions 7, 10 and 11?    
Yes => Exclude  
No  
   




Full Text Screening 1: Guide 
 
Please complete all of the questions in the form. Stop completing the form if you choose an 
exclusion answer. 
 
Questions 1-3: We are only interested in studies that were published in English from 1990 to 
2007, and that examine adult population. 
 
1. Year of publication 1990-2007:   
Yes 
 No => Exclude 
  
2. Is the population comprised of:   
Adults 18+ 
 Other => Exclude 
  
3. Is the article in English?   
Yes 
 No (Specify) __________________ => Exclude 
 
Question 4: We are interested in articles that report quantitative or qualitative (highly unlikely) 
data. Studies that present opinions or recommendations should be excluded. 
  
4. Does the study report data? 
Yes 
No (narrative description of a tool) => Exclude 
No (any other)=> Exclude 
  
Question 5. The study must be a primary study or describe the development of a tool or 
standardized approach for collecting/capturing/collating family history or for risk assessment  
  
5. Study type:   
Primary study 
Tool development and testing (reports data) 
Review => Exclude  
Other => Exclude 
 
Question 6: We are only interested in studies about Breast, Ovarian, Prostate and Colorectal 
Cancers.  If the study examines more than 1 cancer type and the results are given separately for 
each cancer of interest, it should be included.  If the study examines breast and ovarian cancer 
and the results are presented in aggregated form it should be included. If the study examines the 
cancers of interest  with or without other cancers and the results for all the cancers are presented 
together, it should be excluded.”  
  
 B-9





Presents aggregate data for breast and ovarian cancers only => Include   
Presents aggregate date for two or more of the above cancers other than breast and  
   ovarian cancer => Include  
Presents aggregate data for the above cancers for other types of cancers  
   =>Exclude   
None of the above (specify) __________________________________________     
   =>Exclude  
  
Questions 7 and 8: If the family history is not verified by any method (i.e. medical record) 
answer NO to question 7 and go to question 9. 
 
7. Does this article examine the accuracy, completeness, adequacy of patients or members of the 
public in knowing and reporting their family history AND is the accuracy verified by a method 
such as relative's medical record, physician, death certificate, a population cancer registry?   
Yes 
  No 
  
8. If you answered yes to question 7, was the verification done for: (Check all that apply)    
positive family history only: please specify method of verification 
  negative family history: please specify method of verification 
 
Question 9: We are interested in unselected general population and primary care clinics 
population. If the paper is about accuracy, then we are interested in primary care and specialty 
clinics population. 
 
9. Where did the probands/participants came from?   
General population (e.g. from a population survey database) 
  Specialty clinic (including cancer centers, genetic counseling clinics etc.)   
Primary care (as defined for this study) 
Other (Specify) __________________________________________     
   
Question 10: We are interested in collecting/collating/capturing/reporting family history in a 
systematic way (tool).   
 
10. Does this original article contain a standardized method, approach or tool to collect, capture, 
collate information related to family history of disease or history of illness in other family 





Question 11: We are interested in a family history tool that helps primary care providers to 
identify/calculate/interpret/make management decisions/promote risk stratification and 
assessment for cancers of interest 
 
11. Does this original article contain a standardized method, tool or measure to help primary care 
health practitioners to identify, calculate, interpret, make clinical management decisions, 




Question 12: We are interested in papers that examine the accuracy of family history or that 
analyze a tool for collecting/capturing/collating family history or a tool to interpret family 
history or evaluate risks for specific cancers. If the paper doesn’t examine/analyze any of these 
then exclude it. 
 
12. Did you answer NO to questions 7, 10 and 11?   
Yes => Exclude 
 No 
  




Full Text Screening 2 
 
Reviewer Comments (Add a Comment ) __________________________________________     
 
        
1. To what research question does this article apply?  (Check all that apply) 
Question 1: Accuracy      
  Question 2: Tool      
  Question 3: Risk      




Guideline to Full Text Screening 2 
 
1) To what research question does this article apply? 
 
A) Question 1: Accuracy 
 
Please check this if the article fulfills the question: 
 
1) What is the evidence that patients or members of the public, accurately know and report their 
family history of each one of, or a combination of, the following cancers: breast cancer, ovarian 
cancer, prostate cancer, and colorectal cancer?  
 
B) Question 2: Tool 
 
Please check this if the article fulfills the question: 
 
2) How well do the different systematic family history collection forms and tools, such as take-
home tools, web-based tools, etc., improve non-systematic approaches to family history 
collection by primary care providers? 
 
a. Identify tools intended to improve family history collection by primary care providers. 
b. Compare these tools against current practice. 
 
C) Question 3: Risk 
 
Please check this if the article fulfills the question: 
 
3) What tools exist to enable primary care providers to calculate, interpret, and act upon family 
history-based risk information, and how well do they perform? 
 
For each cancer of interest,  
a. Identify tools designed to facilitate calculation and/or interpretation of family history-
based risk information, with the purpose of promoting recommended clinical actions.  
b. Assess the evidence for effectiveness of these tools in facilitating calculating and/or 
interpretation of family history-based information. 
c. Assess the evidence for effectiveness of these tools in promoting recommended clinical 
actions.  
d. For each tool, identify the evidence base for each recommendation.  
 
D) None of these 
 
Articles for example using record reviews where a tool is not used to ask patients about their 
family history will fall into this category as well as articles where the focus is surveying opinions 
of practitioners about collecting family history.   
 
2) Was the focus of this article about: 
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Mutation models and guidelines are very often used as the backbone to build tools to collect 
family history. 
 
A) A mutation prediction model (specify) 
 
Examples of well known mutation models that you might encounter are: Frank, 
_____________________________________________________ 
 
B) A guideline/consensus statement (specify) 
 
For example the Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer. 
 
C) A hypothetical mutation model => Exclude 
 
For example the authors hypothesize that along BRCA1 and BRCA2 there could be a BRCAu 
mutation.  This does not correspond to real practice, therefore should be excluded. 
 
3) If this article is about a tool, for what setting was it created? 
 
A) Primary care 
Please check if a setting where family physicians, general internists, obstetricians, gynecologists, 
nurses, nurse practitioners, physicians assistants, nutritionists, behaviouralists operate.  
B) Specialist genetic clinic 
Please check if a setting where geneticists or genetics counselors operate 
C) Other specialist clinic 
 
Please check if a setting where surgeons, oncologists or other specialists operate 
 
D) Research  
 
Please check if it was a research setting 
 
4) If the tool was created for a specialist or research setting, is it transferable to primary 
care? 
If the tool is not applicable or usable in primary care it should be excluded.  Please explain why 
in the space provided. 
   
  
 B-14
Generic Data Abstraction Form 
 
Generic  
         















Other    
 
2. If you answered "other" to question 1 please specify:  ____________________ 
 
3. Type of article. (Check all that apply) 
Journal article reporting a primary study      
Conference proceedings      
Thesis      
Technical report      
Letter with primary study data      
  Guideline      
  Other __________________________________________     
  
 4. Study design. (Check only 1) 
Randomized trial - experiment      
  Non-randomized trial      
  Prospective cohort      
  Other design with concurrent comparison group      
  Retrospective cohort study      
  Case control study      
  Time series study      
  Before-after study      
  Cross-sectional study      
  Non-comparative study      
  Tool development study      
  Other (specify) __________________________________________     
  Not reported      
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5. Other inclusion criteria:  __________________________________________     
 
6. Participants. (Check all that apply) 
General population      
  Patients from a Primary Care Provider Setting      
  Cancer patients      
  First degree relatives of a cancer patient      
  Primary care provider      
  Hospitalized patients      
  Patients from a cancer registry      
  Other (specify)   __________________________________________       
  
7. Who was the provider who collected family history/used family history/risk assessment tool?  
(Check all that apply) 
Family physician      
  General Internist      
  Obstetrician/Gynecologist      
  Nurse      
  Nurse practitioner      
  Physician's assistant      
  Nutritionist/Dietician      
 Psychologist      
  None (self-administered by patient)      
  Geneticist      
  Other (specify) __________________________________________      
  Not reported      
  
8. Does the paper describe the provider's attitudes towards collecting or using family history in 
clinical practice?   
Yes      
  No      
   
9. What was the method used to collect family history? (Check all that apply) 
Face-to-face personal interview      
  Telephone interview      
  Self-completed survey       
  Mail      
  Other (specify) __________________________________________        
  Not reported  
  
10. How were data collected?  (Check all that apply) 
On paper medium      
  On electronic medium      
  Other (Specify) __________________________________________      
  Not reported      
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 11. Was the information collected using a:  (Check all that apply) 
Pedigree format      
  Non-pedigree format      
  Other information format      
  Not reported      
   
 12. Family history included:  (Check all that apply) 
Parents      
  Siblings      
  Children      
Second degree relatives (uncles and aunts, nieces and nephews, grandparents) 
   Specify:      
  3rd degree relatives and beyond (cousins, great aunts and great uncles) Specify:      
  Other (specify)  __________________________________________        
  Not reported      
  




Accuracy Data Abstraction Form 
        
1. Age was reported for: (Check all that apply) 
Patients or probands (please specify age data as provided in the study)      
  Providers (please specify age data as provided in the study)      
  Relatives (please specify age data as provided in the study)      
  Other (Specify) __________________________________________     
  Not reported      
   
2. Method used to validate family history for AFFECTED relatives. (Check all that apply) 
Personal interview with relatives      
  Self completed survey (site completed) with relatives      
  Self-completed survey (postal) with relatives      
  Relatives' medical record      
  Cancer registry      
  Death certificate      
  Physician's report      
  Other (specify)  __________________________________________        
  Not reported      
  
3. If applicable: method used to validate family history of NON AFFECTED relatives.  
 (Check all that apply) 
Personal interview with relatives      
  Self-completed survey (site completed) with relatives      
  Self-completed survey (postal) with relatives      
  Relatives'' medical record      
  Cancer registry      
  Death certificate      
  Physician's report      
  Other (specify) __________________________________________         
  Not reported      
  
 4. Setting where family history was collected.  (Check all that apply) 
Patient's home/Community setting      
  Primary care setting      
 Specialty clinic      
  Hospital      
  Genetic counseling clinic      
  Other   __________________________________________       
  Not reported      
  
 Group 1 Group 2 Group 3 Group 4 Group 5 
5. Participants' 
distribution       
     
6. Number recruited 
at onset of  study       
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7. Included in 
analysis   
     
8. Lost to follow-up 
(provide reason  
if available) 
     
9. # of participants 
with POSITIVE  
family history for 
cancer in first degree 
relatives       
     
10. # of participants 
with NEGATIVE  
family history for 
cancer in first degree  
relatives       
     
            
11. What was the metric used to evaluate accuracy?  (Check all that apply) 
Sensitivity (#, %)      
  Specificity (#,%)      
  + Likelihood ratio (#, CI)      
  - Likelihood ratio (#, CI)      
  Diagnostic Odds Ratio (#, CI)      
  Summary ROC curves      
  Proportions      
  Other (specify) __________________________________________          
   
12. Were there outcomes measured other than accuracy (please specify)?   
1 __________________________________________          
  2 __________________________________________       
  3 __________________________________________        
  4 __________________________________________         
  5 __________________________________________         
  6 __________________________________________          
  




QUADAS Data Abstraction Form  
  
      Yes No Unclear 
1. Was the spectrum of patients representative of the 
patients who will receive the test in practice?     
   
2. Were selection criteria clearly described?        
3. Is the reference standard likely to correctly classify 
the target condition?     
   
4. Is the time period between reference standard and 
index test short enough to be reasonably sure that the 
target condition did not change between the tests? 
   
5. Did the whole sample or a random selection of the 
sample, receive verification using a reference standard 
of diagnosis?     
   
6. Did patients receive the same reference standard 
independent of the index test results?     
   
7. Was the reference standard independent of the index 
test (i.e. the index test did not form part of the 
reference standard)?    
   
8. Was the execution of the index test described in 
sufficient detail to permit replication of the test?     
   
9. Was the execution of the reference standard 
described in sufficient detail to permit its replication?    
   
10. Were the index test results interpreted without 
knowledge of the results of the reference standard?     
   
11. Were the reference standard results interpreted 
without knowledge of the results of the index test?     
   
12. Were the same clinical data available when test 
results were interpreted as would be available when 
the test is used in practice?  
   
13. Were uninterpretable/ intermediate test results 
reported?     
   
14. Were withdrawals from the study explained?       
 
15. Comments:  __________________________________________     
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Common Q2 & Q3 Data Abstraction Form 
      
1. Was the tool developed:  (Check all that apply) 
In Primary Care:      
  In settings other than Primary Care, but it is applicable to Primary Care      
  
 2. If the tool was developed in settings other than Primary Care where was it developed?  
(Check all that apply) 
Specialist genetic clinic      
  Other specialist clinic      
  Research      
  
 3. What was the purpose of the tool?  (Check all that apply) 
 Clinical use      
  Research      
  
 4. How was the tool being used?  (Check all that apply) 
Proactively (everybody receives it)      
  Reactively (received under patient query)  
As a method of data collection (i.e. not other purposes after data collection)  
  
5. How are data presented after collection?  (Check all that apply) 
Table      
  Pedigree      
  Other (Specify) __________________________________________        
  Not reported      
  
 6. Is the information collected integrated with an electronic record?   
Yes      
No      
 
7. Age was reported for:  (Check all that apply) 
Patients or probands (please specify age data as provided in the study)      
  Providers (please specify age data as provided in the study)      
  Relatives (please specify age data as provided in the study)      
  Other (Specify) __________________________________________         
  Not reported      
   
8. Setting where family history tool was used:  (Check all that apply) 
Patient's home/Community setting      
  Primary care general setting      
Primary care-specific clinic (e.g. good health clinic, preconceptual clinic,     
    hormone replacement therapy clinic)      
  Specialty clinic      
  Hospital      
  Genetic counseling clinic      
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  Other (specify) __________________________________________         
  Not reported      
  
9. Tool Format A. Was the tool designed to prompt information about: (Check all that apply) 
Parents      
  Siblings      
  Children      
  Second degree relatives (aunts and uncles, nieces and nephews, grand parents)      
  3rd degree relatives and BEYOND (cousins, grand aunts and uncles)      
  2 generations      
  3 generations      
  Not reported      
  Other (specify) __________________________________________          
    
10. Tool Format B. Was the tool designed to collect information on relatives with: (Check all 
that apply) 
One specified cancer      
  One syndrome cancer      
  Any cancers      
  Cancer and other conditions      
  Other (specify) __________________________________________         
  Not reported  
   
11. Tool Format C.  Does the tool collect information about patient's affected relatives in order 
to:  (Check all that apply) 
Identify exact relationship to proband      
  Determine the age of diagnosis      
  Determine the cause of death      
  Determine the age of death      
  Determine exact diagnosis      
  Determine the site of cancer      
  Other (specify) __________________________________________         
  Not reported      
    
12. Tool Format C (a): Does the tool collect information about unaffected relatives in order to:  
(Check all that apply) 
Identify exact relationship to proband      
  Determine the age of the diagnosis      
 Identify ethnicity      
 Determine the cause of death      
   Determine the age of death      
  Other __________________________________________       
  Not reported      
    
13. Does the tool collect information on:  (Check all that apply) 
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Mother's side relatives      
 Father's side relatives      
  Not specified      
  Participant's relevant past medical history      
  Other (specify) __________________________________________         
  Not reported  
   
14. Did the tool collect information about relatives' ethnic background?   
Yes      
  No      
    




Q2 Data Abstraction Tool 
       
1. What are the tools/ approaches for family history collection being compared?   
1 __________________________________________     
2 __________________________________________         
  3 __________________________________________         
  4 __________________________________________         
  5 __________________________________________          
  
 Tool 1 Tool 2 Tool 3 Tool 4 Tool 5 
2. Participants' distribution       
3. If applicable: Number 
of practices recruited      
     
4. Number of participants 
recruited at onset of  
 study     
     
5. Included in analysis           
6. Number or percentage 
of first degree relatives 
recorded 
     
7. Number of percentage 
of second degree relatives 
 recorded      
     
      
8. What was the metric used to evaluate accuracy?  (Check all that apply) 
Sensitivity (#, %)      
  Specificity (#,%)      
  + Likelihood ratio (#, CI)      
  - Likelihood ratio (#, CI)      
  Diagnostic Odds Ratio (#, CI)      
  Summary ROC curves      
  Other (specify)  __________________________________________        
  Not reported      
  
 9. Were there outcomes measured other than accuracy (please specify)?   
1 __________________________________________         
  2 __________________________________________         
  3 __________________________________________         
  4 __________________________________________         
  5 __________________________________________         
  6 __________________________________________         
  Not reported      
    




Q3 Risk Tool Data Abstraction Form 
       
1. Tool purposes: (Check all that apply) 
Stratify risk      
  Calculate risk      
  Communicate risk to the patient      
  Define/suggest a clinical management strategy      
  Other (specify) __________________________________________         
  Not reported      
  
 2. Was a consensus/ guideline/ model/ decision aid used for this tool to measure risk?   
Yes      
  No      
  Not applicable      
  Not reported      
  
3. If you answered Yes to Question 2: What was the consensus/ guideline/ model/ decision aid 
used for this family history tool to measure risk?  (Check all that apply) 
BRCAPRO      
  Claus      
  Gail      
  Ottman      
  Anderson      
  Taplin      
  Amsterdam      
  Bethesda      
  Ramsey      
  Other (specify)      
  
 4. Does the tool collect information on:  (Check all that apply) 
Mother's side relatives      
  Father's side relatives      
  Not specified      
  Participant's relevant past medical history      
  Other (specify) __________________________________________          
  Not reported  
   
5. What comparison interventions non/current practice, other tool were evaluated?   
1 __________________________________________        
  2 __________________________________________         
  3 __________________________________________         
  4 __________________________________________         
  5 __________________________________________         
  None      
  Not reported      
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 1 2 3 4 5 
6. What were the 
outcomes used to assess 
the effectiveness  
of the tool?      
     
7. Sensitivity (#, %)             
8. Specificity (#, %)              
9. Positive Likelihood 
ratio (#, CI)      
     
10. - Likelihood ratio (#, 
CI)      
     
11. Diagnostic Odds Ratio 
(#, CI)      
     
12. Summary ROC curves        
13. Other (specify)           
14. Not reported           
            
   
 Group 1 Group 2 Group 3 Group 4 Group 5 
15. Participants' 
distribution      
     
16. Included in analysis           
17. If applicable: Number 
of practices 
 recruited      
     
18. Number of participants 
recruited at 
onset of study      
     
19. Lost to follow-up 
(provide reason if  
available)      
     
20. Number or percentage 
of first degree  
relatives recorded      
     
21. Number of percentage 
of second  
degree relatives recorded     
     
      
22. What was the timing used to measure the outcomes?   
1 __________________________________________        
  2 __________________________________________         
  3 __________________________________________         
  4 __________________________________________         
  5 __________________________________________         
  
 23. Reviewers' comments __________________________________________   
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  Internet Sites Accessed 
 
Family History Tools Available on the Internet 
Title Website address Type 
The U.S. Surgeon General’s 
Family History Initiative  
  
Department of Health and 




Website accessed on June 28th, 2007. 
Family Health Portrait – Paper Version  
Agencies involved in this project: Human Genome 
Research Institute (NHGRI), the Centers for 
Disease Control and Prevention (CDC), the Agency 
for Healthcare Research and Quality (AHRQ), the 
American Society of Human Genetics (ASHG) the 
Health Resources and Services Administration 
(HRSA), the National Society of Genetic Counselors 
and the Genetic Alliance 




Website accessed on June 28th, 2007. 
Genetic Tools Website– Genetics Through a 
Primary Care Lens 




Website accessed on June 28th, 2007. 
Genetic Tools Website – Genetics Through a 
Primary Care Lens 
American Medical Association 




Website accessed on June 28th, 2007. 
Electronic Family History Form 





Website accessed on June 28th, 2007. 
Family History Questionnaire for Hereditary Cancers 
paper version 






Website accessed on June 28th, 2007. 
Family History Tool Kit – paper version 
Norwich Union Health Tree http://www.norwichunion.com/healthtree/index.htm 
 
Website accessed on June 28th, 2007. 
Electronic Family History Builder (pedigree) 
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Title Website address Type 
JamesLink: Personalized 
Cancer Risk Assessment 
Ohio State University 
Comprehensive Cancer Center – 
James Cancer Hospital and 




Website accessed on June 28th, 2007. 
Interactive tool that estimates cancer risk by 
reviewing patterns of cancer in a  
The Munroe-Meyer Institute for 
Genetics and Rehabilitation 
and the Eppley Cancer Center 




Website accessed on June 28th, 2007. 
Interactive Cancer Family Tree 
Evanston Northwestern Center 






Website accessed on June 28th, 2007. 
 
Interactive Family History Tools  
Genetic Susceptibility to 
Breast and Ovarian Cancer: 
Assessment, Counseling and 
Testing Guidelines 






Website accessed on June 29th, 2007. 
 





Scoring Criteria for the Family History Tools (FHT) 
 
Attribute Original scoring range Corrected scoring 
1 = lowest score; 5 =highest score 
Length of tool 1= too short 
3 = adequate size 
5 = too long 
Score 1 = 1    
Score 2 = 3 
Score 3 = 5    
Score 4 = 3 
Score 5 = 1 
Ease of completion 1= very difficult 
5 = very easy 
No change 
Need specialist knowledge to complete FHT 1= need specialist knowledge 
5 = complete without knowledge input 
No change 
Minimum collect details on ALL 1st degree relatives 1 = no details collected 
5 = details collected on all 1st degree relatives 
No change 
Clarity of family history collection including 
appropriate structure, layout & logical sequence 
1 = poor clarity 
5 = excellent clarity 
No change 
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FHTs were independently scored by 2 assessors & any discrepancy resolved through planned consensus discussion using the criteria above 
 
*Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility.  Journal of Clinical Oncology 2002 Jan 2;20(2):528-37. 
 
Abbreviations:  NE=not evaluated 
Scoring of Available Family History Tool 
 







The U.S. Surgeon General’s 
Family History Initiative  3 4 5 5 3   20 
 
AAFP Family Disease 
Checklist  5 3 3 3 2   16 
 
AAFP Your Family Medical 
History 3 4 5 5 3   20 
Ethnicity 
reported 
American Medical Association 
Adult Family History Form 3 2 3 5 2   15 
Ethnicity 
reported 
Myriad Tests Family History 
Questionnaire 3 4 3 1 2   13 
 
Utah Department of Health 
NE NE NE NE NE NE 
NOT enough 
information on 
tool to evaluate 
Norwich Union Health Tree 3 4 5 3 2   17  
JamesLink: Personalized 
Cancer Risk Assessment 
      
Assessed as 
part of article 
by Sweet et al.* 
The Munroe-Meyer Institute  3 4 3 4 2   16  
Evanston Northwestern Center 
for Medical Genetics NE NE NE NE NE NE 
NOT enough 
information on 
tool to evaluate 
Guidelines 
American College of Medical 
Genetics Foundation 
3 4 5 4 3   19 
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Reviews Available on the Internet describing Family History Tools 
Title Website address Type 
The Genetic Family History In 




Website accessed on June 28th, 2007. 
NCHPEG Newsletter for Health Care 
Professionals 
The Genetic Family History In 




Website accessed on June 28th, 2007. 
NCHPEG Newsletter for Health Care 
Professionals 
The Genetic Family History In 




Website accessed on June 28th, 2007. 
NCHPEG Newsletter for Health Care 
Professionals 
The Genetic Family History In 




Website accessed on June 28th, 2007. 










Title Website address Type 
BRCA and Breast/Ovarian 





Website accessed on June 28th, 2007. 
 
Draft Genetic Test Review 
Decision aid for the 
introduction of population-
based genetic screening 
programs (work in progress). 
www.aetmis.gouv.qc.ca 
 
Website accessed on June 28th, 2007. 
 
Agence d’évaluation des technologies et des 
modes d’intervention en santé (AETMIS) Report 
 
Contribution of BRCA1/2 
Mutation Testing to Risk 
Assessment for Suceptibility to 




Website accessed on June 28th, 2007. 
 
Summary Report from Agence D’Évaluation des 
Technologies et des Modes D’Intervention en 
Santé Summary Report 
Predictive Genetic Testing for 
Breast and Prostate Cancer 
www.ccohta.ca 
 
Website accessed on June 28th, 2007. 
 
Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA) Technology 
Report 
Molecular Diagnosis for 
Hereditary Cancer 
Predisposing Syndromes: 




Website accessed on June 28th, 2007. 
 
Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA) Technology 
Report 
BRCA1 and BRCA2 Predictive 
Genetic Testing for Breast and 
Ovarian Cancers: Asystematic 
Review of Clinical Evidence 
www.ccohta.ca 
 
Website accessed on June 28th, 2007. 
 
Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA) Technology 
Report 
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Appendix C. Evidence Tables 
 
Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer Site 
and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 








Interview with geneticist 
 
Patients: Patients scheduled for 
genetics consultation at 
university genetics centre 
 
Age: Mean 40 years (SD 12) 
 
Cancer site: Cancer free and 
cancer not specified 
 
Setting: Genetics counseling 
centre 
Method of collection:  
Computerized tool “Genetic 
Risk Easy Assessment Tool 
(GREAT)” and compared to 
face to face interview 
 
Medium: Paper and electronic 
 
Format: Pedigree format 
Relatives characteristics:  
First degree relatives 
 
Affected relatives: Not verified due to 
reliability study 
 
Unaffected relatives: Not verified due to 





Study design: Case 
control  
 
Criterion standard:  
Relatives self report; 
relatives doctors report; 
pathology reports; 
information from 
hospitals and death 
certificates 
Patients: Patients undergoing 
colonoscopy at a teaching 
hospital; cases had  hyperplastic 
or adenomatous polyp diagnosed 
at colonoscopy; controls were 
free of polyps 
 
Age: 20 to 75 years  
 
Cancer site: colorectal  
 
Setting: Hospital 
Method of collection:  
Mail survey 
 




Relatives characteristics:  
First degree relatives 
 
Affected relatives:  
Medical records; medical history 
questionnaires mailed to living relatives and 
surviving spouses  
 










(although author states 
that personal interview 
is the standard relative 
to registry) 
Patients: Population based 
cancer patients derivd from a 
surveillance program of Orange 
county registry; complete family 
history data available for 252 of 
359 patients  
 
Age: 30 to 80 years 
 
Cancer site: Breast  
 
Setting: Population based 
surveillance program in Orange 
county   
Method of collection:  
Telephone interview using 
structured family history 
questionnaire 
 
Medium: Paper and electronic 
 
Format: Interview (questions 
included types of cancer dates 
of diagnosis, birth and death of 
all informant family members) 
 
 
Relatives characteristics:  
First degree relatives 
 
Affected relatives:  
Cancer registry 
 




Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history (continued) 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer 
Site and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 










Patients: Patients attending 
High Risk program (patients 
had positive history for 
breast cancer in relatives) 
 
Age: Mean age 45 years 
 
Cancer site: Breast  
 
Setting: Specialty clinic for 
high risk patients 
Method of collection:  
Self completed questionnaire 
administered to patients prior 




Format: Not reported but after 
collection, data presented in a 
flow chart 
Relatives characteristics:  
First and second degree  
 
Affected relatives:  
Personal interview with relatives and 
relatives medical record 
 








Hospital records of the 
patients and relatives 
reported having 
cancer 
Patients: Cancer patients 
diagnosed before the age of 
40 and those with bilateral 
disease  
 
Age: 20 to 70 years 
 
Cancer site: Breast  
 
Setting: University hospital 
Method of collection:  






Relatives characteristics:  
First  through to fifth degree 
Families traced back as far as the first 
healthy parents of the oldest known breast 
or ovarian cancer generation 
 
Affected relatives: Medical records, cancer 
registry and parish registry 
 
Unaffected relatives: Medical records, 









Patients: Men free from 
cancer with a history of two 
or more relatives with 
prostate cancer or one 
relative with a history of 
prostate cancer before the 
age of 55 ; patients recruited 
from a population based 
study on prostate cancer 
  
Age: Mean 58 years (range 
39 to 87) 
 
Cancer site: Prostate  
 
Setting: Patients home, 
community setting (mailed 
survey) 
Method of collection:  
Face to face interview and  
mailed survey 
 
Medium: Paper  
 
Format: Non-pedigree format 
Relatives characteristics:  
First, second and third degree relatives and 
beyond if available 
 
Affected relatives: Relatives medical 
records 
 
Unaffected relatives: NR 
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Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history (continued) 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer 
Site and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 











Patients: Random sample 
of patients undergoing  
mammography (from the 
Vermont Breast Cancer 
Surveillance System) where 
the patients had no personal 
history of breast cancer, and 
a negative mammography  
 
Age: <65 years  
 











Relatives characteristics: First, second 
and third degree relatives 
 
Affected relatives:  Personal interview with 
relatives, cancer registry - Vermont Breast 
Cancer Surveillance System 
 












reports confirming the 
colorectal cancer 
diagnoses) 
Patients: Population based 
case control study; first 
degree relatives of colon 
cancer patients  
 
Age: < 60 years; mean age 
of relatives was 50 years 
(range 19 to 84 years) 
 
Cancer site: Colorectal  
 
Setting: Patients home, 
community setting  
 
Method of collection:  
Mailed survey  
 
Medium: Paper  
 
Format: NR 
Relatives characteristics:  
First degree relatives 
 
Affected relatives:  
Mailed survey to relatives 
 
Unaffected relatives:  













Patients: Cancer patients 
derived from a prospective 




Cancer site: Colorectal  
 
Setting: Specialty surgical 
clinic 
 
Method of collection:  
Interview by surgeon  
 
Medium: Paper  
 
Format: Pedigree  
Relatives characteristics:  
First  and second degree relatives 
 
Affected relatives: Relatives medical 
record; cancer registry; death certificate 
 
Unaffected relatives: NR 
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Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history (continued) 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer 
Site and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 












population and from primary 
care setting 
 
Age: 30 to 79 years 
 
Cancer site: Breast, 
ovarian, prostate, colorectal  
 
Setting: Patients home in a 
community setting 
Method of collection:  








Relatives characteristics: First degree 
relatives 
 
Affected relatives:  
Utah Cancer registry 
Utah Population Database 
 
Unaffected relatives:  








Medical records and 
death certificates 




Cancer site: Prostate 
 
Setting: Prostate clinic  
Method of collection:  
Face to face interview: type of 





Relatives characteristics:  
First degree relatives 
 
Affected relatives:  
Relatives medical record 
 















autopsy reports  
Patients: Patients at high 








and at cancer clinic 






Format: Pedigree  
Relatives characteristics:  
First degree relatives 
 
Affected relatives:  
Relatives medical record; pathology and 
operative reports,hospital admissions and 
discharge summaries; death certificate, 
autopsy reports  
 









Patients: Controls, general 
population and spouses of 
cases controls  
Cancer patients: colorectal 
cancer cases 
 
Age: Mean age 64 years  
 
Cancer site: Colorectal  
 
Setting: Regional hospitals  
Method of collection:  
Face to face interview 
conducted by genetics nurse 
 
 
Medium: Paper  
 
Format: Pedigree  
 
 
Relatives characteristics:  
First and second degree relatives 
 
Affected relatives:  
Scottish Cancer Registry 
 
Unaffected relatives:  
Scottish Cancer Registry  
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Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history (continued) 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer 
Site and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 










Hospital records  
Patients:  Cases: French 
Canadian women recently 
diagnosed with cancer 
Controls: General population 
 
Age: Mean age 59 years, 
(range 30 to 79 years) 
 
Cancer site: Breast cancer 
 
Setting: Patient's home, 
community setting 
Method of collection:  





Relatives characteristics:   
First degree relatives 
 
Affected relatives:  
Relatives medical record 
 








Medical records or 
death certificates 
Patients: First degree 
relatives of a Li-Fraumeni 
Syndrome cancer patient or 
an hereditaty breast ovarian 








Method of collection:  
Self completed survey 
 
Medium: Paper  
 
Format: Pedigree  
Relatives characteristics:  
First and second degree relatives 
 
Affected relatives:  
Relatives medical record, death certificate  
 











Patients:  Referred to 
genetic counseling clinic 
with and without cancer 
 
Age:  NR 
 
Cancer site: Breast, 
ovarian, colorectal 
 
Setting: Patients home and 
genetic clinic 
Method of collection:  




Format:  Pedigree 
Relatives characteristics:  
First to fourth degree relatives 
 
Affected relatives:  
Medical records 
 
Unaffected relatives:  
NR 
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Evidence Table 1: Characteristics of studies focusing on the accuracy of reporting cancer family history (continued) 
Author, Year, Country Study Design and 
Criterion Standard 
Study Population, Cancer 
Site and Clinical setting 
Method of Family History 
Information Collection 
Relatives Characteristics and Methods 








Relatives self report, 
medical records and 
Ontario Cancer 
Registry  
Patients: Cancer patients 
 
Age: Range 31 to 70 years  
 
Cancer site: Breast, 
ovarian, prostate and 
colorectal 
 
Setting: Patients home, 
community and clinical  
Method of collection:  
Face to face interview and self 
completed survey (mail) 
 
Medium: Paper  
 
Format: NR 
Relatives characteristics:  
First and second degree relatives 
 
Affected relatives:  
Personal interview with relatives 
 
Unaffected relatives: A random sample of 
100 first-degree relatives reported as 
unaffected by cancer submitted to the 









Hospital records  
Patients: Patients from a 
cancer registry and the 
African American Hereditary 
Cancer Study 
 
Age: Range 40 to70 years, 
mean age 50.4 years  
(SD=7.6) 
 
Cancer site: Prostate  
 
Setting: Patient's home, 
community setting 
Method of collection:  
Face to face interview first time 





Format: One Question “Have 
any of your men blood 
relatives ever had prostate 
cancer?” 
Relatives characteristics:  
First, second and third degree relatives and 
beyond 
 
Affected relatives: Relatives medical 
record 
 









tumor tissue samples 
or clinical records; 
relatives self-reports; 
death certificates  
Patients: Cancer patients 
recruited from population 
based and clinic based 
family registries of breast, 





Cancer site: Breast, 
ovarian, prostate, colorectal  
 
Setting: Patients home, 
community setting 





entered data into Genetics 
Registry In System (GRIS)) 
 
Format: Pedigree produced 
from GRIS  
Relatives characteristics:  
First degree, second degree, third degree 
relatives and beyond  
 
Affected relatives:  
Personal interview with relatives 
Self completed survey, medical records, 
death certificate 
 
Unaffected relatives:  
Personal interview with relatives 
Self completed survey, medical records, 
death certificate 
 
Abbreviations: GRIS=Genetics Registry in System; NR=not reported; SD=standard deviation 
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Tool Purpose, Data 
Collection Strategy 
and Format 



















clinic, mean age 40 yrs 
 
Setting:  
Cancer genetics clinics 
 
Cancer type:  
24 types of cancer 
excluding non-
melanoma skin cancer 
 
Tool implementation: 





comparator study  
Tool: 



















Risk factors for cancer  
 
Strategy: 
General enquiry about 
1DR, 2DR and first 
cousins 
Details of cancer in 
affected relatives 
Information from more 
distant relatives only if 
they had cancer 
 
 





1DR, 2DR, 1st cousin 
 
Information on 
affected relatives:  
Primary site of cancer, 
age of diagnosis, 




unaffected relatives:  

















Tool vs comparator: 
 
1.  Mean % per family 
of all members 
recognized 
a.  1DR - 98.5 v 97.3 
(p > 0.05) 
b.  2DR - 93.9 v 74.3 
(p < 0.001);  
c.  First cousin -  94.5 
v 48.6 (p > 0.001) 
 
2.  Agreement on risk 
categories 
a. kappa=0.7 
b. correlation= 0.77 
 
3.  Test-retest 
reliability 
a. 1DR 97% 
b. 2DR 93% 
c. cancer 98% 
 
*Data relating to performance as a FHxT reported here pertain only to the RAGS prototype tool 21.  For performance of GRAIDS as a RAT, please see Evidence Table Q3 
 
Abbreviations: CI = confidence interval; DR = degree relative; FH = family history; FHxT = Family History Tool; GP = general practitioner; NR = not reported; PMH = past 









Tool Purpose, Data 
Collection Strategy 
and Format 




























































Direct questions for 
details of relatives 
with breast cancer; 
details of cancers;  
number of relatives 
with ovarian and 
colorectal cancers; 
note of relatives with 
sarcoma,  leukemia or 
brain tumor 





1DR, 2DR, 3DR 
 
Information on 
affected relatives:  
Age, diagnosis and 







Genetics interview  
 











1.  Sensitivity = 
95% (95% CI 89 
to 99%)   
2.  Specificity = 
96% (95% CI 79 










with family history of 





















































FH comparator:  
Genetics interview 
 

















Tool Purpose, Data 
Collection Strategy 
and Format 



























































‘Dynamic data input’ 
capturing family 
history 





































practice patients, 25 





































Not clear  
 









Exact relationship to 
informant; age of 
diagnosis; cause of 
death; age of death; 








FH comparator:  
None 
 

















Tool Purpose, Data 
Collection Strategy 
and Format 
































Design:   
Randomized cross-








Assessment in an 














RAGS – no 
GRAIDS – potentially, 













NR, from presented 





Exact relationship to 
informant, age of 






From Emery21 2000 
FH comparator:  
1.  Current practice 
(pen & paper) 




Sample size for 
analysis:  
completing pedigrees 
for 6 simulated 
patients per arm n=36 
 
Sample size 







1.  Median # 
correct 
pedigrees. 
RAGS – 5.06/6 
Cyrillic – 3.5/6 




2.  Preferred 
method  
RAGS - 75% 
Cyrillic – 8% 
Pen & paper – 
17% 
 
3.  Ease of use 
RAGS - 86% 
Cyrillic – 8% 












Setting:  Breast 
screening clinic 
 
Cancer type:  






























Direct questions on 
breast cancer and 
age of diagnosis in 
specific relatives 
(1DR, DR) - linked 
with guideline 
recommendation 
Side of family 















Genetic interview  
 











1.  Agreement on 
risk 
categorization on 
basis of FH data 
(population  v 
elevated) - 100% 
agreement 
 
2.  Errors in 
completing FHQ 
risk category not 
identified - 5% 
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Tool Purpose, Data 
Collection Strategy 
and Format 



















clinic, age  range 21 



































Not clear - focus on 
specific conditions 
 















Patient charts  - 






Sample size for 
analysis: 
Tool group  n=39 
Interview group  n=39 
 
Sample size 








1.  # at risk on 
basis of FH data, 
a.  breast/ovarian 
cancer 
tool – 2/39,  
chart 0/39 
interview – 5/39, 
chart 2/39 
b.  colon cancer 
tool – 3/39,  
chart – 1/39 















































































1.  Concordance 
of relatives’ 
diagnosis and 
type of cancer 
258/387 = 67%  
 
2.  Of 311 with 
1DR or 2DR with 
cancer (either 
method) – 
184/311 = 59% 
concordance 
 
3.  Of 127 where 
data discordant, 
37/127 charts did 
not record or 
recorded a 
negative FH 
where tool had 
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Tool Purpose, Data 
Collection Strategy 
and Format 













4.  834 cancers 
reported in FHxT, 









All patients on a 










































about PMH or FH of 
1DRs with colorectal 
cancer or polyp; if 
positive FH it 
specifies details on 
affected 1DRs and FH 
for other specified 
cancers  









Exact relationship to 
informant; age of 
diagnosis; cause of 
death; age of death; 



























Patients in an internal 
medicine practice, 





Cancer type:  



















cancer, ethnicity  
 
Strategy: 
Not clear; set of 
specific questions and 
tick boxes 
 









Exact relationship to 























Tool Purpose, Data 
Collection Strategy 
and Format 




























Female relatives of 


















































Exact relationship to 
informant;  age of 



































Cancer type:  




























Direct questions on 
affected relatives 
 









Exact relationship to 
informant, age of 






FH comparator:  
Genetics interview 
 
Sample size for 




calculation for FH 
outcomes: 
With 53 participants, 
80% power to detect 
a difference in 
marginal proportions 
in the amount of 
unspecified data 











a.  Missing data  
age – 5/53 9.4%) 
• diagnosis – 
6/53 (11.3%) 









Tool Purpose, Data 
Collection Strategy 
and Format 

















methods of 0.14 at 
α=0.05 
 
b.  Unspecified 
data  
• age – 2/53 
(3.8%) 
• diagnosis – 
2/53 (3.8%) 



















































inserted into table 
where diagnoses and 
details entered 
 










informant, age of 






















1.  # 1DR 
relatives reported 
to have cancer 
a. colorectal = 19 
vs 11 
b. breast = 64 vs 
51 
c. ovarian = 11 
vs 6 
 
2.  # 2DR 
relatives reported 
to have cancer 
a. colorectal = 79 
vs 31 
b.  breast = 184 
vs 52 
c. ovarian = 26 
vs 5 
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Tool Purpose, Data 
Collection Strategy 
and Format 











































































Sample size for 
analysis: 
Tool group - residents 
n=33, patients n=57 









Tool group vs 
control group  
 
1.  % patients 
report physician 
asked about 
family history of 
colorectal 
cancer: 
Tool group - 33% 
Control group - 
25%, p=0.30, 
2.  % patients 
report physician 
asked about 
family history of 
colorectal 
adenomas:  
Tool group -  
25% Control 











oncology clinic  
 
Setting:  Cancer 
centre clinic 
 
Cancer type:  
Breast, ovarian, 






































1DR, 2DR, some 3DR 
 
Information on 
affected relatives:  








Patient charts  
 











1. Of 362 
patients whose 
family histories 
captured by tool, 
only 308 (85%) 
had some FH 
recorded in 
medical records  




captured by tool 
and those 
recorded in 
medical records  
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Tool Purpose, Data 
Collection Strategy 
and Format 

















Women in an ongoing 
cancer prevention 
prospective mortality 
study, median age in 








































Direct questions on 
parents, siblings, 
details of cancers in 
relatives 










informant, age of 






FH comparator:  
None 
 



















and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  



































Reviewed FHxT; not 
applicable to primary 
care  
 
Setting where used: 
Community setting  
 




















N/A (validation study) 
 
Age of Participants: 
NR 
 
Details on Relatives: 












Strategy for FH 
enquiry: 
General enquiry 
about 1DR relative’s 
age and age of death, 












Colorectal and any 
cancers or bowel 
polyp or obstruction 
 
Information on 
affected relatives:  
Determine the age of 







Family and personal 
medical history 
questionnaire was 
mailed to the cases 
and controls, 
compared to relatives 
medical records & 
death certificates 
 
# of participants 












# of second degree 
relatives: NR 
 
Metric used to 
evaluate the 
adequacy of the 
tool:  
Accuracy of FH: 
Sensitivity (#, %): 
Overall: 0.84 (95% CI 
0.77 - 0.88); Cases: 
0.87; Controls: 0.82, 
Specificity (#,%): 
Overall: 0.97 (95% CI 
0.95 - 0.98); Cases: 
0.97; Controls: 0.97, 
% overall agreement 












+details collected on participants and relatives; † extent of details collected on i) relatives’ conditions ii) affected relatives iii) unaffected relatives; * a) comparison with clinical genetics 
pedigree (i.e. gold standard) b) other tool; ^other measures - accuracy, validity, reliability 
Abbreviations: BE = best estimate; Br Ca= Breast Cancer; Ca=Cancer; CASH=Cancer and Steroid Hormone; CFHF= Comprehensive Family History Form CR = cancer registry; 
CRC=colorectal cancer; Cyr = cyrillic; DARCC= Diet, Activity and Reproduction in Colon Cancer; DOB=date of birth; DQ=direct question; DR=degree relative; EsPeR= Personalized 
Estimate of Risks; FCAT = familial cancer assessment tool; FH=family history; FHQ=family history questionnaire; FHxT = family history tool; GCI = genetic counselor interview; GI = 
genetic interview; GNI = genetic nurse interview; GP=general practitioner; GRACE = Genetic Risk Assessment in the Clinical Environment; GRAIDS = Genetic Risk Assessment in an 
Intranet and Decision Support; GRIS= Genetics Registry In System; HNPCC= Hereditary Non-polyposis Colorectal Cancer; IM=Internal Medicine; MR = Medical Record; NICE= 
National Institute for Clinical Excellence; NR = NR; Ov Ca= Ovarian Cancer; PAC= probability of agreement of cancer; PANC= probability of agreement of no cancer PC = primary care; 
PDA=Personal Digital Assistant; PMH=past medical history; PSA = Prostate-Specific Antigen; PSI = physician structured interview; RR = relative risk; RAGs = Risk Assessment in 
Genetics; TRACE=Trial of genetic assessment in breast cancer 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







To estimate the 




cancers and to 
examine how 
















from a population 
cancer registry 










not available for 
review 
 
Setting where used: 
Community setting  
 
Cancer type:  
Colorectal  
 





Method used to 

























1DR; 2DR  
 
Strategy for FH 
enquiry: 
General enquiry 
about all 1DR and 
2DR - DOB and age 
of death 
Specific enquiry of 
DQ each relatives 
medical history of 
cancer, age and 







Colorectal (also site 
specified), 
21 other cancers 
documented: uterus-












the age of diagnosis, 
determine the cause 
of death, determine 
the age of death, 









Compared to details 
on relatives in cancer 
registry & medical 
records  
 
# of participants 









# of first degree 
relatives:  
Group 1: n=6160 
 







Metric used to 
evaluate the 
adequacy of the 
tool:  
% Confirmed 




risk of developing 
CRC: 1.54 (95% CI 
1.26-1.86), for first 
degree relatives RR 
1.71 (95% CI 1.35-
2.13) and for second 
degree relatives (RR 












and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







1) To evaluate 
the validity of 
family history 
information on 
breast cancer in 
mother and 









series of breast 
cancer patients 























Reviewed FHxT; not 
applicable to primary 
care  
 














Method used to 
collect FH: 
Telephone interview 
(From original FH-T): 
using structured FHQ 
 
Format: NR; Table 
 







Age of participants: 

















Strategy for FH 
enquiry: 
General enquiry 
about “All relatives’” 
DOB & age of death. 
Specific enquiry: DQ 
each relatives 
medical history of 













the age of diagnosis, 
determine the cause 
of death, determine 







exact relationship to 
informant, determine 
the age of the 
diagnosis, determine 
the cause of death, 
determine the age of 
death 
Tools compared:  





# of participants 
recruited in each 
group:  
Group 1: n=359 
Group 2: n=359 
 
# of participants in 
analysis:  
Group 1: n=359 
Group 2: n=359 
 
# of first degree 
relatives:  
Group 1: NR 
Group 2: NR 
 
# of second degree 
relatives:  
Group 1: NR  
Group 2: NR 
 
Metric used to 
evaluate the 
adequacy of the 
tool: Sensitivity (#, 
%): 92% mothers and 





















who attended the 














Format: Did not 
report the format of 
Age of participants: 
Patients or 
informants: mean 















Tools compared:  
Group 1 patients 
report 
Group 2 hospital 
records 
 
# of participants 
recruited in each 
group:  
Metric used to 
evaluate the 
adequacy of the 
tool: Wilcoxon's rank 
sums test and 












and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  
status in first-
degree relatives 
of women with a 
strong family 





Specialist clinic  
 
Applicability: FHxT 
not available for 
review 
 











data collection.  After 
collection data were 
presented in a flow 
chart 
 














First and second 
degree relatives 
informant and 
determine the age of 
diagnosis; determine 
the cause of death; 
determine exact 
diagnosis; determine 





Group 1: n=112 
Group 2: n=112 
 
# of participants in 
analysis: group 1: 
n=94, group 2: n=94 
 
# of first degree 
relatives: group 1: 
NR, group 2: NR 
 
# of second degree 
relatives: group 1: 












and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  





























not available for 
review 
 













Method used to 
collect FH: Face to 
face personal 
interview: with health 





Format: It doesn’t 
report the format of 
data collection; data 
are presented in a 









Age of participants: 
Patients or 
























determine the age of 
diagnosis; determine 
the cause of death; 
determine the age of 
death; determine 
exact diagnosis; 






Tools compared:  
# of participants 
















Metric used to 
evaluate the 






levels of men tested. 
Risk of cancer in men 
screened 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







To develop and 











from a Primary Care 
Provider Setting; 
First degree relatives 






Research: pilot test. 
 
Applicability: FHxT 
not available for 
review 
 





























Age of participants: 
Patients or 
informants: 24 - 54 
years; 


































determine the age of 
diagnosis; determine 
exact diagnosis; 






Tools compared: 1: 




# of participants 
recruited in each 
group: Group 1: 42. 
 
# of participants in 
analysis: group 1: 
39. 
 
# of first degree 
relatives: group 1: 
NR. 
 
# of second degree 
relatives: group 1: 
NR. 
 
Metric used to 
evaluate the 













and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  




Study purpose:  
To assess the 

















subjects were invited 
to participate in the 









FHxT not available 
for review 
 
Setting where used: 
General population 
 























































To identify exact 
relationship to 
informant determine 
the age of diagnosis 





relatives: Number of 




Tools compared:  
One Family history 
questionnaire 
 
# of participants 
recruited in each 
group:  
5072 eligible for the 
study 
 





# of first degree 
relatives: N/A 
 
# of second degree 
relatives: N/A 
 
Metric used to 
evaluate the 
adequacy of the 
tool:  

















and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







1) To evaluate 
the validity of 
the family 
history of breast 
cancer reported 
by patients 
2) To evaluate 



















not available for 
review 
 





Cancer type:  
Breast  
 
Study design:  
Non-comparative 





Method used to 
collect FH: Self-
completed survey: 










Age of participants: 
Patients or 
informants less that 
40 years; 













First degree relatives 
3rd degree relatives 
and beyond: grand 














the age of diagnosis; 
determine the cause 






Tools compared: 1: 
Young patients< 40, 
2: Bilateral patients, 
3: Unselected 
patients were 




# of participants 




# of participants in 
analysis: group 1: 
170, group 2: 118, 





# of first degree 
relatives: group 1: 
NR, group 2: NR, 
group 3: NR. 
 
# of second degree 
relatives: group 1: 
NR, group 2: NR, 
group 3: NR. 
Metric used to 
evaluate the 




- Hospital records 
- Cancer registry 




- Population register 
centre 
Other outcomes 
measured: 1: Family 







cases, 3: Potential 














Patients from a 
primary care provider 
 
Practitioners: 















Age of Participants: 
















To identify exact 
relationship to 
informant, determine 
Tools compared:  
Survey vs medical 
record 
 
# of participants 
recruited in each 
group:  
n=1870 patients who 
returned the survey 
 
Metric used to 
evaluate accuracy: 
 















and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  






Primary Care and in 




FHxT not available 
for review 
 
























All blood relatives 




Strategy for FH 
enquiry: 
Survey (self-reported 
FH) and medical 
chart review 
the age of diagnosis, 









# of participants in 
analysis:   




# of first degree 
relatives: 1DR with 
onset age ≤60 years 
or 2 or more 1st 
degree relatives at 
any age= 53 (2.9%); 
1st degree relative 
with onset at ≥60 




# of second degree 
relatives: other 








history of colorectal 
cancer 
-Beliefs 
-Identification of risk: 
407 (39.1%, 95% CI 
36.1%, 42%) out of 
1041 respondents < 
50 respondents that 
their clinician had 
asked for FH 
colorectal cancer; 
72.2% (95% CI 70.0, 
76.4) of respondents 
50 years or older said 































In settings other than 
primary care, but it is 






Method used to 
collect FH: 
































To identify exact 
relationship to 
informant, determine 
the age of diagnosis, 




Tools compared:  
Ontario Familial 
Colorectal Cancer 





# of participants 




# of participants in 
analysis:   
Metric used to 
evaluate the 
adequacy of the 
tool: 
Confirmed diagnosis 
of family member 






Newfoundland rate of 
FDR affected with 
CRC is 1.5-fold 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  
Applicability: 
FHxT not available 
for review 
 





Cancer type:  
Colorectal 
 











Strategy for FH 
enquiry: 









# of first degree 
relatives: In 
Newfoundland 31% 
(n=220) and in 
Ontario 20.4% 
(n=764) of cases had 
at least 1 first degree 
relative affected with 
CRC 
 
# of second degree 
relatives: N/A 
 











and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







To evaluate the 
interest of first 
degree relatives 
of colorectal 
cancer patients  
to participate in 
colonoscopy 
screening and  
to compare the 
findings to 


















Reviewed FHxT; not 
applicable to primary 
care  
 














Method used to 














Age of participants: 
Patients or 
informants: Mean 
age at diagnosis 65.9 
+/-12.1; 
Relatives: over 40 
years or 10 years 
younger than the 
youngest case of 






























determine the age of 
diagnosis; determine 





Tools compared: 1: 




# of participants 
recruited in each 
group: Group 1: 34 
patients 
 
# of participants in 
analysis: group 1: 34 
patients 
 
# of first degree 
relatives: group 1: 
237 
 
# of second degree 
relatives: NR 
 
Metric used to 
evaluate the 





Presence of at least 
1 first degree relative 
with CRC in the 
family history was 
noted in 12 patients 
(35.5%), 2: Mean of 
first degree relatives 
with positive family 
history: 6.3 + - 3.4, 3: 













and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







To evaluate the 
accuracy of 























not available for 
review 
 
Setting where used: 
Surgical clinic 
 













structured FHQ (not 
clear if  face to face 
or phone) 
 





















info on CRC 
 
Relatives identified: 
First degree relatives 
second degree 
relatives (2DR 
consider if patients 
were diagnosed 
before the age of 50 
or if colorectal cancer 
was reported among 
first-degree relatives) 
 
Strategy for FH 










determine the age of 
diagnosis; determine 
the site of cancer 
determine the cause 
of death; determine 




relatives: NR  
Supplementary 
genealogical details 
on relatives recorded 
from church registers 
Tools compared: 
questionnaire used 
by patient's surgeon 
compared to relatives 
medical records +/- 
autopsy report +/- 
cancer registry +/- 
death certificates 
 
# of participants 
recruited in each 




# of participants in 
analysis: Group 1: 
n=1200 completed 
the questionnaire,  
reported that their 
families belonged to 
Amsterdam ii 
categories 1, 2 or 3 
and these families 
were subjects of this 
study 
 
# of first degree 
relatives: Group 1 a 






# of second degree 
relatives: Group 1: 
second degree 
relatives were 
considered if the 
patients were 
Metric used to 
evaluate the 
adequacy of the 
tool:  
Correct cancer 
reported in relatives: 
1DR correct  68.4% 








into risk categories= 
meet Amsterdam I & 
II 
False + 21% (3/14) 
False - 32% (7/18) 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  
diagnosed before the 
age of 50 years or if 
colorectal cancer was 
reported among first-
degree relatives 
















and records in 

















Northern California;  
2) the Twin Cities 
metropolitan area; 
and 3) an eight-
county metropolitan 




Reviewed FHxT; not 
applicable to primary 
care  
 




Method used to 













Age of participants: 



























the age of diagnosis; 
determine the cause 
of death; determine 







Tools compared: 1: 
Computer-assisted 
in-person 
interviewing, 2: Utah 
Population Database 
 
# of participants 
recruited in each 
group: Group 1: 881, 
group 2: 331 
 
# of participants in 
analysis: group 1: 
881, group 2: 331 
 
# of first degree 
relatives: group 1: 
881, group 2: 331 
 
# of second degree 
relatives: group 1: 
NR, group 2: NR 
 
Metric used to 
evaluate the 
adequacy of the 
tool: Sensitivity (#, 
%): Colorectal 73%, 
Uterine 30%, Ovarian 
60%, breast 83%, 
prostate 70% 
Other outcomes 
measured: 1: Risk of 
colon cancer 
associated with 
family histories of 
various cancers 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  
1) Kaiser 
Permanente Medical 
Care Program  
Northern California; 
2) the Twin Cities 
metropolitan area; 
and 3) an eight-
county metropolitan 
area surrounding Salt 
Lake City, Utah,  
 















and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







1) To examine 




cancer types in 
their families; 
2) To report on 




on their FH 
status 
 
Patients: Men with 









Applicability:  FHxT 
not available for 
review 
 
Setting where used: 
Prostate Clinic 
 
Cancer type:  
Prostate 
 
Study design:  
Non-comparative 




Method used to 
collect FH: personal 
structured interview: 
(Not clear if face to 



























First degree relatives 
(1DR) 
 
Strategy for FH 
enquiry: ask about 
all 1DR. If cancer 
identified in relatives, 










age of relatives; 
determine the date of 
diagnosis; determine 
the cause of death; 
determine the date of 
death; determine the 
site of cancer; locality 






relatives: age of 




to medical record,  
pathology report , 
death certificate 
 
# of participants 
recruited in each 
group: Group 1: 442, 
group 2: 442 
 
# of participants in 
analysis: group 1: 
143, group 2: 249 
 
# of first degree 
relatives: group 1: 
263, group 2: 263 
 
# of second degree 
relatives: group 1: 
NR, group 2: NR 
 
Metric used to 
evaluate the 
adequacy of the 
tool:  
% agreement 
between self-report & 
actual relatives 
medical history 
Vary by site: 
Bladder/kidney 
(100% x/y) 
Prostate (80% x/y) 
Ovarian (50% x/y) 
1DR accuracy 62-



















population  General 
population: women 







Method used to 






Age of participants: 
Patients: General 
population no older 
than 79 years; Mean 
age of women 
reporting positive 
family history of 
breast cancer was 









determine the age of 
diagnosis; determine 
the site of cancer, 
Tools compared: 
Home FH interview 
compared to medical 
record (+/- path 





recruited in each 
Metric used to 
evaluate the 





data; 1: 68 cases and 
37 controls reported 
a history of breast 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  






















not available for 
review  
 





















Participant PMH NR 
 
Relatives identified 
First degree relatives 
Other: they were 
asked if they has 
relatives affected in 
general 
 
Strategy for FH 
enquiry: Not clear 






group: 843 women; 





analysis: 68 women 
with breast cancer 
and 37 without 
 
Number of first 
degree relatives: 87, 
38 by control reports 
of breast cancer in 
first-degree relatives 
 
Number of second 
degree relatives: 
NR 
cancer in at least one 
first degree relative. 
67 (91%) cases 
accurate 













history of breast 




population patient’s  













Method used to 
collect FH: Self-
completed survey : 
Questionnaire was 





Medium: paper  
 
Age of participants: 
40 years or older; 
largest proportion:  
55.8% age 40-49.  














cancer: focus of 
study on Breast 












# of participants 
recruited in each 
group: 899 
  
# of participants in 
analysis: as  above 
 
# of first degree 
relatives: NR 
# of second degree 
Metric used to 
evaluate the 






McNemar odds of 
reporting a maternal 
family history of 
breast cancer was 
1.71 times greater 
than the odds of 
 C-33







and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  








Reviewed FHxT; not 
applicable to primary 
care  
 
Setting where used: 
Primary care 
women's health clinic 
 














Reported with details 







with Breast cancer) 
 
Strategy for FH 
enquiry: DQ: list 
relatives with any 
form of cancer, with 
prompts for side of 
family, “kind of 
cancer”, age of 
diagnosis, and if died 
from cancer 
the age of diagnosis: 
determine the cause 
of death: if died from 
cancer, determine 








# of relatives; 202 
 
reporting paternal 
family history (p< 
0.01, 95% CI 1.26 – 
2.34). 
FH not validated 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  








accuracy of the 






Patient referred to 













Reviewed FHxT; not 
applicable to primary 
care  
  




Cancer type:  
Breast, ovarian and 
colorectal  
 
Study design:  
Non-comparative 
study (case series) 
Purpose:  
Clinical use - reactive 
and proactive 
 
Format: Pedigree  
 






Age of participants: 
Patients age NR 















First and second 
degree relatives  















DOB; date of death; 
determine the age of 
diagnosis; determine 
the cause of death; 
determine exact 
diagnosis; determine 




















# of participants 
recruited in each 
group: 129  
 
# of participants in 
analysis: 120 
 
# of first degree 
relatives: group 1: 
NR, group 2: NR 
 













Metric used to 
evaluate the 
adequacy of the 
tool: Accuracy of Ca 
by site: 









Study Purpose:  
To evaluate the 
impact of the 
computerized 
Type of article 
Journal article 





























To identify exact 
Tools compared:  
CRIS (Cancer Risk 
Intake System) 
 
# of participants 
recruited in each 
group:  
227 






cancer risk high 
enough to warrant 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  




Patients from a 
primary care 











Cancer type:  
Breast, colorectal 
 





It displays messages 


























the age of diagnosis, 








# of participants in 
analysis:  215 
 
# of first degree 
relatives: N/A 
 
# of second degree 
relatives: N/A 
 





(33%) had breast, 
ovarian or colon 
cancer risk high 
enough to warrant 
receipt of tailored 




(14%) had colon 
cancer risk high 













and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  







To compare FH 
data of women 
with breast 
cancer obtained 
















Tool 2 by 





Secondary care clinic  
 
Applicability: FHxT 
not available for 
review 
 
Setting where used: 
Secondary care clinic  
 
Cancer type:  
Breast/ovarian, 








Method used to 
collect FH: Tool 1: 
Self-completed FHQ 
FH (mail) 
Tool 2: follow-up 
Face to face personal 
GI 
 
Format: Tool 1: 
Tabular 
 








Age of participants: 













First and second 
degree relatives. 
 













the cause of death; 
determine the date of 
death; 
determine the age of 
diagnosis; determine 
exact diagnosis; 
determine the site of 






exact relationship to 
informant; determine 
the cause of death; 
determine the date of 
death. 
Tools compared: 
tool 1: questionnaire 
(FHQ), tool 
2:followup Interview 
(GI),; compared to 
contact relatives +/- 
medic records +/- ca 
register +/- death 
certificates 
# of participants 
recruited in each 
group: 203. 
# of participants in 
analysis: 165. 
# of first degree 
relatives: 1,200 for 
both groups. 
# of second degree 
relatives: 3, 456 for 
both groups. 
 
Metric used to 
evaluate the 
adequacy of the 
tool:  
Compare accuracy 
FHQ & GI 
(1) Quantitative 
First degree relatives 
(presence of cancer; 
site & age diagnosis) 
GI slightly better FHQ 
Second degree 
relatives   
GI better  
(age of diagnosis 
[11%]>presence of 
cancer [7%] >  site 




of FH: age of 
diagnosis 1DR>2DR 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  









used to estimate 
the risk for 
breast cancer in 















not available for 
review 
 














Method used to 










Age of participants: 
Patients: NR; 
relatives: younger 















First, second, third 




















Tools compared: 1: 
one tool - NR asking 
detailed family history 
extending to at least 
3 generations 
 
# of participants 
recruited in each 
group: Group 1: 200 
women participating 
in the TRACE study. 
 
# of participants in 
analysis: group 1: 
200. 
# of first degree 
relatives: NR 
 
# of second degree 
relatives: NR 
 
Metric used to 
evaluate the 




measured: 1: Risk 
assessment as 
measured with 3 
methods: 1) CASH, 
2) Houlston/Murday 
and 3) Qualitative 




























Method used to 
collect FH: DQ on 
Face to face personal 
interview: in-person 
interview first time, 
Identical Telephone 
interview: second 
interview one year 
later 
Age of participants: 
Patients or 
informants:  mean 


















determine the site of 
cancer 
 
Tools compared: 1: 
question at time 1, 2: 
question at time 2. 
# of participants 
recruited in each 
group: 96 
 
# of participants in 
analysis: 96 
 
# of first degree 
relatives: group 1: 
Metric used to 
evaluate the 





change between time 
1 and time 1 self-
report (one year 
later) (Precision) 
48 different response 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  
time Nursing student 







not available for 
review 
 
Setting where used: 
Face to face 
interview at a 
community-based 
educational program 
on prostate cancer 
screening 
 




comparative study / 
reliability 
 














If positive family 
history for Prostate 
Cancer; identify  







Strategy for FH 
enquiry:  specific 
direct enquiry about 
FH Prostate cancer. 






NR, group 2: NR. 
 
# of second degree 
relatives: group 1: 
NR, group 2: NR 
 














































data into Genetics 
Registry In System 
(GRIS) 
 
Age of participants: 




subdivided in 5 age 
groups from <40 













cancer: focus on 
breast, ovarian, 







the age of diagnosis, 
determine the cause 
of and age of death 
Tools compared: 1: 
Telephone interview, 




# of participants 








# of first degree 
Metric used to 
evaluate the 
adequacy of the 
tool: False positive 








PAC, probability of 
agreement of cancer; 
PANC, probability of 
agreement of no 
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and tool format 




Details on Relatives 
† 
Tool evaluation:  
Comparison* 
Tool evaluation:  
other measures ^  








cancer status in 





3) to determine 
the effect of the 
characteristics 
of the patient’s 








applicable to primary 
care  
 









Study design:  
Non-comparative 
study (case series) 
Integrated with e-









in 5 age groups from 




medical history: NR 
 
Relatives identified: 
1DR, 2DR, 3DR 
 
Strategy for FH 





exact relationship to 
informant, determine 
the age of the 
diagnosis 
relatives: not clear 
 
# of second degree 
relatives: not clear  
 









Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   






Tool:   
Familial Cancer Assessment Tool 
(FCAT) 
Purpose:  
Stratify risk of familial breast 
cancer  
Content: Directed family history 
questions based on guideline with 
suggested onward management  
Format:   
Nurse-administered interview-
based questionnaire, following 
patient completed advance family 
history questionnaire  
Underlying guidelines:  
Eccles DM et al.  J Med Genet 
2000; 37: 203-9 
Study population: 
Patients referred to joint 
surgical/genetics family history breast 
screening clinic 
Cancer type:  
Breast 
Setting:  
Specialist genetic clinic 
Applicability:   
Potentially applicable to, but not 






Tool development and 
description 
Comparison groups: 





3: Genetic interview 
(gold standard) 
Groups sample size 




Ease of completion rated by nurse 
interviewer on 1-10 scale (easy-difficult) 
• 60/100 scales were rated 1-3 
Other outcomes reported:  
Sensitivity, specificity, positive 
predictive value, negative predictive 




Abbreviations: AMA=American Medical Association; Chi-square= χ2; EsPeR=Personalized Estimate Risks; FCAT=Familial Cancer Assessment Tool; FHAT=Family 
History Assessment Tool; GP=General Practitioner; GRACE=Genetic Risk Assessment in the Clinical Environment; GRAIDS= Genetic Risk Assessment in an Intranet 
and Decision Support; ICC=Inter Class Correlation; NR=NR; PC=Primary Care; OR=Odds Ratio; RAGs=Risk Assessment in Genetics; SD=Standard deviation; 








Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   






Genetic Risk Assessment in the 
Clinical Environment (GRACE) 
Purpose:  
Cancer risk assessment and 
communication 
Content:  
Pedigree-based family history data 
collection with personalized risk 
report 
Format:   
Patient-completed, computer-based 
questionnaire 
Underlying guidelines:  
Claus, EB et al. Am J Human 
Genetics 1991; 48( 2), 232-42 
 
 
Study population:  
Women with family history of breast 
cancer recruited from general 
population through advertisements 
Cancer type:  
Breast  
Setting:  
Unspecified ‘clinical environment’  
Applicability:   
Potentially applicable to, but not 




Design:   
Randomized controlled 
trial 
Comparison group(s):  





postal family history 
questionnaire at 
baseline 
Sample size:  
GRACE: n=38 





1. Acceptability to patients (post-clinic) 
(a)  Attitude to interventions – six 
attributes, 5-point scale 
• 2/6 comparisons statistically 
significant, favored control arm 
(b) Perceived benefits of interventions – 
seven attributes, 5-point Likert scale 
• 7/7 comparisons statistically 
significant, favored control arm 
(c) Perceptions of risk information – five 
attributes, 5-point Likert scale  
• 5/5 comparisons statistically 
significant, favored control arm 
(d) Satisfaction and risk  
communication preferences – single 
item, 4-point Likert scale 
• 1/1 comparisons statistically 
significant, favored control arm 
2. Cognitive outcomes (all baseline, 
post-clinic, 3 months)  
(a)  Comparative risk perception – 
single item, 5-point scale 
• No significant difference between 
GRACE and control arms; 
statistically significant time x 
treatment interaction indicated 
reduction in elevated risk 
perceptions in control arm 
compared to GRACE arm 
(b) Risk accuracy – binary concordance 
between participant and 
guideline/clinical nurse specialist  
• No significant improvements in 
accuracy of risk perception 
observed in GRACE and control 
arms.  Baseline differences 
between arms 
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Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   
Key Results Relating to Clinical 
Utility 
3. Affective outcomes 
(a) Hospital Anxiety and Depression 
Scale score (baseline, 3 months) 
• No significant difference between 
arms or between baseline and 3 
months 
(b) Current anxiety - Spielberger’s 
State-Trait Anxiety Inventory (short 
form) (baseline, post-clinic, 3 months) 
• Statistically significant increase in 
scores baseline-3 months in both 
arms; statistically significant 
treatment effect, favored control 
(c) Cancer worry (baseline, 3 months) 
• statistically significant decrease in 
cancer worry in both arms;  no 
statistically significant difference 
between arms 













Family history collection, pedigree 
drawing, risk estimation based on 
published models, individualization 
of guidelines, printable summary of 
prevention messages for physicians 




Underlying guidelines:  
Colombet I et al.  Proc AMIA Symp 
2002; 175-9; Gail model 
Study population:  
Physicians in individual practice, 
teaching, health centers  
Cancer type:  




Some formative, but not definitive,  
evaluation in primary care 
 
 
Design:   
Description of tool  
Comparison groups: 
N/A  







Other outcomes measured:  
N/A 
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Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   












Genetic Risk Assessment in an 
Intranet and Decision Support 
(GRAIDS), for which Risk 
Assessment in Genetics (RAGS) 
was the prototype 
Purpose:  
Management of familial cancer in 
primary care  
Content:  
Family history collection;  pedigree 
drawing;  patient-specific risk report;  
clinical practice 
guidelines/management advice;  
patient-specific explanations for the 
management advice  
Format:   
Web-based program designed to be 
used by a single lead physician in 
each practice.  Preceded by an 
educational visit and a 2 hour 
training session;  patients asked to 
complete family history 
questionnaire before attending 
practice 
Underlying guidelines:  
Claus, EB et al. Am J Human 
Genetics 1991; 48( 2), 232-42 
 
Patients:  
Family practice patients, family 
physicians 
Cancer type:  
Breast, ovarian, colorectal  
Setting:  







controlled trial with 
adaptive sub-group in 
intervention arm 
Comparison groups: 
1.  45 minute 
educational session 
plus mailing of  regional 
guidelines 
2.  Intervention as 
described, in fixed and 
adaptive sub-arms  
(adaptive received 
further input to promote 
greater software use) 
Sample size: 
1.  Practices n=22 
Referred patients n=84 
2.  Practices n=23  
(12 fixed, 11 adaptive) 




20 practices per arm 
required to demonstrate 
15% difference between 




1.  Appropriateness of referrals  
a)  consistency of family history 
reported in referral letter with regional 
guidelines 
• Breast cancer – intervention 
99/107, control 44/60, OR (95%CI)  
= 4.5 (1.6-13.1) 
• Bowel cancer – intervention 75/76, 
control 23/25, OR (95%CI) = 6.5 
(0.5-83.7) 
• Combined – intervention 174/183, 
control – 67/85, OR(95%CI) = 5.2 
(1.7-15.8), p=0.006 
b) final expert risk assessment of 
referred patients 
• Breast cancer – intervention 60/78, 
control 23/33, OR (95%CI) = 1.4 
(0.6-3.5) 
• Bowel cancer – intervention 30/54, 
control 17/20, OR (95%CI) = 0.2 
(0.1-0.8) 
• Combined – intervention 90/132, 
control – 40/53, OR(95%CI) = 0.7 
(0.3-1.5), p=0.35 
2.  Patients 
a) Risk perception 
Mean scores (SD) – intervention 
(referred) 4.99 (1.14), intervention (not 
referred) 4.25 (0.80) control 5.04 (0.88), 
Intervention (referred) v control, mean 
difference (95% CI)= -0.09 (0.34-0.51), 
NS 
Intervention (not referred) v intervention 
(referred), mean difference (95%CI) = 








Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   
Key Results Relating to Clinical 
Utility 
Mean scores (SD) – intervention 5.77 
(2.9), control 5.66 (2.78), mean 
difference (95% CI)= 0.11 (-1.05-1.27), 
NS 
Colorectal cancer: 
Mean scores (SD) – intervention 5.50 
(2.46), control 4.86 (3.3), mean 
difference (95% CI)= 0.64 (-1.01-2.29), 
NS 
c) Cancer worry  
Mean scores (SD) – intervention 
(referred) 5.74 (3.04), intervention (not 
referred) 4.95 (2.99), control 7.18 (3.43) 
Intervention (referred) v control, mean 
difference (95% CI) = -1.44 (-2.64-
0.23), P=0.02 
Intervention (not referred) v intervention 
(referred), mean difference (95%CI) = 




Tool:   
Triage tool embedded in family 
history questionnaire  
Purpose:  
Permit women to assess their own 
risk of familial breast cancer 
Content:  
Directed family history questions; 
risk triage (population or increased 





Underlying guidelines:  
Advice about familial aspects of 
breast cancer and ovarian cancer:  
a guide for health professionals.  
Kings Cross, New South Wales: 
National Breast Cancer Centre, 
2000 
Study population:  
Patients having repeat 
mammograms  
Cancer type:  
Breast 
Setting:  
Breast screening clinic 
Applicability:   





Design:   
Uncontrolled trial  
Comparison groups: 
None 
Sample size:  
Total n=559  




# participants making errors affecting 
risk categorization - 29/559 
Other outcomes measured:  
Concordance between questionnaire-
based category (I, II or III, population, 
moderate, potentially high risk, 
according to cited guideline) and risk 









Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   






Family History Assessment Tool 
(FHAT) 
Purpose:  
Identify patients for referral 
Content:  
Directed family history questions 
with points specified for each 
affected family member  
Format:  
Clinician-oriented, paper-based  
Underlying guidelines:  
Predictive scoring system, 
described in same paper  
 
 
Study population:  
Familial breast cancer registry plus 
patients referred to genetics clinic 
Cancer type:  
Breast, ovarian cancer 
Setting:  
Specialist genetic clinic 
Applicability:   
Designed to be applicable to, but 














Other outcomes measured:  
Sensitivity, specificity, positive 
predictive value, negative predictive 





‘Brief tool’ for physicians 
Purpose:  
Rapid assessment of family history  
Content: 
Risk stratification criteria; lifetime 
probability benchmark ranges;  
screening recommendations; 
genetics services contact numbers 
Format:   
Coat pocket laminated card for 
physicians, plus monograph on 
managing inherited breast cancer 
risk 
Underlying guidelines:  
USPSTF screening 
recommendations; 
AMA Monograph, Managing 
inherited breast cancer risk 
 
Study population:  
Internal medicine, family physicians 
Cancer type:  
Breast  
Setting:  
Internal medicine, family practice  
Applicability:  
Developed for primary care settings 
 
Design:  








1. Frequency of discussing inherited 
risk with patients with a family history of 
breast cancer (baseline, 3 months) 
• 5/7 reported decrease in frequency, 
2/7 reported no change 
2. Subjective threshold for classifying a 
woman as ‘high risk’ (baseline, 3 
months) 
• 6/7 reported increase in subjective 
threshold  






Cancer Risk Intake System(CRIS) 
Purpose: 
Study population: 






1.  For those participants whose risk 
warranted a tailored tamoxifen 
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Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   
Key Results Relating to Clinical 
Utility 
 Risk assessment, recommendations 
for discussion with provider 
Content: 
Risk assessment algorithm 
Tailored printouts 
Format: 
Touch-screen computer application 
linked to printer 
Underlying guidelines: 
Expert opinion based on 
Hampel et al, J Med Genet 2004; 
41: 81-91. 
Burt RW, Gastroenterology 2000; 
119: 837-53 
Winawer S et al, Gastroenterology 
2003; 124: 544-60. 
Smith RA et al, CA Cancer J Clin 













message, pre-post change in proportion 
who reported discussing tamoxifen with 
clinician 
Pre - 4/83, Post - 23/83  
P=0.00026 (McNemar’s χ2) 
2.  For those participants whose risk 
warranted a tailored cancer genetic 
counseling message, pre-post change 
in proportion who reported discussing 
cancer genetic counseling with clinician 
Pre - 2/71, Post - 20/71 
P=0.00012 (McNemar’s χ2)  
3.  For those participants whose risk 
warranted a tailored colonoscopy 
message, pre-post change in proportion 
who reported discussing colonoscopy 
with clinician 
Pre - 5/31, Post - 14/31 










Risk assessment, clinical 
management  
Content:  
Referral guidelines; background 
information; patient leaflets 
Format:   
Laminated summary card plus 
booklet, presented as part of 
interactive education session 
Underlying guidelines:  
Report of the consensus meeting on 
the management of women with a 
family history of breast cancer.  
London: Wellcome Trust, 1998. 
Eccles DM et al.  J Med Genet 
2000; 37: 203-9 
 
Study population:  
Family physicians 
Cancer type:  
Breast/ovarian  
Setting:  
Family practice  
Applicability:  
Family practice 
Design:   
Cluster randomized 
controlled trial  
Comparison groups: 
1: Tool alone 
2: None  
Sample size:  
Group A - Tool plus 
education,  
  Practices n=56,  
  Physicians n=225 
Group B - Tool alone,  
   Practices n=57    
  Physicians n=233 
Group C - No 
intervention,  





Timing unclear, ‘post-intervention’ 
1. Proportion of physicians making 
‘correct’ referral decision for ≥ 5/6 
vignettes 
• Group A:  111/140 (79%)       
• Group B:  100/124 (81%)       
• Group C:  63/162 (63%)       
Overall p<0.001 (one way ANOVA);  
group A vs C – p<0.001 (χ2); group B vs 
C, p<0.001 (χ2); group A vs B, p=0.45 
(χ2)  
2. Confidence scores in four aspects of 
managing patients with family history of 
cancer, 4-point Likert scale. 
• Mean (SD) overall confidence 
scores, possible scores 0-4:    
Group A: 2.3 (1.0); Group B: 2.0 
(1.1); Group C: 1.5 (1.0)  P<0.001 
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Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   
Key Results Relating to Clinical 
Utility 
physicians required per 
group (allowing for 
clustering) to detect an 
increase in primary 
outcome from 15% in 
Group C to 35% in 
Group B, or from 35% in 
Group B to 55% in 
Group A 
 
(ANOVA linear trend) 







Multifaceted decision aid 
Purpose:  
Familial cancer risk management 
Content:  
Targeted family history questions; 
risk assessment module; 
background information on cancer 
genetics; printer-friendly patient 
information leaflets; weblinks; email 
link to cancer genetics service; 




computer package.  Implemented 
with offer of education session 
Underlying guidelines:  
Scottish Cancer Group Cancer 
Genetics Sub-Group.  Cancer 
genetics services in Scotland.  
Guidance to support the 
implementation of genetics services 
for breast, ovarian and colorectal 
cancer predisposition.  Edinburgh: 




Women consulting family 
physicians with queries about 
familial breast cancer;  family 
physicians 
Cancer type:  










guidelines mailed by 
Department of Health 
Sample size: 
Physicians 
Intervention group -  
Responders pre-
intervention n=179;  
Responders post-
intervention n=151 


















1:  Self-reported physician confidence,  
4-point scale 
Patients 
• very confident or confident  
taking FH – intervention group, 91/151 
(60%), control group 56/92 (61%); 
p=0.93 (χ2)  
• very confident or confident  
knowing who to refer – intervention 
group 60/151 (40%),  control group 
30/91 (33%);  p=0.27 (χ2) 
• very confident or confident  
reassuring low risk – intervention group 
85/151 (57%), control group 48/92 
(52%); p=0.46 (χ2) 
• very confident or confident  
able to answer questions – intervention 
group 35/151 (23%), control group 
20/92 (22%); p=0.77 (χ2) 
2: Genetic risk of referred patients 
• Proportion of referred patients 
assessed as elevated genetic risk 
Intervention group 14/29 (48%), 
control group 22/34 (65%), NS 
(reported as risk ratio) N.B. Baseline 
differences between groups 
3: Patients’ breast cancer beliefs 
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Tool, Purpose, Content and 
Format of tool, Underlying 
Guidelines/Models 
Study Population, Cancer Type, 





Sample Size   
Key Results Relating to Clinical 
Utility 
Power calculation: 
168 interventions, 84 
control practices 
required (2:1 allocation 
ratio) to detect absolute 
difference of 20% in 
physicians responding 
very confident or 
confident in attitude 
items, 80% power, α = 
0.05, ICC 0.05   
 
Proportion of referred patients agreeing 
with ‘incorrect’ causal statement 
• ‘Stress always increases your risk’ 
intervention group 17/74 (23%), 
control group 5/22 (23%);  p=0.98 (χ2) 
• ‘Having one close relative with 
breast cancer always increases your 
risk’ – intervention group 66/75 (88%), 
control group 20/22 (91%); p=0.71 
(χ2) 
• ‘Minor injury always increases your 
risk’ – intervention group 15/75 (20%), 
control group 5/22 (23%); p=0.78 (χ2). 
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